

2012 focused update of the ESC Guidelines for the mana

Europace

14, 1385-1413

DOI: [10.1093/europace/eus305](https://doi.org/10.1093/europace/eus305)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cys-tRNACys formation and cysteine biosynthesis in methanogenic archaea: two faces of the same problem?. Cellular and Molecular Life Sciences, 2004, 61, 2437-2445.	2.4	10
2	Biological functions of the ING family tumor suppressors. Cellular and Molecular Life Sciences, 2004, 61, 2597-2613.	2.4	109
3	Biochemistry and biology of mammalian DNA methyltransferases. Cellular and Molecular Life Sciences, 2004, 61, 2571-2587.	2.4	462
4	Pharmacological attenuation of apoptosis in reoxygenated endothelial cells. Cellular and Molecular Life Sciences, 2004, 61, 3076-3086.	2.4	9
5	Study of molecular events in cells by fluorescence correlation spectroscopy. Cellular and Molecular Life Sciences, 2005, 62, 535-550.	2.4	90
6	Alzheimer's disease: the impact of age-related changes in reproductive hormones. Cellular and Molecular Life Sciences, 2005, 62, 281-292.	2.4	41
7	The potential role of endogenous bacteriophages in controlling invading pathogens. Cellular and Molecular Life Sciences, 2005, 62, 511-519.	2.4	137
8	Compensatory caspase activation in MPP+-induced cell death in dopaminergic neurons. Cellular and Molecular Life Sciences, 2005, 62, 227-238.	2.4	23
9	Association, mutual stabilization, and transcriptional activity of the STRA13 and MSP58 proteins. Cellular and Molecular Life Sciences, 2005, 62, 471-484.	2.4	35
11	Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database. BMJ Open, 2012, 2, e001768.	0.8	48
12	Stroke and Thromboembolism in Atrial Fibrillation. Circulation Journal, 2012, 76, 2289-2304.	0.7	131
13	European Society of Cardiology (ESC) Congress Report From Munich 2012. Circulation Journal, 2012, 76, 2530-2535.	0.7	7
14	Antiarrhythmic drug treatment after cardioversion of atrial fibrillation. Lancet, The, 2012, 380, 1467-1468.	6.3	0
15	Antiarrhythmic drug treatment after cardioversion of atrial fibrillation " Authors' reply. Lancet, The, 2012, 380, 1468.	6.3	0
16	Avances en el tratamiento antitrombótico. Nuevos anticoagulantes orales para reemplazar a acenocumarol (Sintrom®). Medicine, 2012, 11, 1421-1427.	0.0	1
17	Left atrial appendage occlusion for prevention of thromboembolic events in patients with non-valvular atrial fibrillation: Closing the door to hell. Archives of Cardiovascular Diseases, 2012, 105, 619-622.	0.7	0
18	Impact of controlling atrial fibrillation on outcomes relevant to the patient: focus on dronedarone. Patient Related Outcome Measures, 2012, 3, 95.	0.7	0
19	Clinical performance of bleeding risk scores for predicting major and clinically relevant non-major bleeding events in patients receiving warfarin. Journal of Thrombosis and Haemostasis, 2013, 11, 1647-1654.	1.9	32

#	ARTICLE	IF	CITATIONS
20	Epidemiology of Atrial Fibrillation in Spain in the Past 20 Years. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 561-565.	0.4	20
21	Practical management of heart failure with preserved ejection fraction. A modest proposal. <i>Archives of Cardiovascular Diseases</i> , 2013, 106, 345-348.	0.7	2
22	Mean platelet volume is associated with the presence of left atrial stasis in patients with non-valvular atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2013, 13, 40.	0.7	23
23	Genetics of Coagulation: What the Cardiologist Needs to Know. <i>Canadian Journal of Cardiology</i> , 2013, 29, 75-88.	0.8	7
24	Novel oral anticoagulants in non-valvular atrial fibrillation. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 115-129.	0.7	27
25	Novel oral anticoagulants in secondary prevention of stroke. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 131-139.	0.7	9
26	Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 225-237.	0.7	27
27	Safety and Efficacy of New Anticoagulants in Patients with Heart Failure. <i>Current Heart Failure Reports</i> , 2013, 10, 18-25.	1.3	3
28	Retinal vein and artery occlusions: a risk factor for stroke in atrial fibrillation. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1485-1492.	1.9	44
29	Role of the new target specific oral anticoagulants in the management of anticoagulation for cardioversion and atrial fibrillation ablation. <i>Journal of Thrombosis and Thrombolysis</i> , 2013, 36, 175-186.	1.0	4
34	Dabigatran in clinical practice – One-year experience at SkÅne University Hospital. <i>Thrombosis Research</i> , 2013, 132, 316-317.	0.8	3
35	Features and costs of patients admitted for cardiac arrhythmias in Spain. <i>Revista Cl&#x00ed;nica Espan&#x00f5;la</i> , 2013, 213, 235-239.	0.3	2
37	Heart Failure, Atrial Fibrillation, and Catheter Ablation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1904-1905.	1.2	3
38	Left atrial appendage and thromboembolism: Shape matters. <i>Heart Rhythm</i> , 2013, 10, 926-927.	0.3	1
39	Flecainide versus vernakalant for conversion of recent-onset atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 2423-2425.	0.8	31
41	Atrial Fibrillation: Food for Thought in 2013. <i>American Journal of Medicine</i> , 2013, 126, 937-938.	0.6	4
42	Every patient with atrial fibrillation has his (her) own optimal heart rate. <i>Medical Hypotheses</i> , 2013, 81, 972-975.	0.8	1
43	An update and current expert opinions on percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation. <i>Europace</i> , 2013, 15, 652-656.	0.7	40

#	ARTICLE	IF	CITATIONS
44	Safety and efficacy of dabigatran etexilate during catheter ablation of atrial fibrillation: a meta-analysis of the literature. <i>Europace</i> , 2013, 15, 1407-1411.	0.7	92
45	Cardioversion for atrial fibrillation in current European practice: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 915-918.	0.7	38
46	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2013, 34, 3035-3087.	1.0	1,758
47	Bleeding risk during oral anticoagulation therapy for atrial fibrillation. <i>Europace</i> , 2013, 15, 773-774.	0.7	2
48	Atrial selectivity of antiarrhythmic drugs. <i>Journal of Physiology</i> , 2013, 591, 4087-4097.	1.3	73
49	Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2013, 15, 1540-1556.	0.7	125
51	Immediate and medium-term outcomes of cryoballoon-based pulmonary vein isolation in patients with paroxysmal and persistent atrial fibrillation: single-centre experience. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2013, 38, 187-195.	0.6	39
52	Antiarrhythmic Drugs in Atrial Fibrillation: Do They Have a Future?. <i>Canadian Journal of Cardiology</i> , 2013, 29, 1158-1164.	0.8	3
53	Novel Therapeutics for Thromboprophylaxis in Nonvalvular Atrial Fibrillation. <i>Drug Development Research</i> , 2013, 74, 485-491.	1.4	0
54	Atrial fibrillation prevalence revisited. <i>Journal of Internal Medicine</i> , 2013, 274, 461-468.	2.7	210
55	Atrial Fibrillation in the Elderly: To Ablate or Not to Ablate. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 739-741.	0.8	4
56	Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional study. <i>BMJ Open</i> , 2013, 3, e003343.	0.8	67
57	TÃ©lÃ©surveillance de la fibrillation auriculaire: Ã©tude de faisabilitÃ© et rÃ©sultats sur 200 patients. <i>European Research in Telemedicine</i> , 2013, 2, 113-120.	0.6	6
58	Estado actual de la anticoagulaci3n. Nuevas estrategias preventivas y terapÃ©uticas. <i>Medicine</i> , 2013, 11, 2723-2729.	0.0	0
59	New Oral Anticoagulants. <i>Hospital Medicine Clinics</i> , 2013, 2, e456-e471.	0.2	0
60	Stroke Prevention in Atrial Fibrillation in Heart Failure. <i>Heart Failure Clinics</i> , 2013, 9, 427-435.	1.0	2
61	Usefulness of Dronedarone in Patients With Atrial Arrhythmias. <i>American Journal of Cardiology</i> , 2013, 111, 1311-1314.	0.7	8
63	Les nouveaux anticoagulants oraux dans le traitement de la fibrillation atriale. <i>Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique</i> , 2013, 2013, 9-12.	0.0	0

#	ARTICLE	IF	CITATIONS
65	Anticoagulation in "real world" patients with atrial fibrillation in Italy: Results from the ISPAF (Indagine Sicoa Paziente Con Fibrillazione Atriale) survey study. <i>International Journal of Cardiology</i> , 2013, 168, 4729-4733.	0.8	10
66	First-in-Man Randomized Clinical Trial of Renal Denervation for Atrial Arrhythmia Raises Concern. <i>Journal of the American College of Cardiology</i> , 2013, 62, e445-e446.	1.2	10
67	Sequential changes in renal function and the risk of stroke and death in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 4678-4684.	0.8	52
68	Indicaciones actuales del cierre percutáneo de la orejuela auricular izquierda en la fibrilación auricular no valvular. <i>Cardiocre</i> , 2013, 48, 91-92.	0.0	1
69	Percutaneous Left Atrial Appendage Occlusion. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 919-922.	0.4	3
70	Defining the Role of Left Atrial Appendage Closure in Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013, 66, 79-82.	0.4	2
72	Treatment failure of low molecular weight heparin in diabetic patient. <i>International Journal of Cardiology</i> , 2013, 168, e63-e64.	0.8	27
73	Atrial Fibrillation in Heart Failure in the Older Population. <i>Heart Failure Clinics</i> , 2013, 9, 451-459.	1.0	6
74	Indicaciones de rivaroxabán en diferentes situaciones clínicas. <i>Semergen</i> , 2013, 39, 24-29.	0.2	1
75	Fine Tuning Risk Stratification for Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2013, 61, 2285-2287.	1.2	8
76	Role of Preablation Neutrophil/Lymphocyte Ratio on Outcomes of Cryoballoon-Based Atrial Fibrillation Ablation. <i>American Journal of Cardiology</i> , 2013, 112, 513-519.	0.7	52
77	European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2013, 15, 625-651.	0.7	721
79	Receptor for advanced glycation end products (RAGE) in atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 5072-5073.	0.8	4
80	Tiempo en rango terapéutico de los pacientes que siguen tratamiento con derivados cumarínicos en la práctica clínica diaria. <i>Cardiocre</i> , 2013, 48, 158-161.	0.0	0
81	Treatment failure of low molecular weight heparin in post-surgery orthopedic case. <i>International Journal of Cardiology</i> , 2013, 169, e36-e37.	0.8	2
82	Treatment failure of low molecular weight heparin bridging therapy. <i>International Journal of Cardiology</i> , 2013, 167, e106-e107.	0.8	11
85	Relation of renal dysfunction to the increased risk of stroke and death in female patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2013, 168, 1502-1508.	0.8	25
86	Atrial Fibrillation and Thrombosis: The Missing Molecular Links. <i>Journal of the American College of Cardiology</i> , 2013, 61, 861-862.	1.2	1

#	ARTICLE	IF	CITATIONS
87	Cierre percutáneo de la orejuela izquierda. Revista Espanola De Cardiologia, 2013, 66, 919-922.	0.6	7
88	Cost analysis of radiofrequency catheter ablation for atrial fibrillation. International Journal of Cardiology, 2013, 167, 2462-2467.	0.8	10
89	1:1 atrial-flutter. Prevalence and clinical characteristics. International Journal of Cardiology, 2013, 168, 3287-3290.	0.8	14
91	Reply. Journal of the American College of Cardiology, 2013, 61, 482-483.	1.2	0
92	¿Qué dicen las guías sobre la anticoagulación en la fibrilación auricular no valvular?. Semergen, 2013, 39, 17-23.	0.2	1
93	Mapping and ablation of focal arrhythmia: Should we use three-dimensional mapping systems?. International Journal of Cardiology, 2013, 168, 5073.	0.8	0
94	Left atrial appendage occlusion: Single center experience with PLAATO LAA Occlusion System® and AMPLATZER® Cardiac Plug. Journal of Cardiology, 2013, 62, 44-49.	0.8	12
95	Low stroke risk after elective cardioversion of atrial fibrillation: An analysis of the Flec-SL trial. International Journal of Cardiology, 2013, 168, 3977-3981.	0.8	17
96	Managing anticoagulation for atrial fibrillation: current issues and future strategies. Journal of Internal Medicine, 2013, 273, 31-41.	2.7	9
97	New directions in antiarrhythmic drug therapy for atrial fibrillation. Future Cardiology, 2013, 9, 71-88.	0.5	47
98	The Use of the Chronic Kidney Disease Epidemiology Collaboration Equation and Global Cardiovascular Risk Assessment in Patients with Atrial Fibrillation. Cardiology, 2013, 124, 220-221.	0.6	1
99	Efficacy and Safety of Dabigatran Etxilate and Warfarin in "Real-World" Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 61, 2264-2273.	1.2	387
100	Improving the use of direct oral anticoagulants in atrial fibrillation. European Journal of Internal Medicine, 2013, 24, 288-294.	1.0	11
101	Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. BMJ, The, 2013, 346, f2573-f2573.	3.0	115
102	Effects of obstructive sleep apnoea on heart rhythm. European Respiratory Journal, 2013, 41, 1439-1451.	3.1	103
103	Nouveaux anticoagulants oraux. Actualites Pharmaceutiques, 2013, 52, 55-58.	0.0	0
104	Update on Heart Failure, Heart Transplant, Congenital Heart Disease, and Clinical Cardiology. Revista Espanola De Cardiologia (English Ed), 2013, 66, 290-297.	0.4	2
105	Oral Antithrombotic Therapy in Atrial Fibrillation Associated With Acute or Chronic Coronary Artery Disease. Canadian Journal of Cardiology, 2013, 29, S60-S70.	0.8	11

#	ARTICLE	IF	CITATIONS
106	Recent Developments in Understanding Epidemiology and Risk Determinants of Atrial Fibrillation as a Cause of Stroke. <i>Canadian Journal of Cardiology</i> , 2013, 29, S4-S13.	0.8	29
107	Recommendations for thromboprophylaxis in the 2012 focused update of the ESC guidelines on atrial fibrillation: a commentary. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 615-626.	1.9	28
108	Practice Implications of the Atrial Fibrillation Guidelines. <i>American Journal of Cardiology</i> , 2013, 111, 1660-1670.	0.7	11
109	Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. <i>Europace</i> , 2013, 15, 1587-1593.	0.7	53
110	Pharmacokinetic considerations for antithrombotic therapies in stroke. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1335-1347.	1.5	4
111	Inappropriate use of antiarrhythmic drugs in paroxysmal and persistent atrial fibrillation in a large contemporary international survey: insights from RealiseAF. <i>Europace</i> , 2013, 15, 1733-1740.	0.7	15
112	Factor Xa Inhibitors Versus Vitamin K Antagonists for Preventing Cerebral or Systemic Embolism in Patients With Atrial Fibrillation. <i>Stroke</i> , 2013, 44, .	1.0	2
113	Novel oral anticoagulants for stroke prevention in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 1526-1532.	0.7	19
115	Determination of burn depth on biological tissues by dielectric measurement at microwave frequencies. , 2013, , .		4
116	CardioPulse Articles. <i>European Heart Journal</i> , 2013, 34, 791-795.	1.0	0
117	Reduction of stroke and mortality in patients with atrial fibrillation by catheter ablation? Finally, tackling the hard endpoints. <i>Europace</i> , 2013, 15, 620-622.	0.7	2
118	Current management of atrial fibrillation: an observational study in NHS primary care. <i>BMJ Open</i> , 2013, 3, e003004.	0.8	6
119	Letter by Providencia et al Regarding Article, "Atrial Fibrillation and the Risk of Ischemic Stroke: Does It Still Matter in Patients With a CHA ₂ -DS ₂ -VASc Score of 0 or 1?" <i>Stroke</i> , 2013, 44, e38.	1.0	3
120	Atrial Fibrillation, Stroke Risk, and Warfarin Therapy Revisited. <i>Stroke</i> , 2013, 44, 3103-3108.	1.0	268
121	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up?. <i>Europace</i> , 2013, 15, 460-460.	0.7	0
122	'Patient choice' concept in AF ESC Guidelines: is the clinician giving up? Reply. <i>Europace</i> , 2013, 15, 460-461.	0.7	0
123	Questionable levels of evidence in new atrial fibrillation guidelines?. <i>Europace</i> , 2013, 15, 461-461.	0.7	1
124	Questionable levels of evidence in new atrial fibrillation guidelines? Reply. <i>Europace</i> , 2013, 15, 461-462.	0.7	0

#	ARTICLE	IF	CITATIONS
125	Sodium channel block by ranolazine in an experimental model of stretch-related atrial fibrillation: prolongation of interatrial conduction time and increase in post-repolarization refractoriness. <i>Europace</i> , 2013, 15, 761-769.	0.7	36
126	The right recommendations for the wrong reasons?. <i>Europace</i> , 2013, 15, 615-617.	0.7	2
127	Cost-effectiveness of a specialized atrial fibrillation clinic vs. usual care in patients with atrial fibrillation. <i>Europace</i> , 2013, 15, 1128-1135.	0.7	86
128	Current practice of antiarrhythmic drug therapy for prevention of atrial fibrillation in Europe: The European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 478-481.	0.7	19
129	Arrhythmic complications after electrical cardioversion of acute atrial fibrillation: The FinCV study. <i>Europace</i> , 2013, 15, 1432-1435.	0.7	52
130	Acute direct current cardioversion: how 'dangerous' is it?. <i>Europace</i> , 2013, 15, 1387-1388.	0.7	0
131	Current practice for diagnosis and management of silent atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 1223-1225.	0.7	35
132	Bleeding Risk Assessment in Patients With Atrial Fibrillation Who Are Taking Oral Anticoagulants. <i>Hospital Practice (1995)</i> , 2013, 41, 71-78.	0.5	5
133	Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide study. <i>BMJ Open</i> , 2013, 3, e002758.	0.8	155
134	Left atrial appendage occlusion for stroke prevention in atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2013, 15, 141-143.	0.7	30
135	Atrial fibrillation and anticoagulation management: a wake-up call to practitioners, patients, and policymakers. <i>Journal of Medical Economics</i> , 2013, 16, 1190-1192.	1.0	0
136	Advances in Stroke Prevention in Atrial Fibrillation: Enhanced Risk Stratification Combined With the Newer Oral Anticoagulants. <i>Clinical Cardiology</i> , 2013, 36, 312-322.	0.7	4
137	Effects of Dronedaron Started Rapidly After Amiodarone Discontinuation. <i>Clinical Cardiology</i> , 2013, 36, 88-95.	0.7	7
138	Effectiveness of catheter ablation of atrial fibrillation in Belgian practice: a cohort analysis on administrative data. <i>Europace</i> , 2013, 15, 663-668.	0.7	22
139	Awareness and treatment of atrial fibrillation in older adults: the present and the future. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013, 106, 393-394.	0.2	0
140	Ethnicity and stroke risk in patients with atrial fibrillation. <i>Heart</i> , 2013, 99, 1087-1092.	1.2	35
141	Stroke prevention in older adults with atrial fibrillation. <i>Cmaj</i> , 2013, 185, 1479-1480.	0.9	6
142	Caution over use of catheter ablation for atrial fibrillation. <i>BMJ, The</i> , 2013, 347, f5277-f5277.	3.0	10

#	ARTICLE	IF	CITATIONS
143	Anticoagulation Therapy for Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 147-152.	1.5	16
144	Even Cooler?!. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 666-667.	2.1	0
145	Renin-angiotensin System Inhibitors Prevent the Recurrence of Atrial Fibrillation. <i>Journal of Cardiovascular Pharmacology</i> , 2013, 62, 405-415.	0.8	27
146	Dronedaron for the treatment of non-permanent atrial fibrillation: National Institute for Health and Clinical Excellence guidance. <i>Heart</i> , 2013, 99, 1476-1480.	1.2	4
147	A New Risk Scheme to Predict Ischemic Stroke and Other Thromboembolism in Atrial Fibrillation: The ATRIA Study Stroke Risk Score. <i>Journal of the American Heart Association</i> , 2013, 2, e000250.	1.6	315
148	Novel oral anticoagulants in the electrophysiology lab: are we really ready to forget warfarin?. <i>Europace</i> , 2013, 15, 1535-1537.	0.7	0
149	Renal Dysfunction, Stroke Risk Scores (CHADS ₂ , CHA ₂ DS ₂ -VASc, and R ₂ CHADS ₂), and the Risk of Thromboembolic Events After Catheter Ablation of Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 868-874.	2.1	53
150	for Renal and for Risk. <i>Circulation</i> , 2013, 127, 169-171.	1.6	14
151	Neuropsychological Effects of MRI-Detected Brain Lesions After Left Atrial Catheter Ablation for Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2013, 6, 843-850.	2.1	59
152	The epidemiology of atrial fibrillation in end-stage renal disease. <i>Journal of Nephrology</i> , 2013, 26, 617-623.	0.9	9
153	Using the CHADS ₂ and CHA ₂ DS ₂ -VASc Scores for Stroke Risk Prediction as well as the Identification of Stroke Outcomes and Cardiac Complications in Patients with and without Atrial Fibrillation. <i>Cerebrovascular Diseases</i> , 2013, 36, 281-282.	0.8	11
154	CHADS ₂ and CHA ₂ DS ₂ -VASc score to assess risk of stroke and death in patients paced for sick sinus syndrome. <i>Heart</i> , 2013, 99, 843-848.	1.2	43
155	ENGAGE AF: Effective anticoagulation with factor Xa in next generation treatment of atrial fibrillation. <i>Global Cardiology Science & Practice</i> , 2013, 2013, 41.	0.3	4
156	Finding atrial fibrillation: just keep looking, just keep looking (but remember stroke prevention). <i>Journal of Internal Medicine</i> , 2013, 274, 457-460.	2.7	1
157	Guidelines for Management of Patients with Transient Ischemic Attack. <i>Frontiers of Neurology and Neuroscience</i> , 2014, 33, 103-114.	3.0	5
158	Luminal Esophageal Temperature Monitoring for the Prevention of Esophageal Injury During Left Atrial Ablation: LET It Be?. <i>Journal of Cardiovascular Electrophysiology</i> , 2013, 24, 965-967.	0.8	5
159	Propafenone Versus Vernakalant for Conversion of Recent-onset Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2013, 31, 377-380.	1.1	18
160	The Hemorrhagic Risk: How to Evaluate It. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 1191-1197.	0.5	2

#	ARTICLE	IF	CITATIONS
161	Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why?. <i>European Heart Journal</i> , 2013, 34, 1041-1049.	1.0	141
162	Target International Normalized Ratio Values for Preventing Thromboembolic and Hemorrhagic Events in Japanese Patients With Non-Valvular Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 2264-2270.	0.7	118
163	Stroke Prevention With Oral Anticoagulation Therapy in Patients With Atrial Fibrillation. <i>Circulation Journal</i> , 2013, 77, 1380-1388.	0.7	35
164	Drug-Eluting Coronary Stents for Left Main Coronary Artery Disease. <i>Circulation Journal</i> , 2013, 77, 2469-2470.	0.7	0
165	Guideline Adherence of Antithrombotic Treatment Initiated by General Practitioners in Patients With Nonvalvular Atrial Fibrillation: A Danish Survey. <i>Clinical Cardiology</i> , 2013, 36, 427-432.	0.7	24
166	Does catheter ablation of atrial fibrillation eliminate the need for anticoagulation?. <i>Interventional Cardiology</i> , 2013, 5, 171-178.	0.0	1
167	Vitamin K antagonists in heart disease: Current status and perspectives (Section III). <i>Thrombosis and Haemostasis</i> , 2013, 110, 1087-1107.	1.8	347
168	Comparison of calibrated dilute thrombin time and aPTT tests with LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. <i>Thrombosis and Haemostasis</i> , 2013, 110, 543-549.	1.8	92
169	Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2013, 110, 723-731.	1.8	141
170	Pleiotropic Effects of Antiarrhythmic Agents: Dronedaron in the Treatment of Atrial Fibrillation. <i>Clinical Medicine Insights: Cardiology</i> , 2013, 7, CMC.S8445.	0.6	24
171	Reversible sinus node dysfunction after multiple ablations along the course of sinus nodal artery in patient with paroxysmal atrial fibrillation. <i>Europace</i> , 2013, 15, 1388-1388.	0.7	7
172	Catheter ablation for atrial fibrillation in the elderly. <i>Clinical Practice (London, England)</i> , 2013, 10, 493-502.	0.1	0
173	Practical approaches to the treatment of atrial fibrillation: focus on stroke prevention using oral anticoagulant drugs. <i>Clinical Practice (London, England)</i> , 2013, 10, 317-332.	0.1	0
174	A specialized atrial fibrillation clinic: improving care and costs for patients with atrial fibrillation. <i>Europace</i> , 2013, 15, 1065-1066.	0.7	3
175	Development of a Novel Composite Stroke and Bleeding Risk Score in Patients With Atrial Fibrillation. <i>Chest</i> , 2013, 144, 1839-1847.	0.4	37
176	New atrial fibrillation guidelines: implementation in the clinic. <i>Clinical Practice (London, England)</i> , 2013, 10, 31-38.	0.1	1
178	Beneficial effects of an angiotensin-II receptor blocker on structural atrial reverse-remodeling in a rat model of ischemic heart failure. <i>Experimental and Therapeutic Medicine</i> , 2013, 5, 1009-1016.	0.8	16
180	Avoiding permanent atrial fibrillation: treatment approaches to prevent disease progression. <i>Vascular Health and Risk Management</i> , 2014, 10, 1.	1.0	25

#	ARTICLE	IF	CITATIONS
181	Patient preferences at ten years following initial diagnosis of atrial fibrillation: the Belgrade Atrial Fibrillation Study. <i>Patient Preference and Adherence</i> , 2013, 7, 835.	0.8	4
182	New Oral Anticoagulants in Atrial Fibrillation. , 2013, , .		0
183	Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2013, 43, 151-158.	0.2	3
184	Flecainide versus Electrical Cardio Version in Patients with a Recent-Onset Atrial Fibrillation. <i>Emergency Medicine: Open Access</i> , 2013, 03, .	0.1	0
185	s New oral anticoagulants “ will they be used with antiplatelet drugs in patients with atrial fibrillation after acute coronary syndrome?. <i>Postepy W Kardiologii Interwencyjnej</i> , 2013, 4, 348-352.	0.1	1
187	Relationship of CHA2DS2-VASc and CHADS2 Score to Left Atrial Remodeling Detected by Velocity Vector Imaging in Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2013, 8, e77653.	1.1	11
188	Preventive Effects of the Angiotensin-II Receptor Blocker on Atrial Remodeling in an Ischemic Heart Failure Model of Rats. <i>Korean Circulation Journal</i> , 2013, 43, 686.	0.7	6
189	Thyroid Disorders in Chronic Heart Failure: From Prognostic Set-up to Therapeutic Management. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2013, 13, 22-37.	0.6	21
190	Use of Oral Anticoagulation Therapy in Atrial Fibrillation after Stroke: Results from a Nationwide Registry. <i>Thrombosis</i> , 2013, 2013, 1-7.	1.4	15
191	The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients. <i>Vascular Health and Risk Management</i> , 2013, 9, 341.	1.0	16
192	Direct oral anticoagulants in real practice: which doses for which patients. Limitations and bleeding risk compared to vitamin K antagonists. <i>Italian Journal of Medicine</i> , 2013, 7, 41.	0.2	0
193	Current Treatment Options in Aortic Stenosis. , 2013, , .		0
194	Clinical trials update: recent and ongoing studies in anticoagulation for atrial fibrillation. <i>Open Access Journal of Clinical Trials</i> , 0, , 101.	1.5	0
195	New oral anticoagulants: key messages for clinicians. <i>Italian Journal of Medicine</i> , 2013, 7, 74.	0.2	0
196	Blood Stasis Secondary to Heart Failure Forms Warfarin-Resistant Left Atrial Thrombus. <i>International Heart Journal</i> , 2014, 55, 506-511.	0.5	15
197	Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. <i>Therapeutics and Clinical Risk Management</i> , 2014, 10, 197.	0.9	10
198	Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk. <i>Vascular Health and Risk Management</i> , 2014, 10, 101.	1.0	21
199	XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. <i>Vascular Health and Risk Management</i> , 2014, 10, 425.	1.0	29

#	ARTICLE	IF	CITATIONS
200	Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. <i>Thrombosis and Haemostasis</i> , 2014, 112, 808-816.	1.8	39
201	Genetic Polymorphisms in ZFX3 Are Associated with Atrial Fibrillation in a Chinese Han Population. <i>PLoS ONE</i> , 2014, 9, e101318.	1.1	29
202	Economic Evaluation of Apixaban for the Prevention of Stroke in Non-Valvular Atrial Fibrillation in the Netherlands. <i>PLoS ONE</i> , 2014, 9, e103974.	1.1	23
203	Acute Coronary Syndromes in Patients with Atrial Fibrillation and Heart Failure. Could Novel Oral Anticoagulants be the Solution of the Optimal Antithrombotic Therapy Puzzle?. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 12, 14-20.	0.4	0
204	Stroke and Bleeding Risk in Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2014, 44, 281.	0.7	32
205	Burden of disease from atrial fibrillation in adults from seven countries in Latin America. <i>International Journal of General Medicine</i> , 2014, 7, 441.	0.8	27
206	Serum Potassium Levels Inversely Correlate with D-Dimer In Patients with Acute-Onset Atrial Fibrillation. <i>Arquivos Brasileiros De Cardiologia</i> , 2014, 104, 181-4.	0.3	4
207	Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation. <i>Cardiovascular and Hematological Agents in Medicinal Chemistry</i> , 2014, 12, 3-8.	0.4	19
208	Comparison of the clinical features and outcomes in two age-groups of elderly patients with atrial fibrillation. <i>Clinical Interventions in Aging</i> , 2014, 9, 1335.	1.3	9
209	Contact force mapping during catheter ablation for atrial fibrillation: procedural data and one-year follow-up. <i>Archives of Medical Science</i> , 2014, 2, 266-272.	0.4	31
210	A survey on the treatment of atrial fibrillation in South Africa. <i>South African Medical Journal</i> , 2014, 104, 623.	0.2	11
211	Patient's values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. <i>Thrombosis and Haemostasis</i> , 2014, 112, 381-383.	1.8	64
212	Left Atrial Appendage Percutaneous Closure with Watchman Device: Single Centre Experience and a Review of Literature. <i>Angiology: Open Access</i> , 2014, 02, .	0.1	0
213	CARDIAC SURGERY Truly low and high thromboembolic risk – impact of risk scores in real life. <i>Kardiochirurgia I Torakochirurgia Polska</i> , 2014, 1, 1-6.	0.1	3
214	COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 275-282.	0.3	2
215	ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE. <i>Rational Pharmacotherapy in Cardiology</i> , 2014, 10, 328-333.	0.3	7
216	Editorial Percutaneous elimination of the left atrial appendage in quest for effective and safe prevention of stroke in patients with atrial fibrillation. <i>Postepy W Kardiologii Interwencyjnej</i> , 2014, 2, 71-74.	0.1	2
219	Massive haemoptysis following dabigatran administration in a patient with bronchiectasis. <i>BMJ Case Reports</i> , 2014, 2014, bcr2013201001-bcr2013201001.	0.2	2

#	ARTICLE	IF	CITATIONS
220	Practical Management of Stroke Prevention in Patients with Atrial Fibrillation and Renal Impairment Receiving Newer Oral Anticoagulants: Focus on Rivaroxaban. <i>Journal of General Practice (Los Angeles)</i> , 2014, 63, 107-110.	0.0	10
221	High Prevalence of Atrial Fibrillation Among Patients With Ischemic Stroke. <i>Stroke</i> , 2014, 45, 2599-2605.	1.0	239
222	Surgical treatment of atrial fibrillation: an updated review. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 167-178.	0.6	30
223	Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. <i>Family Practice</i> , 2014, 31, 298-302.	0.8	19
224	Prevalence of Atrial Fibrillation in Patients with High CHADS ₂ and CHA ₂ DS ₂ -VASc Scores: Anticoagulate or Monitor High-Risk Patients?. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1651-1657.	0.5	33
225	Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden. <i>Thrombosis Journal</i> , 2014, 12, 29.	0.9	15
227	Atrial fibrillation patients do not benefit from acetylsalicylic acid. <i>Europace</i> , 2014, 16, 631-638.	0.7	73
228	Comparison of CHADS ₂ and CHA ₂ DS ₂ -VASc anticoagulation recommendations: evaluation in a cohort of atrial fibrillation ablation patients. <i>Europace</i> , 2014, 16, 195-201.	0.7	11
229	Updated NICE guideline: management of atrial fibrillation (2014). <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 1037-1040.	0.6	32
230	CHADS ₂ and CHA ₂ DS ₂ -VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study. <i>Hypertension Research</i> , 2014, 37, 463-466.	1.5	16
231	Current periprocedural management of ablation for atrial fibrillation in Europe: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 378-381.	0.7	21
232	Edoxaban: a new oral direct factor Xa inhibitor for the prevention and treatment of thromboembolic disorders. <i>Clinical Investigation</i> , 2014, 4, 619-639.	0.0	2
233	Warfarin Use and the Risk for Stroke and Bleeding in Patients With Atrial Fibrillation Undergoing Dialysis. <i>Circulation</i> , 2014, 129, 1196-1203.	1.6	296
234	Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the Qbleed scores. <i>BMJ</i> , 2014, 349, g4606-g4606.	3.0	65
235	Dabigatran in Secondary Stroke Prevention: Clinical Experience with 106 Patients. <i>BioMed Research International</i> , 2014, 2014, 1-6.	0.9	5
236	Characterization of patients with atrial fibrillation not treated with oral anticoagulants. <i>Scandinavian Journal of Primary Health Care</i> , 2014, 32, 226-231.	0.6	23
237	Use of MRI for Risk Stratification in Anticoagulation Decision Making in Atrial Fibrillation: Promising, but More Data are Needed for a Robust Algorithm. <i>Frontiers in Neurology</i> , 2014, 5, 3.	1.1	6
238	Management of Non-Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting. <i>BioMed Research International</i> , 2014, 2014, 1-16.	0.9	23

#	ARTICLE	IF	CITATIONS
239	Development of a Tool to Identify Patients' Preference for Vitamin K Antagonist or Direct Oral Anticoagulant Therapy. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 121-128.	1.5	18
240	Prevention of Stroke in Patients With Atrial Fibrillation. , 2014, , 1129-1137.		0
241	Race against the clock: Overcoming challenges in the management of anticoagulant-associated intracerebral hemorrhage. <i>Journal of Neurosurgery</i> , 2014, 121, 1-20.	0.9	40
242	Current approaches in atrial fibrillation treatment. <i>Dicle Medical Journal</i> , 2014, 41, 614-622.	0.2	1
243	Catheter-tissue contact force for pulmonary veins isolation: a pilot multicentre study on effect on procedure and fluoroscopy time. <i>Europace</i> , 2014, 16, 335-340.	0.7	55
244	'Preferred' management of atrial fibrillation in Europe. <i>Europace</i> , 2014, 16, 1-3.	0.7	38
245	Dronedaron: an alternate choice to sotalol and amiodarone in the treatment of atrial fibrillation/flutter in patients who have coronary heart disease. <i>Europace</i> , 2014, 16, 153-155.	0.7	0
246	Low incidence of permanent complications during catheter ablation for atrial fibrillation using open-irrigated catheters: a multicentre registry. <i>Europace</i> , 2014, 16, 1154-1159.	0.7	29
247	Second-generation cryoballoon ablation for paroxysmal atrial fibrillation: a step forward?. <i>Europace</i> , 2014, 16, 621-622.	0.7	7
248	Application of a Conceptual Framework for the Modelling and Execution of Clinical Guidelines as Networks of Concurrent Processes. <i>Procedia Computer Science</i> , 2014, 35, 671-680.	1.2	6
249	Relation of Nonsteroidal Anti-inflammatory Drugs to Serious Bleeding and Thromboembolism Risk in Patients With Atrial Fibrillation Receiving Antithrombotic Therapy. <i>Annals of Internal Medicine</i> , 2014, 161, 690.	2.0	81
250	The European Heart Rhythm Association symptom classification for atrial fibrillation: validation and improvement through a simple modification. <i>Europace</i> , 2014, 16, 965-972.	0.7	161
251	Non-invasive evaluation of the effect of metoprolol on the atrioventricular node during permanent atrial fibrillation. <i>Europace</i> , 2014, 16, iv129-iv134.	0.7	7
252	Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage. <i>Neurology</i> , 2014, 82, 135-138.	1.5	58
254	Atrial fibrillation and stroke prevention: brief observations on the last decade. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 403-406.	0.6	13
255	Effects of human atrial ionic remodelling by \hat{I}^2 -blocker therapy on mechanisms of atrial fibrillation: a computer simulation. <i>Europace</i> , 2014, 16, 1524-1533.	0.7	21
256	Dabigatran for Stroke Prevention in Nonvalvular Atrial Fibrillation: Focus in the Geriatric Population. <i>The Consultant Pharmacist</i> , 2014, 29, 169-178.	0.4	5
258	Author reply. <i>Europace</i> , 2014, 16, 151-152.	0.7	2

#	ARTICLE	IF	CITATIONS
260	Increased risk of atrial fibrillation and stroke during active stages of inflammatory bowel disease: a nationwide study. <i>Europace</i> , 2014, 16, 477-484.	0.7	107
261	Prognosis and treatment of atrial fibrillation patients by European cardiologists: One Year Follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF) Tj ETQq1 1 0.0784314293T /O	0.7	107
262	Platelet Activation After Radiofrequency Ablation in Atrial Fibrillation. <i>Circulation</i> , 2014, 129, 5-7.	1.6	3
263	History of Atrial Fibrillation as a Risk Factor in Patients With Heart Failure and Preserved Ejection Fraction. <i>Circulation: Heart Failure</i> , 2014, 7, 960-966.	1.6	35
264	Left Atrial Appendage Occlusion Addresses the Tremendous Unmet Needs of Stroke Prevention in Atrial Fibrillation That Persist Despite Recent Advances in Anticoagulation Therapy. <i>Circulation</i> , 2014, 130, 1516-1523.	1.6	8
265	Prevalência da anticoagulação oral em doentes com fibrilhação auricular em Portugal: revisão sistemática e meta-análise de estudos observacionais. <i>Revista Portuguesa De Cardiologia</i> , 2014, 33, 555-560.	0.2	16
266	Visually guided laser ablation: a single-centre long-term experience. <i>Europace</i> , 2014, 16, 1746-1751.	0.7	41
267	Evolution of the complex permittivity of biological tissue at microwaves ranges: Correlation study with burn depth. , 2014, 2014, 4054-7.		3
268	Practical Considerations for Using Novel Oral Anticoagulants in Patients With Atrial Fibrillation. <i>Clinical Cardiology</i> , 2014, 37, 32-47.	0.7	72
269	Unmasking a naked left atrial appendage closure device: A case of a silent embolic threat. <i>Heart Rhythm</i> , 2014, 11, 2314-2315.	0.3	6
270	Differences of two cryoballoon generations: insights from the prospective multicentre, multinational FREEZE Cohort Substudy. <i>Europace</i> , 2014, 16, 1434-1442.	0.7	50
271	Comparative Safety of Periablation Anticoagulation Strategies for Atrial Fibrillation: Data from a Large Multicenter Study. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 665-673.	0.5	31
272	The Influence of Gender on Heart Rhythm Disease. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 650-657.	0.5	9
273	Work-up and management of lone atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 1521-1523.	0.7	12
274	The Left Atrial Appendage: Anatomy, Function, and Noninvasive Evaluation. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 1251-1265.	2.3	377
275	Fluoroscopy-free recrossing of the interatrial septum during left atrial ablation procedures. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 41, 261-266.	0.6	6
278	Atrial fibrillation in patients with haemophilia: a cross-sectional evaluation in Europe. <i>Haemophilia</i> , 2014, 20, 682-686.	1.0	36
279	Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines. <i>Europace</i> , 2014, 16, 162-173.	0.7	64

#	ARTICLE	IF	CITATIONS
282	Electrophysiological study 6 months after Epicorâ„¢ high-intensity focused ultrasound atrial fibrillation ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 41, 245-251.	0.6	8
283	Anticoagulant treatment in German family practices â€“ screening results from a cluster randomized controlled trial. <i>BMC Family Practice</i> , 2014, 15, 170.	2.9	12
284	Validation and clinical use of a novel diagnostic device for screening of atrial fibrillation. <i>Europace</i> , 2014, 16, 1291-1295.	0.7	115
285	Peripheral pulse measurement after ischemic stroke. <i>Neurology</i> , 2014, 83, 598-603.	1.5	18
286	Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 873-879.	0.6	36
287	CHA2DS2-VASc in the prediction of early atrial fibrillation relapses after electrical or pharmacological cardioversion. <i>Journal of Cardiovascular Medicine</i> , 2014, 15, 636-641.	0.6	13
288	Atrial fibrillation and coronary artery disease. <i>Current Opinion in Cardiology</i> , 2014, 29, 595-600.	0.8	0
289	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD â€“ Summary. <i>Diabetes and Vascular Disease Research</i> , 2014, 11, 133-173.	0.9	173
290	Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. <i>Thrombosis and Haemostasis</i> , 2014, 112, 781-782.	1.8	142
291	Brain MRI to personalise atrial fibrillation therapy: current evidence and perspectives. <i>Heart</i> , 2014, 100, 1408-1413.	1.2	32
292	Safe use of antithrombotics for stroke prevention in atrial fibrillation: consideration of risk assessment tools to support decision-making. <i>Therapeutic Advances in Drug Safety</i> , 2014, 5, 21-37.	1.0	13
294	Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and Allâ€“Cause Mortality: A Systematic Review and Metaâ€“analysis of Randomized Controlled Trials. <i>Journal of the American Heart Association</i> , 2014, 3, e000515.	1.6	85
295	Pulmonary vein isolation using a circular, open irrigated mapping and ablation catheter (nMARQ): a report on feasibility and efficacy. <i>Europace</i> , 2014, 16, 1296-1303.	0.7	42
296	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <i>Europace</i> , 2014, 16, 1397-1416.	0.7	259
297	Current perspectives on cardioembolic ischemic stroke in very old patients. <i>Research Reports in Clinical Cardiology</i> , 0, , 1.	0.2	1
298	The CHA2DS2-VASc Score as a Predictor of Left Atrial Thrombus in Patients with Non-Valvular Atrial Fibrillation. <i>Medical Principles and Practice</i> , 2014, 23, 234-238.	1.1	23
299	Plasma CX₃CL1 Levels and Long Term Outcomes of Patients with Atrial Fibrillation: The West Birmingham Atrial Fibrillation Project. <i>Cerebrovascular Diseases</i> , 2014, 38, 204-211.	0.8	11
300	Refinement of Ischemic Stroke Risk in Patients with Atrial Fibrillation and CHA₂DS₂-VASc Score of 1. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1442-1447.	0.5	48

#	ARTICLE	IF	CITATIONS
301	Comparison of Different Approaches to Atrioventricular Junction Ablation and Pacemaker Implantation in Patients with Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2014, 37, 1686-1693.	0.5	5
302	Assessment of clinical factors associated with a successful catheter ablation outcome in younger patients with atrial fibrillation. <i>Journal of Cardiology</i> , 2014, 63, 438-443.	0.8	9
303	Cryoballoon Ablation in Young Patients With Lone Paroxysmal Atrial Fibrillation. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 558-563.	0.4	3
304	Usefulness of a Low CHADS2 or CHA2DS2-VASc Score to Predict Normal Diagnostic Testing in Emergency Department Patients With an Acute Exacerbation of Previously Diagnosed Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 113, 1668-1673.	0.7	2
305	Type 1 Brugada pattern exacerbation and 1:1 atrioventricular conduction induced by vernakalant. <i>Heart Rhythm</i> , 2014, 11, 895-897.	0.3	6
306	Treatment failure of low molecular weight heparin bridging therapy in atrial fibrillation after acute coronary syndrome. <i>International Journal of Cardiology</i> , 2014, 171, 289-291.	0.8	3
307	Net clinical benefit outcome should be standardized in trials evaluating antithrombotic drugs: The example of NOACs in atrial fibrillation. <i>International Journal of Cardiology</i> , 2014, 174, 405-406.	0.8	4
309	Direct Oral Anticoagulants in Atrial Fibrillation. <i>Seminars in Hematology</i> , 2014, 51, 139-146.	1.8	2
310	Left Atrial Appendage Closure with Transcatheter-Delivered Devices. <i>Interventional Cardiology Clinics</i> , 2014, 3, 209-218.	0.2	16
311	Radiotherapy and prevention of thrombosis in a patient with atrial fibrillation. <i>International Journal of Cardiology</i> , 2014, 173, e18-e19.	0.8	0
312	The quality of oral anticoagulation in general practice in patients with atrial fibrillation. <i>European Journal of Internal Medicine</i> , 2014, 25, 247-254.	1.0	30
313	CHADS 2 , CHA 2 DS 2 -VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. <i>Thrombosis Research</i> , 2014, 133, 560-566.	0.8	58
314	Use of anticoagulants for atrial fibrillation in older subjects across different countries: Cyprus, France, Netherlands, Norway. <i>European Geriatric Medicine</i> , 2014, 5, 60-65.	1.2	3
315	Use of the HAS-BLED bleeding score in real-life settings. <i>Thrombosis Research</i> , 2014, 134, 202.	0.8	2
316	Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?. <i>Europace</i> , 2014, 16, 619-620.	0.7	3
317	The young patient with asymptomatic atrial fibrillation: what is the evidence to leave the arrhythmia untreated?. <i>European Heart Journal</i> , 2014, 35, 1439-1447.	1.0	20
318	Atrial electromechanical delay in type 2 diabetes mellitus. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 101-105.	1.0	10
323	Left atrial mechanics predict the success of pulmonary vein isolation in patients with atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 53-62.	0.6	20

#	ARTICLE	IF	CITATIONS
325	Warfarin or novel oral anticoagulants for atrial fibrillation?. <i>Lancet</i> , The, 2014, 383, 931-933.	6.3	23
326	Joint British Societiesâ€™ consensus recommendations for the prevention of cardiovascular disease (JBS3). <i>Heart</i> , 2014, 100, ii1-ii67.	1.2	441
327	Improving Safety in Catheter Ablation for Atrial Fibrillation: A Prospective Study of the Use of Ultrasound to Guide Vascular Access. <i>Journal of Cardiovascular Electrophysiology</i> , 2014, 25, 680-685.	0.8	38
328	Vernakalant for the Conversion of Atrial Fibrillation: The New Kid On the Block?. , 2014, 19, 299-302.		2
329	First, Let's See Where We Stand. Then, Let's See How Far We Can or Want to Go. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 249-250.	0.4	0
330	Triple Antithrombotic Therapy: Risky but Sometimes Necessary. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2014, 67, 171-175.	0.4	3
331	GuÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃn con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.	0.6	15
332	Perioperative management of patients on new oral anticoagulants. <i>British Journal of Surgery</i> , 2014, 101, 742-749.	0.1	74
333	Biomarkers in atrial fibrillation: an overview. <i>International Journal of Clinical Practice</i> , 2014, 68, 434-443.	0.8	37
334	Lone atrial fibrillation - an overview. <i>International Journal of Clinical Practice</i> , 2014, 68, 418-433.	0.8	23
335	Management of acute coronary syndrome in patients with non-valvular atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2014, 16, 293-298.	0.7	32
336	A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 39-44.	1.0	11
337	Targeting Inflammation and Oxidative Stress in Atrial Fibrillation: Role of 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibition with Statins. <i>Antioxidants and Redox Signaling</i> , 2014, 20, 1268-1285.	2.5	85
338	â€Real-Worldâ€™ Antithrombotic Treatment in Atrial Fibrillation: The EORP-AF Pilot Survey. <i>American Journal of Medicine</i> , 2014, 127, 519-529.e1.	0.6	144
339	Antiplatelet Therapy for Stable Coronary Artery Disease in Atrial Fibrillation Patients Taking an Oral Anticoagulant. <i>Circulation</i> , 2014, 129, 1577-1585.	1.6	256
340	Surgical vs. transcatheter pulmonary vein isolation as first invasive treatment in patients with atrial fibrillation: a matched group comparison. <i>Europace</i> , 2014, 16, 33-39.	0.7	35
342	Electrophysiological profile of vernakalant in an experimental whole-heart model: the absence of proarrhythmia despite significant effect on myocardial repolarization. <i>Europace</i> , 2014, 16, 1240-1248.	0.7	18
343	Electrophysiological and haemodynamic effects of vernakalant and flecainide in dyssynchronous canine hearts. <i>Europace</i> , 2014, 16, 1249-1256.	0.7	8

#	ARTICLE	IF	CITATIONS
344	CHADS2 and CHA2DS2-VASc scores to predict morbidity and mortality in heart failure patients candidates to cardiac resynchronization therapy. <i>Europace</i> , 2014, 16, 71-80.	0.7	64
345	A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. <i>Europace</i> , 2014, 16, 308-319.	0.7	280
346	Prevalence of atrial fibrillation and its associated factors in Spain: An analysis of six population-based studies. DARIOS Study. <i>Revista Clínica Española</i> , 2014, 214, 505-512.	0.3	4
347	Atrial fibrillation: state of the art. <i>Wiener Klinische Wochenschrift</i> , 2014, 126, 692-704.	1.0	0
348	Atrial fibrillation â€¦ more than simply being irregularly irregular. <i>International Journal of Clinical Practice</i> , 2014, 68, 408-409.	0.8	0
349	Quantitative Analysis of Aortic Valve Stenosis and Aortic Root Dimensions by Three-Dimensional Echocardiography in Patients Scheduled for Transcatheter Aortic Valve Implantation. <i>Current Cardiovascular Imaging Reports</i> , 2014, 7, 929-6.	0.4	14
350	AF prognosis and treatmentâ€”the European perspective. <i>Nature Reviews Cardiology</i> , 2014, 11, 689-690.	6.1	0
351	New Biomarkers and Risk Stratification in Atrial Fibrillation. <i>Circulation</i> , 2014, 130, 1837-1839.	1.6	11
352	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 585-599.	0.9	7
353	Early cerebral thromboembolic complications after radiofrequency catheter ablation of atrial fibrillation: Incidence, characteristics, and risk factors. <i>Heart Rhythm</i> , 2014, 11, 1934-1940.	0.3	22
354	Left Atrial Appendage Exclusion for Atrial Fibrillation. <i>Cardiology Clinics</i> , 2014, 32, 601-625.	0.9	17
355	Pharmacokinetic and pharmacodynamic profile of dronedarone, a new antiarrhythmic agent for the treatment of atrial fibrillation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1751-1764.	1.5	12
356	Poststroke atrial fibrillation: Cause or consequence?. <i>Neurology</i> , 2014, 82, 1180-1186.	1.5	93
357	Cryoballoon ablation for atrial fibrillation. <i>Interventional Cardiology</i> , 2014, 6, 373-382.	0.0	1
358	A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. <i>Thrombosis Research</i> , 2014, 134, 1253-1264.	0.8	48
359	Late MitraClip procedure after left atrial appendage occlusion. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 83, 291-296.	0.7	0
360	Ranolazine enhances the efficacy of amiodarone for conversion of recent-onset atrial fibrillation. <i>Europace</i> , 2014, 16, 973-979.	0.7	62
361	Management of Recent-onset Sustained Atrial Fibrillation: Pharmacologic and Nonpharmacologic Strategies. <i>Clinical Therapeutics</i> , 2014, 36, 1151-1159.	1.1	10

#	ARTICLE	IF	CITATIONS
362	Enfermedades cardiovasculares, respiratorias y renales. <i>Medicine</i> , 2014, 11, 3677-3690.	0.0	0
363	Nuevos anticoagulantes orales en fibrilaci3n auricular valvular: ¿Hasta d3nde llegan?. <i>Cardiocre</i> , 2014, 49, 99-101.	0.0	1
364	Atrial Fibrillation: Antiarrhythmic Therapy. <i>Current Problems in Cardiology</i> , 2014, 39, 351-391.	1.1	6
365	Ischaemic stroke prevention in patients with atrial fibrillation and high bleeding risk: opportunities and challenges for percutaneous left atrial appendage occlusion. <i>Europace</i> , 2014, 16, 626-630.	0.7	34
367	Vernakalant in an Experimental Model of Pacing-Induced Heart Failure: Lack of Proarrhythmia Despite Prolongation of Repolarization. <i>Journal of Cardiac Failure</i> , 2014, 20, 786-792.	0.7	12
369	Cost-effectiveness of rivaroxaban for stroke prevention in atrial fibrillation in the Portuguese setting. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 535-544.	0.2	21
370	Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation. <i>Europace</i> , 2014, 16, 1137-1144.	0.7	79
372	The definition of valvular and non-valvular atrial fibrillation: results of a physicians' survey. <i>Europace</i> , 2014, 16, 1720-1725.	0.7	60
373	Percutaneous left atrial appendage occlusion for stroke prevention in atrial fibrillation: an update. <i>Open Heart</i> , 2014, 1, e000020.	0.9	52
374	When It Comes to Radiofrequency Catheter Ablation of Atrial Fibrillation, Have All of Our Wishes Been Granted?. <i>Journal of the American College of Cardiology</i> , 2014, 64, 657-659.	1.2	3
375	Oral Anticoagulant Use in Patients With Chronic Kidney Disease: How to Choose, and the Importance of Empiric Human Data. <i>Canadian Journal of Cardiology</i> , 2014, 30, 853-854.	0.8	2
376	Guías de la European Association for Cardiothoracic Surgery 2013 sobre el tratamiento quirúrgico de la fibrilaci3n auricular. <i>Cirugía Cardiovascular</i> , 2014, 21, 199-203.	0.1	0
377	Adherence to warfarin treatment among patients with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2014, 103, 998-1005.	1.5	47
378	Antiarrhythmic therapy of atrial fibrillation: are we treating too late?. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2014, 25, 210-213.	0.3	0
379	Stroke prevention in atrial fibrillation: Commentary regarding the AAN's evidence-based guideline update. <i>Neurology: Clinical Practice</i> , 2014, 4, 96-98.	0.8	3
380	Cardiac Potassium Channel Subtypes: New Roles in Repolarization and Arrhythmia. <i>Physiological Reviews</i> , 2014, 94, 609-653.	13.1	181
381	Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1541-1550.	1.2	84
382	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. <i>European Heart Journal</i> , 2014, 35, 3155-3179.	1.0	490

#	ARTICLE	IF	CITATIONS
385	Potential use of NOACs in developing countries: pros and cons. <i>European Journal of Clinical Pharmacology</i> , 2014, 70, 817-828.	0.8	14
386	Remote magnetic navigation for circumferential pulmonary vein ablation: single-catheter technique or additional use of a circular mapping catheter?. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 41, 65-73.	0.6	4
387	Comment "Évaluer le risque ischémique et hémorragique cérébral dans la fibrillation atriale ? Place des approches morphologiques et biologiques. <i>Archives of Cardiovascular Diseases Supplements</i> , 2014, 6, 120-131.	0.0	0
388	Stroke and bleeding risk evaluation in atrial fibrillation: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2014, 16, 698-702.	0.7	7
389	Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2014, 40, 277-284.	0.6	48
390	Left Atrial Appendage Exclusion for Prevention of Stroke in Atrial Fibrillation: Review of Minimally Invasive Approaches. <i>Current Cardiology Reports</i> , 2014, 16, 448.	1.3	15
391	Practical introduction of novel oral anticoagulants through an anticoagulation nurse. The Leeuwarden model. <i>Netherlands Heart Journal</i> , 2014, 22, 297-300.	0.3	3
392	Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation. <i>Pharmacoeconomics</i> , 2014, 32, 601-612.	1.7	43
393	Cryptogenic Stroke and Underlying Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2014, 370, 2478-2486.	13.9	1,694
394	Depression in paroxysmal and persistent atrial fibrillation patients: a cross-sectional comparison of patients enrolled in two large clinical trials. <i>Europace</i> , 2014, 16, 812-819.	0.7	45
395	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>Europace</i> , 2014, 16, 1655-1673.	0.7	105
396	Additional benefit of cryoballoon-based atrial fibrillation ablation beyond pulmonary vein isolation: modification of ganglionated plexi. <i>Europace</i> , 2014, 16, 645-651.	0.7	54
397	External Validity of the ARISTOTLE Trial in Real-Life Atrial Fibrillation Patients. <i>Cardiovascular Therapeutics</i> , 2014, 32, 214-218.	1.1	15
398	Screening for atrial fibrillation in patients with obstructive sleep apnoea to reduce ischaemic strokes. <i>International Journal of Cardiology</i> , 2014, 172, 297-298.	0.8	11
399	The use of direct oral anticoagulants for stroke prevention in atrial fibrillation: A study on physicians' perspective and preferences. <i>International Journal of Cardiology</i> , 2014, 175, 188-191.	0.8	8
400	Prevalence of patent foramen ovale in atrial fibrillation patients with history of cerebral ischemia: A stand-alone additional risk?. <i>International Journal of Cardiology</i> , 2014, 172, e290-e291.	0.8	3
401	Dronedarone. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2385-2387.	1.2	3
402	The Impact of Early Detection of Atrial Fibrillation on Stroke Outcomes. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 125-132.	0.7	0

#	ARTICLE	IF	CITATIONS
403	Rapid slowing of the atrial fibrillatory rate after administration of AZD7009 predicts conversion of atrial fibrillation. <i>Journal of Electrocardiology</i> , 2014, 47, 316-323.	0.4	7
405	Can Silent Brain Lesions Be a Target to Guide Anticoagulation Treatment in Patients With Low-Risk Atrial Fibrillation to Reduce Cognitive Impairment?. <i>Journal of the American College of Cardiology</i> , 2014, 63, 2174-2175.	1.2	3
406	HRS Expert Consensus Statement on the Diagnosis and Management of Arrhythmias Associated With Cardiac Sarcoidosis. <i>Heart Rhythm</i> , 2014, 11, 1304-1323.	0.3	1,077
407	Distribution of electrical reconnection after pulmonary vein isolation using a duty-cycled radiofrequency circular ablation catheter. <i>Cor Et Vasa</i> , 2014, 56, e11-e18.	0.1	0
408	Clinical significance of atrial fibrillation detected by cardiac implantable electronic devices. <i>Heart Rhythm</i> , 2014, 11, 719-724.	0.3	30
409	Current status and future catheter ablation strategies in atrial fibrillation. <i>Cor Et Vasa</i> , 2014, 56, e19-e26.	0.1	4
411	A quality study to improve prophylactic antithrombotic therapy prescribed to patients with atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2014, 33, 89-94.	0.2	4
412	Stroke and Bleeding Risks in Patients with Atrial Fibrillation. <i>Interventional Cardiology Clinics</i> , 2014, 3, 175-190.	0.2	0
413	Nationwide survey of catheter ablation for atrial fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (Jâ€‘CARAF) â€‘ Report on antiarrhythmic drug therapy. <i>Journal of Arrhythmia</i> , 2014, 30, 362-366.	0.5	4
414	Clinical Results with Percutaneous Left Atrial Appendage Occlusion. <i>Interventional Cardiology Clinics</i> , 2014, 3, 291-300.	0.2	0
415	Common Questions in Anticoagulation Management in Atrial Fibrillation. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 79-86.	0.7	1
417	Managing Novel Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Device Surgery: Canadian Survey. <i>Canadian Journal of Cardiology</i> , 2014, 30, 231-236.	0.8	35
418	Tratamiento antitrombÃ³tico combinado triple: arriesgado pero aÂ‘ veces necesario. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 171-175.	0.6	8
419	Software-based detection of atrial fibrillation in long-term ECGs. <i>Heart Rhythm</i> , 2014, 11, 933-938.	0.3	17
420	Vascular response after percutaneous sympathectomy: Not all devices are equal. <i>International Journal of Cardiology</i> , 2014, 174, 406-407.	0.8	9
421	Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2014, 114, 577-582.	0.7	45
422	Coronary embolization following electrical cardioversion in a patient treated with dabigatran. <i>International Journal of Cardiology</i> , 2014, 175, 571-572.	0.8	6
423	Mechanical closure devices for atrial fibrillation. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 225-231.	2.3	2

#	ARTICLE	IF	CITATIONS
424	Possible limitations of using the HAS-BLED bleeding score in real life settings. <i>Thrombosis Research</i> , 2014, 133, 959-960.	0.8	3
425	SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. <i>American Journal of Medicine</i> , 2014, 127, 1083-1088.	0.6	112
426	Anticoagulant therapy is prescribed less often in paroxysmal atrial fibrillation regardless of thromboembolic risk: Results from the Registry of Atrial Fibrillation To Investigate New Guidelines (RAFTING). <i>International Journal of Cardiology</i> , 2014, 175, 569-570.	0.8	3
427	MY APPROACH to the use of NOACs for stroke prevention in patients with atrial fibrillation*. <i>Trends in Cardiovascular Medicine</i> , 2014, 24, 265-266.	2.3	2
428	Cerebrovascular Complications Related to Atrial Fibrillation Ablation and Strategies for Periprocedural Stroke Prevention. <i>Cardiac Electrophysiology Clinics</i> , 2014, 6, 111-123.	0.7	5
430	Prevention and treatment of venous thromboembolism: the nurse's role in management. <i>British Journal of Cardiac Nursing</i> , 2014, 9, 534-540.	0.0	2
432	Interventional Closure of the Left Atrial Appendage for Stroke Prevention. <i>Circulation Journal</i> , 2014, 78, 619-624.	0.7	23
433	Nationwide Survey of Catheter Ablation for Atrial Fibrillation: The Japanese Catheter Ablation Registry of Atrial Fibrillation (J-CARAF). <i>Circulation Journal</i> , 2014, 78, 1091-1096.	0.7	32
434	Stroke and Bleeding Risk in Atrial Fibrillation: Navigating the Alphabet Soup of Risk Score Acronyms (CHADS ₂ , CHA ₂ DS ₂ -VASc, R ₂ CHADS ₂), Tj ETQq000 rgB15/Overlock	0.0	0
435	Unusual Case of a Free-floating Ball Thrombus with Preserved Attachment to the Left Atrial Appendage Causing Recurrent Obstruction of the Left Ventricular Outflow Tract. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8s2, CMC.S18547.	0.6	1
436	Left Atrial Appendage Closure Devices. <i>Clinical Medicine Insights: Cardiology</i> , 2014, 8, CMC.S14043.	0.6	18
437	The role of valvular regurgitation in catheter ablation outcomes of patients with long-standing persistent atrial fibrillation. <i>Europace</i> , 2014, 16, 848-854.	0.7	30
438	Improved lesion formation using the novel 28 mm cryoballoon in atrial fibrillation ablation: analysis of biomarker release. <i>Europace</i> , 2014, 16, 987-993.	0.7	33
439	Stroke/Thromboembolism and Intracranial Hemorrhage in a Real-world Atrial Fibrillation Population. <i>Chest</i> , 2014, 146, 1073-1080.	0.4	7
440	Assessment of Burn Depths on Organs by Microwave. <i>Procedia Engineering</i> , 2014, 87, 308-311.	1.2	6
442	The Value of the European Society of Cardiology Guidelines for Refining Stroke Risk Stratification in Patients With Atrial Fibrillation Categorized as Low Risk Using the Anticoagulation and Risk Factors in Atrial Fibrillation Stroke Score. <i>Chest</i> , 2014, 146, 1337-1346.	0.4	34
443	Comment on "Stroke Prevention in Atrial Fibrillation: A Systematic Review". <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 509-510.	0.2	0
444	Trends in Oral Anticoagulant Choice for Acute Stroke Patients with Nonvalvular Atrial Fibrillation in Japan: The SAMURAI-NVAF Study. <i>International Journal of Stroke</i> , 2015, 10, 836-842.	2.9	100

#	ARTICLE	IF	CITATIONS
445	Atrial fibrillation, CHA2DS2-VASc score, antithrombotics and risk of non-traffic-, non-cancer-related bone fractures: A population-based cohort study. <i>European Journal of Internal Medicine</i> , 2015, 26, 798-806.	1.0	8
446	Incidence of thromboembolism following detection by trans-oesophageal echocardiography of left atrial thrombus. <i>IJC Heart and Vasculature</i> , 2015, 8, 95-97.	0.6	2
447	Oral anticoagulation in patients with atrial fibrillation and chronic kidney disease. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 480.	0.1	0
448	Comentário a «A prevenção do AVC em fibrilhação auricular» uma revisão sistemática». <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 509-510.	0.2	0
449	Does novel oral anticoagulant improve anticoagulation for non-valvular atrial fibrillation associated stroke: An inpatient registration study in Shanghai. <i>Chronic Diseases and Translational Medicine</i> , 2015, 1, 203-209.	0.9	2
450	Satisfacción con el cuidado médico de pacientes con fibrilación auricular anticoagulados con antagonistas de la vitamina K o nuevos anticoagulantes. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 537-539.	0.6	10
451	APOLLO I: Anticoagulation control in atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English)</i> Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.2	3
453	Dabigatran for left ventricular thrombus. <i>Indian Heart Journal</i> , 2015, 67, 495-496.	0.2	24
454	Antithrombotic treatment in elderly patients with atrial fibrillation: a practical approach. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 143.	0.7	56
455	The future of left atrial appendage occlusions: When extraordinary claims require evidence». <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 613-616.	0.7	4
456	Measurement of Non-Vitamin K Antagonist Oral Anticoagulants in Patient Plasma Using Heptest-STAT Coagulation Method. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 375-380.	1.0	8
457	Role of cardiovascular magnetic resonance in the guidelines of the European Society of Cardiology. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2016, 18, 6.	1.6	125
458	Automatic detection of atrial fibrillation using MEMS accelerometer. , 2015, , .		10
459	Age-Related Differences in Presentation, Treatment, and Outcome of Patients With Atrial Fibrillation in Europe. <i>JACC: Clinical Electrophysiology</i> , 2015, 1, 326-334.	1.3	52
460	2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview: A professional societal overview from the American College of Cardiology, Heart Rhythm Society, and Society for Cardiovascular Angiography and Interventions. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 791-807.	0.7	34
461	The Value of Magnetic Resonance Imaging in Catheter Ablation of Atrial Fibrillation. <i>Clinical Cardiology</i> , 2015, 38, 190-194.	0.7	4
462	Benefit of Anticoagulation Therapy in Hyperthyroidism-Related Atrial Fibrillation. <i>Clinical Cardiology</i> , 2015, 38, 476-482.	0.7	24
463	Assessing Bleeding Risk With the HAS-BLED Score: Balancing Simplicity, Practicality, and Predictive Value in Bleeding Risk Assessment. <i>Clinical Cardiology</i> , 2015, 38, 562-564.	0.7	14

#	ARTICLE	IF	CITATIONS
464	Prediction of thromboembolic risk in patients with hypertrophic cardiomyopathy (<sc>HCM</sc>) Tj ETQq0 0.0rgBT /Overlock 10	2.98	114
465	Feasibility of Extended Ambulatory Electrocardiogram Monitoring to Identify Silent Atrial Fibrillation in High-risk Patients: The Screening Study for Undiagnosed Atrial Fibrillation (<sc>STUDYâ€AF</sc>). Clinical Cardiology, 2015, 38, 285-292.	0.7	86
466	Antithrombotic Regimens for Patients Taking Oral Anticoagulation After Coronary Intervention: A Meta-analysis of 16 Clinical Trials and 9185 Patients. Clinical Cardiology, 2015, 38, 499-509.	0.7	25
467	Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation and Associated Intracranial Hemorrhage: A Focused Review. Clinical Cardiology, 2015, 38, 684-691.	0.7	6
468	The <sc>HAS-BLED</sc> Score for Predicting Major Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: A Systematic Review and Meta-analysis. Clinical Cardiology, 2015, 38, 555-561.	0.7	141
469	Optimising stroke prevention in patients with atrial fibrillation. British Journal of General Practice, 2015, 65, 117-117.	0.7	3
470	Effect of catheter ablation versus antiarrhythmic drugs on atrial fibrillation: A meta-analysis of randomized controlled trials. Experimental and Therapeutic Medicine, 2015, 10, 816-822.	0.8	39
471	Is Low Body Weight a Novel Risk Factor for Thromboembolic Events in Patients With Non-Valvular Atrial Fibrillation?. Circulation Journal, 2015, 79, 960-961.	0.7	2
472	Reversal of Rivaroxaban-Induced Alterations on Hemostasis by Different Coagulation Factor Concentrates. Circulation Journal, 2015, 79, 331-338.	0.7	35
473	Catheter Ablation of Atrial Fibrillation and Thromboembolic Risk. Circulation Journal, 2015, 79, 444.	0.7	0
474	Left Atrial Function After Radiofrequency Catheter Ablation of Atrial Fibrillationâ€ Can Pre-Ablation Function Predict Contractile Improvement During Follow-up? â€. Circulation Journal, 2015, 79, 2576-2583.	0.7	4
475	Use of Oral Anticoagulants According to the Degree of Renal Impairment in Japanese Patients With Atrial Fibrillationâ€ Which Non-Vitamin K Antagonist Oral Anticoagulant to Select? â€. Circulation Journal, 2015, 79, 1441-1443.	0.7	1
476	New Modified CHA₂DS₂-VA Scoring System for Japanese Patients With Non-Valvular Atrial Fibrillation. Circulation Journal, 2015, 79, 1682-1684.	0.7	2
477	Silent Atrial Fibrillation: Definition, Clarification, and Unanswered Issues. Annals of Noninvasive Electrocardiology, 2015, 20, 518-525.	0.5	19
479	The Risk/Benefit Analysis of Oral Anticoagulant Treatment in Atrial Fibrillation Using HAS-BLED and CHA2DS2-VASc Score. Acta Marisiensis - Seria Medica, 2015, 61, 269-272.	0.3	0
480	Understanding the cellular mode of action of vernakalant using a computational model: answers and new questions. Current Directions in Biomedical Engineering, 2015, 1, 418-422.	0.2	3
481	Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation. Chest, 2015, 148, 491-498.	0.4	9
483	A review of novel oral anticoagulants in the prevention of stroke for non-valvular atrial fibrillation. British Journal of Neuroscience Nursing, 2015, 11, 279-285.	0.1	0

#	ARTICLE	IF	CITATIONS
484	Managing patients or managing the results of ancillary tests?. , 0, , 244-258.		0
485	Rotational method simplifies 3-dimensional measurement of left atrial appendage dimensions during transesophageal echocardiography. Cardiovascular Ultrasound, 2015, 14, 36.	0.5	9
486	Dronedarone does not affect infarct volume as assessed by magnetic resonance imaging in a porcine model of myocardial infarction. Molecular Medicine Reports, 2015, 12, 5169-5178.	1.1	1
487	Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. British Journal of General Practice, 2015, 65, e16-e23.	0.7	37
488	Rhabdomyolysis complicating percutaneous radiofrequency ablation of persistent atrial fibrillation. HeartRhythm Case Reports, 2015, 1, 169-171.	0.2	0
489	Robotic Ablation of Atrial Fibrillation. Journal of Visualized Experiments, 2015, , e52560.	0.2	8
491	Percutaneous left atrial appendage closure in AF using Amplatzer Cardiac Plug: First single center experience from India. Indian Heart Journal, 2015, 67, S35-S39.	0.2	0
492	Persistence of non-vitamin K antagonist oral anticoagulant use in Japanese patients with atrial fibrillation: A single-center observational study. Journal of Arrhythmia, 2015, 31, 339-344.	0.5	45
493	Performance of the "CCS Algorithm" in real world patients. IJC Heart and Vasculature, 2015, 7, 18-21.	0.6	0
494	2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation. Revista Espanola De Cardiologia (English Ed), 2015, 68, 1125.	0.4	57
495	Race/Ethnicity in Atrial Fibrillation Stroke: Epidemiology and Pharmacotherapy. Journal of the National Medical Association, 2015, 107, 59-67.	0.6	1
496	"To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists". Internal and Emergency Medicine, 2015, 10, 765-767.	1.0	0
497	Stroke prevention in atrial fibrillation: Where are we now?. Indian Heart Journal, 2015, 67, S1-S3.	0.2	1
498	Systematic review and network meta-analysis of the relative efficacy and safety of edoxaban versus other nonvitamin K antagonist oral anticoagulants among patients with nonvalvular atrial fibrillation and CHADS ₂ score. SAGE Open Medicine, 2015, 3, 205031211561335.	0.7	13
499	Interventional Echocardiography: Current Role and Progress. Proceedings of Singapore Healthcare, 2015, 24, 4-15.	0.2	2
500	HEart and BRain interfaces in Acute ischemic Stroke (HEBRAS) " rationale and design of a prospective observational cohort study. BMC Neurology, 2015, 15, 213.	0.8	14
501	Implementation of non-vitamin K antagonist oral anticoagulants in daily practice: the need for comprehensive education for professionals and patients. Thrombosis Journal, 2015, 13, 22.	0.9	37
502	A case-based approach to implementing guidelines for stroke prevention in patients with atrial fibrillation: balancing the risks and benefits. Thrombosis Journal, 2015, 13, 29.	0.9	1

#	ARTICLE	IF	CITATIONS
503	Incident atrial fibrillation in the emergency department in Ontario: a population-based retrospective cohort study of follow-up care. <i>CMAJ Open</i> , 2015, 3, E182-E191.	1.1	12
504	Contraindications to Anticoagulation Therapy and Eligibility for Novel Anticoagulants in Older Patients with Atrial Fibrillation. <i>Cardiovascular Therapeutics</i> , 2015, 33, 177-183.	1.1	67
505	Primary Persistent Atrial Fibrillation: A Distinct Arrhythmia Subentity of an Ablation Population. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 1289-1294.	0.8	15
506	Validation of the SAME-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists. <i>Thrombosis and Haemostasis</i> , 2015, 114, 695-701.	1.8	45
507	Catheter Ablation of Atrial Fibrillation Using Zero-Fluoroscopy Technique: A Randomized Trial. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 797-806.	0.5	107
508	Ablation of paroxysmal atrial fibrillation in 2015: radiofrequency or cryoenergy?. <i>Interventional Cardiology</i> , 2015, 7, 295-303.	0.0	0
509	Cardiac Autoantibody Levels Predict Recurrence Following Cryoballoon-Based Pulmonary Vein Isolation in Paroxysmal Atrial Fibrillation Patients. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 615-621.	0.8	13
510	Role of Outpatient Cardiac Rhythm Monitoring in Cryptogenic Stroke: A Systematic Review and Meta-Analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2015, 38, 1236-1245.	0.5	39
511	Novel oral anticoagulants in atrial fibrillation. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 512-519.	0.6	10
512	Do NOACs Improve Antithrombotic Therapy in Secondary Stroke Prevention in Nonvalvular Atrial Fibrillation?. <i>Medicine (United States)</i> , 2015, 94, e1627.	0.4	6
513	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>European Journal of Heart Failure</i> , 2015, 17, 848-874.	2.9	32
514	Increasing rate of atrial fibrillation from 2003 to 2011 in patients with ischaemic stroke: results from 55,551 patients in a nationwide registry. <i>European Journal of Neurology</i> , 2015, 22, 839-844.	1.7	8
515	Primary Versus Secondary Atrial Fibrillation: Is it Time for a Different Classification of Atrial Fibrillation?. <i>Journal of Cardiovascular Electrophysiology</i> , 2015, 26, 1295-1297.	0.8	1
516	Atrial Fibrillation: Mechanisms, Therapeutics, and Future Directions. , 2015, 5, 649-665.		96
517	Identifying Predictors of Cumulative Healthcare Costs in Incident Atrial Fibrillation: A Population-Based Study. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	15
518	Idarucizumab Improves Outcome in Murine Brain Hemorrhage Related to Dabigatran. <i>Annals of Neurology</i> , 2015, 78, 137-141.	2.8	31
519	Negative outcomes associated with medication in patients with chronic atrial fibrillation who present at the emergency department. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 452-460.	0.7	1
520	Acute embolic occlusion of the right common iliac artery after revision total hip arthroplasty treated with catheter-directed thrombolysis and balloon angioplasty: A case report. <i>SAGE Open Medical Case Reports</i> , 2015, 3, 2050313X1559483.	0.2	1

#	ARTICLE	IF	CITATIONS
521	Clinical utility of dabigatran in United Arab Emirates. Journal of King Abdulaziz University, Islamic Economics, 2015, 36, 1290-1298.	0.5	2
522	Transcatheter Closure of Atrial Septal Defects Improves Cardiac Remodeling and Function of Adult Patients with Permanent Atrial Fibrillation. Chinese Medical Journal, 2015, 128, 780-783.	0.9	4
523	The Need for a Coagulation Assay after Initiation of New Oral Anticoagulants in Patients with Renal		

#	ARTICLE	IF	CITATIONS
539	Stroke risk in atrial fibrillation: Do we anticoagulate CHADS2 or CHA2DS2-VASc ≥ 1 , or higher?. Thrombosis and Haemostasis, 2015, 113, 1165-1169.	1.8	52
540	Optimal Anticoagulation Strategy for Cardioversion in Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2015, 4, 44.	1.3	2
541	Epidemiology, diagnosis, and management of atrial fibrillation in women. International Journal of Women's Health, 2015, 7, 605.	1.1	28
542	Percutaneous closure of the left atrial appendage for secondary prevention of stroke in patients with atrial fibrillation and contraindications to chronic anticoagulant therapy. Postepy W Kardiologii Interwencyjnej, 2015, 1, 14-18.	0.1	2
543	An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation. Core Evidence, 2015, 10, 63.	4.7	2
544	Direct oral anticoagulants: key considerations for use to prevent stroke in patients with nonvalvular atrial fibrillation. Vascular Health and Risk Management, 2015, 11, 317.	1.0	11
545	CHADS2 and CHA2DS2-VASc Scoring Systems for Predicting Atrial Fibrillation following Cardiac Valve Surgery. PLoS ONE, 2015, 10, e0123858.	1.1	30
546	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants versus Vitamin K Antagonist Oral Anticoagulants in Patients Undergoing Radiofrequency Catheter Ablation of Atrial Fibrillation: A Meta-Analysis. PLoS ONE, 2015, 10, e0126512.	1.1	24
547	Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin: A Nationwide Cohort Study. PLoS ONE, 2015, 10, e0141377.	1.1	31
548	Aspirin Compared to Low Intensity Anticoagulation in Patients with Non-Valvular Atrial Fibrillation. A Systematic Review and Meta-Analysis. PLoS ONE, 2015, 10, e0142222.	1.1	9
549	Atrial Fibrillation and Chronic Kidney Disease in Hypertension: A Common and Dangerous Triad. Current Vascular Pharmacology, 2015, 13, 111-120.	0.8	8
550	Secondary stroke prevention: challenges and solutions. Vascular Health and Risk Management, 2015, 11, 437.	1.0	95
551	Helicobacter pylori infection in Chinese patients with atrial fibrillation. Clinical Interventions in Aging, 2015, 10, 813.	1.3	13
552	Atrial fibrillation in Sub-Saharan Africa: epidemiology, unmet needs, and treatment options. International Journal of General Medicine, 2015, 8, 231.	0.8	43
553	Atorvastatin Treatment for Atrial Fibrillation Reduces Serum High-Sensitivity C-Reactive Protein Levels. BioMed Research International, 2015, 2015, 1-10.	0.9	4
554	The Association between Job Strain and Atrial Fibrillation: Results from the Swedish WOLF Study. BioMed Research International, 2015, 2015, 1-7.	0.9	29
555	Surgical Left Atrial Appendage Exclusion Does Not Impair Left Atrial Contraction Function: A Pilot Study. BioMed Research International, 2015, 2015, 1-7.	0.9	17
556	Cierre percutáneo de la aurícula izquierda con dispositivo Watchman: opción para pacientes con fibrilación auricular y alto riesgo de sangrado por anticoagulación. Iatreia, 2015, 28, .	0.1	1

#	ARTICLE	IF	CITATIONS
557	Comparison of health-related quality of life among patients using novel oral anticoagulants or warfarin for non-valvular atrial fibrillation. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 474-481.	0.5	19
558	Estudo FATA: Prevalência de Fibrilhação Auricular e Terapêutica Antitrombótica nos Cuidados de Saúde de Primários de um Concelho do Norte de Portugal. <i>Acta Medica Portuguesa</i> , 2015, 28, 35-43.	0.2	12
559	Does diffuse irrigation result in improved radiofrequency catheter ablation? A prospective randomized study of right atrial typical flutter ablation. <i>Europace</i> , 2015, 17, 295-299.	0.7	6
560	Stroke Prevention in Atrial Fibrillation. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1950.	3.8	258
561	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. <i>Thrombosis Research</i> , 2015, 136, 69-75.	0.8	28
562	Preference for oral anticoagulation therapy for patients with atrial fibrillation in Europe in different clinical situations: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 819-824.	0.7	14
563	Use of Non-Vitamin K Antagonist Oral Anticoagulants in Special Patient Populations with Nonvalvular Atrial Fibrillation: A Review of the Literature and Application to Clinical Practice. <i>Drugs</i> , 2015, 75, 979-998.	4.9	10
564	Cardiac CT angiography for device surveillance after endovascular left atrial appendage closure. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1198-1206.	0.5	126
565	Evaluation of SAME-TT2R2 risk score for predicting the quality of anticoagulation control in a real-world cohort of patients with non-valvular atrial fibrillation on vitamin-K antagonists. <i>Europace</i> , 2015, 17, 711-717.	0.7	47
566	Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation. <i>American Journal of Cardiovascular Drugs</i> , 2015, 15, 323-335.	1.0	9
567	Drug persistence with rivaroxaban therapy in atrial fibrillation patients—results from the Dresden non-interventional oral anticoagulation registry. <i>Europace</i> , 2015, 17, 530-538.	0.7	127
568	Prevalence of atrial fibrillation and the HATCH score. <i>Herz</i> , 2015, 40, 803-808.	0.4	7
569	Comparison of contact force-guided procedure with non-contact force-guided procedure during left atrial mapping and pulmonary vein isolation: impact of contact force on recurrence of atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 861-870.	1.5	22
570	To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort. <i>Internal and Emergency Medicine</i> , 2015, 10, 795-804.	1.0	17
571	Antithrombotic treatment in elderly patients with atrial fibrillation. <i>Revista Clínica Española</i> , 2015, 215, 171-181.	0.3	3
572	Factors predisposing to ventricular proarrhythmia during antiarrhythmic drug therapy for atrial fibrillation in patients with structurally normal heart. <i>Heart Rhythm</i> , 2015, 12, 1490-1500.	0.3	14
573	Management and prognosis of atrial fibrillation in the diabetic patient. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 643-651.	0.6	17
574	Atrial fibrillation and female sex. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 795-801.	0.6	25

#	ARTICLE	IF	CITATIONS
575	Strategies to Incorporate Left Atrial Appendage Occlusion Into Clinical Practice. <i>Journal of the American College of Cardiology</i> , 2015, 65, 2337-2344.	1.2	11
577	Novel nonpharmacologic approaches for stroke prevention in atrial fibrillation: results from clinical trials. <i>Medical Devices: Evidence and Research</i> , 2015, 8, 103.	0.4	7
578	Relationship Between Tei Index and PEP-Derived Myocardial Performance Index in Sinus Rhythm. <i>Medicine (United States)</i> , 2015, 94, e1112.	0.4	6
579	Comparison between CHA2DS2-VASc and the new R2CHADS2 and ATRIA scores at predicting thromboembolic event in non-anticoagulated and anticoagulated patients with non-valvular atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2015, 15, 156.	0.7	20
580	CE. <i>American Journal of Nursing</i> , 2015, 115, 32-42.	0.2	2
581	Role of Calcium-activated Potassium Channels in Atrial Fibrillation Pathophysiology and Therapy. <i>Journal of Cardiovascular Pharmacology</i> , 2015, 66, 441-448.	0.8	35
582	Teager energy based approach to detect atrial peaks to predict atrial fibrillation recurrence. , 2015, , .		1
583	Comparison of non-vitamin K antagonist oral anticoagulants and warfarin on clinical outcomes in atrial fibrillation patients with renal dysfunction. <i>Europace</i> , 2015, 17, ii69-ii75.	0.7	21
584	Peripheral pulse measurement after ischemic stroke: A feasibility study. <i>Neurology</i> , 2015, 84, 962-963.	1.5	0
585	Filling the gap: interventional occlusion of incompletely ligated left atrial appendages. <i>Europace</i> , 2015, 17, 64-68.	0.7	3
586	Pulmonary vein isolation by radiosurgery: implications for non-invasive treatment of atrial fibrillation. <i>Europace</i> , 2015, 17, 1868-1874.	0.7	48
587	Clinical management of arrhythmias in elderly patients: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2015, 17, 314-317.	0.7	30
588	Left atrial catheter ablation subsequent to Watchman® left atrial appendage device implantation: a single centre experience. <i>Europace</i> , 2015, 17, 1402-1406.	0.7	17
589	Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLEACE). <i>Europace</i> , 2015, 17, 1747-1769.	0.7	119
590	Focal impulse and rotor modulation using the novel 64-electrode basket catheter: electrogram characteristics of human rotors. <i>Europace</i> , 2015, 17, 1791-1797.	0.7	18
591	Safety and efficacy of pulmonary vein isolation using a circular, open-irrigated mapping and ablation catheter: A multicenter registry. <i>Heart Rhythm</i> , 2015, 12, 1782-1788.	0.3	21
592	Advances in the Detection and Monitoring of Atrial Fibrillation for Patients with Cryptogenic Ischemic Stroke. <i>Current Atherosclerosis Reports</i> , 2015, 17, 71.	2.0	2
593	Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial. <i>Cardiovascular Drugs and Therapy</i> , 2015, 29, 551-561.	1.3	11

#	ARTICLE	IF	CITATIONS
594	In patients with persistent atrial fibrillation complex ablation techniques were no better than pulmonary vein isolation alone in preventing recurrent atrial fibrillation. Evidence-Based Medicine, 2015, 20, 175-175.	0.6	0
595	Alternative Calculations of Individual Patient Time in Therapeutic Range While Taking Warfarin: Results From the ROCKET AF Trial. Journal of the American Heart Association, 2015, 4, e001349.	1.6	12
596	Sequential Hybrid Procedure for Persistent Atrial Fibrillation. Journal of the American Heart Association, 2015, 4, e001754.	1.6	70
597	Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation. Stroke, 2015, 46, 3354-3361.	1.0	100
598	Idarucizumab, a Humanized, Monoclonal Antibody Fragment for Immediate Reversal of Dabigatran. Journal of Pharmacy Practice, 2015, 28, 548-554.	0.5	8
599	Análisis coste-efectividad de apixabán frente a acenocumarol en la prevención del ictus en pacientes con fibrilación auricular no valvular en España. Revista Espanola De Cardiologia, 2015, 68, 680-690.	0.6	22
600	Echocardiography for Electrophysiology Procedures. Current Anesthesiology Reports, 2015, 5, 429-437.	0.9	0
601	Current ablation techniques for persistent atrial fibrillation: results of the European Heart Rhythm Association Survey. Europace, 2015, 17, 1596-1600.	0.7	46
602	Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: nationwide cohort study. BMJ, The, 2015, 351, h5876.	3.0	120
603	Symptom burden, Metabolic profile, Ultrasound findings, Rhythm, neurohormonal activation, haemodynamics and health-related quality of life in patients with atrial Fibrillation (SMURF): a protocol for an observational study with a randomised interventional component. BMJ Open, 2015, 5, e008723.	0.8	11
604	Ablation for Atrial Fibrillation Combined With Left Atrial Appendage Closure. JACC: Clinical Electrophysiology, 2015, 1, 486-495.	1.3	34
605	Subclinical atrial fibrillation and stroke: insights from continuous monitoring by implanted cardiac electronic devices. Europace, 2015, 17, ii40-ii46.	0.7	17
606	Progress of anticoagulation therapy in atrial fibrillation. Medicina Clínica (English Edition), 2015, 145, 124-130.	0.1	1
607	Percutaneous left atrial appendage closure: a review of the WATCHMAN clinical trial experience. Interventional Cardiology, 2015, 7, 333-344.	0.0	0
609	Case 462015. Journal of Cardiothoracic and Vascular Anesthesia, 2015, 29, 522-531.	0.6	2
611	The Indian consensus guidance on stroke prevention in atrial fibrillation: An emphasis on practical use of nonvitamin K oral anticoagulants. Indian Heart Journal, 2015, 67, S13-S34.	0.2	11
612	Oral anticoagulation in chronic kidney disease with atrial fibrillation. Medicina Clínica (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 100	0.1	3
613	New-Onset Paroxysmal Atrial Fibrillation Diagnosis in Ischemic Stroke Patients. European Neurology, 2015, 74, 211-217.	0.6	11

#	ARTICLE	IF	CITATIONS
614	Patient Blood Management Implementation Strategies and Their Effect on Physicians' Risk Perception, Clinical Knowledge and Perioperative Practice - the Frankfurt Experience. <i>Transfusion Medicine and Hemotherapy</i> , 2015, 42, 91-97.	0.7	33
615	Endoscopic Ultrasound: An Alternative to Transesophageal Echocardiography for Patients With Esophageal Varices During a Structural Interventional Procedure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 70-71.	0.4	2
616	Canadian Cardiovascular Society 2014 Algorithm for Anticoagulation Therapy in Atrial Fibrillation Debated. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1-2.	0.8	4
618	Inappropriate prescribing in a large community-dwelling older population: a focus on prevalence and how it relates to patient and physician characteristics. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2015, 40, 7-13.	0.7	19
619	La ecografÃa endoscÃpica, una alternativa a la ecografÃa transesofÃgica para pacientes con varices esofÃgicas durante el intervencionismo estructural. <i>Revista Espanola De Cardiologia</i> , 2015, 68, 70-71.	0.6	5
620	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2014. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2015, 29, 1-7.	0.6	3
621	Prevalence of Intracardiac Thrombi Under Phenprocoumon, Direct Oral Anticoagulants (Dabigatran) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 <i>Journal of Cardiology</i> , 2015, 115, 635-640.	0.7	35
622	Modified energy settings are mandatory to minimize oesophageal injury using the novel multipolar irrigated radiofrequency ablation catheter for pulmonary vein isolation. <i>Europace</i> , 2015, 17, 396-402.	0.7	36
623	Can the cost of atrial fibrillation be reduced?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2015, 34, 13-15.	0.2	0
624	Antithrombotic Management of Atrial Fibrillation in the Elderly. <i>Medical Clinics of North America</i> , 2015, 99, 417-430.	1.1	16
625	Untreated atrial fibrillation in the United States of America: Understanding the barriers and treatment options. <i>Journal of the Saudi Heart Association</i> , 2015, 27, 44-49.	0.2	8
626	Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. <i>European Heart Journal</i> , 2015, 36, 297-306.	1.0	140
627	Difficult decision making in the management of patients with atrial fibrillation and acute coronary syndrome or invasive cardiovascular interventions: new recommendations for daily practice. <i>Europace</i> , 2015, 17, 1319-1322.	0.7	5
628	Selection of Warfarin or One of the New Oral Antithrombotic Agents for Long-Term Prevention of Stroke among Persons with Atrial Fibrillation. <i>Current Treatment Options in Neurology</i> , 2015, 17, 331.	0.7	1
629	Catheter ablation as first-line treatment for paroxysmal atrial fibrillation: rarely a good value. <i>Europace</i> , 2015, 17, 5-6.	0.7	1
630	Association of the CHADS2 and CHA2DS2-VASc scores with left atrial enlargement: a prospective cohort study of unselected atrial fibrillation patients. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 240-247.	1.0	22
631	Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. <i>International Journal of Cardiology</i> , 2015, 184, 56-61.	0.8	60
632	Ã% possÃvel reduzir o custo da fibrilhaÃ£o auricular?. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 13-15.	0.2	0

#	ARTICLE	IF	CITATIONS
633	Data Strengthen to Support Recommending Anticoagulant Therapy for All Atrial Fibrillation Patients With a CHA ₂ DS ₂ -VASc Score. Journal of the American College of Cardiology, 2015, 65, 643-644.	1.2	4
634	S�curisation de la prise en charge des patients trait�s par dabigatran et rivaroxaban. Pharmacie Hospitalier Et Clinicien, 2015, 50, 155-161.	0.3	1
635	The Association of Serum Galectin-3 Levels with Atrial Electrical and Structural Remodeling. Journal of Cardiovascular Electrophysiology, 2015, 26, 635-640.	0.8	63
636	Prognostic implications of arrhythmias during primary percutaneous coronary interventions for ST-elevation myocardial infraction. Expert Review of Cardiovascular Therapy, 2015, 13, 85-94.	0.6	2
637	Radiofrequency ablation vs. antiarrhythmic drug therapy as first line treatment of symptomatic atrial fibrillation: systematic review and meta-analysis. Europace, 2015, 17, 370-378.	0.7	154
638	Clinical Benefit of American College of Chest Physicians versus European Society of Cardiology Guidelines for Stroke Prophylaxis in Atrial Fibrillation. Journal of General Internal Medicine, 2015, 30, 777-782.	1.3	8
639	Glycated hemoglobin and risk of first episode stroke in diabetic patients with atrial fibrillation: A cohort study. Heart Rhythm, 2015, 12, 886-892.	0.3	40
640	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace, 2015, 17, 187-193.	0.7	152
641	Fondaparinux in atrial fibrillation – old dog, new tricks?. Archives of Cardiovascular Diseases, 2015, 108, 85-87.	0.7	1
642	Inflammation and the pathogenesis of atrial fibrillation. Nature Reviews Cardiology, 2015, 12, 230-243.	6.1	688
643	Warfarin versus dabigatran etexilate: an assessment of efficacy and safety in patients with atrial fibrillation. Expert Opinion on Drug Safety, 2015, 14, 45-62.	1.0	6
644	Does atrial fibrillation pattern affect stroke risk? Data dredging to help the clinician. European Heart Journal, 2015, 36, 265-266.	1.0	1
645	The rs3807989 G/A Polymorphism in CAV1 is Associated with the Risk of Atrial Fibrillation in Chinese Han Populations. PACE - Pacing and Clinical Electrophysiology, 2015, 38, 164-170.	0.5	18
646	Stroke and Systemic Embolism Prevention in Patients with Atrial Fibrillation in Belgium: Comparative Cost Effectiveness of New Oral Anticoagulants and Warfarin. Clinical Drug Investigation, 2015, 35, 109-119.	1.1	23
647	Adding Rigor to Stroke Risk Prediction in Atrial Fibrillation. Journal of the American College of Cardiology, 2015, 65, 233-235.	1.2	13
648	The ratio of early transmitral flow velocity (E _m) to early mitral annular velocity (E _a) predicts improvement in left ventricular systolic and diastolic function 1 year after catheter ablation for atrial fibrillation. Europace, 2015, 17, 1051-1058.	0.7	14
649	Regional differences in presentation and treatment of patients with atrial fibrillation in Europe: a report from the EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace, 2015, 17, 194-206.	0.7	41
650	Cost-effectiveness Analysis Comparing Apixaban and Acenocoumarol in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation in Spain. Revista Espanola De Cardiologia (English Ed), 2015, 68, 680-690.	0.4	14

#	ARTICLE	IF	CITATIONS
651	Non-vitamin K oral anticoagulants in atrial fibrillation: Where are we now?. Trends in Cardiovascular Medicine, 2015, 25, 315-336.	2.3	18
652	Novel oral anticoagulants and valvular atrial fibrillation: are they always contraindicated?. Internal and Emergency Medicine, 2015, 10, 21-24.	1.0	4
653	Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. Journal of Thrombosis and Haemostasis, 2015, 13, 495-504.	1.9	129
654	Ranolazine in the treatment of atrial fibrillation: Results of the dose-ranging RAFFAELLO (Ranolazine) Tj ETQq1 1 0.784314 rgBT /Over	0.3	63
656	Atrial fibrillation and long-term sports practice: epidemiology and mechanisms. Clinical Research in Cardiology, 2015, 104, 369-379.	1.5	17
657	Concomitant Unipolar Radiofrequency Ablation of Nonparoxysmal Atrial Fibrillation in Rheumatic and Degenerative Valve Disease. Journal of Cardiac Surgery, 2015, 30, 117-123.	0.3	4
658	Improvement of the myocardial performance index in atrial fibrillation patients treated with amiodarone after cardioversion. Journal of Interventional Cardiac Electrophysiology, 2015, 42, 107-115.	0.6	6
659	Cardioversion without oral anticoagulation—is it risk-taking?. Europace, 2015, 17, 3-4.	0.7	5
660	Diagnostic yield of external loop recording in patients with acute ischemic stroke or TIA. Journal of Neurology, 2015, 262, 682-688.	1.8	4
661	Benefit of Anticoagulation Unlikely in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1. Journal of the American College of Cardiology, 2015, 65, 225-232.	1.2	192
662	Early pulmonary vein reconnection as a predictor of left atrial ablation outcomes for paroxysmal atrial fibrillation. Europace, 2015, 17, 741-746.	0.7	25
663	Safety and efficacy outcomes in patients undergoing pulmonary vein isolation with second-generation cryoballoon. Europace, 2015, 17, 379-387.	0.7	86
664	Recurrence of paroxysmal atrial fibrillation after pulmonary vein isolation: is repeat pulmonary vein isolation enough? A prospective, randomized trial. Europace, 2015, 17, 1371-1375.	0.7	23
665	Safety and efficacy outcomes of protamine administration for heparin reversal following cryoballoon-based pulmonary vein isolation. Journal of Interventional Cardiac Electrophysiology, 2015, 43, 161-167.	0.6	19
666	The criteria of the Italian Federation of Thrombosis Centres on DOACs: a real world application in nonvalvular atrial fibrillation patients already on Vitamin K Antagonist. Internal and Emergency Medicine, 2015, 10, 157-163.	1.0	12
667	Safety and efficacy of external electrical cardioversion in patients with left ventricular leads. Clinical Research in Cardiology, 2015, 104, 439-445.	1.5	5
668	Managing Atrial Fibrillation. Annals of Emergency Medicine, 2015, 65, 532-539.	0.3	19
671	Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, The, 2015, 385, 2280-2287.	6.3	153

#	ARTICLE	IF	CITATIONS
672	Presence and severity of obstructive sleep apnea and remote outcomes of atrial fibrillation ablations – a long-term prospective, cross-sectional cohort study. <i>Sleep and Breathing</i> , 2015, 19, 849-856.	0.9	43
673	Real life anticoagulation treatment of patients with atrial fibrillation in Germany: extent and causes of anticoagulant under-use. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 40, 97-107.	1.0	30
674	Anticoagulation therapy in 2015: where we are and where we are going. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 264-272.	1.0	12
675	Development of Recommendations to Continue Anticoagulation with One of the Two Types of Oral Anticoagulants Based on the Identification of Patients' Preference. <i>Seminars in Thrombosis and Hemostasis</i> , 2015, 41, 166-177.	1.5	13
676	How are patients with atrial fibrillation approached and informed about their risk profile and available therapies in Europe? Results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 468-472.	0.7	27
677	Is There Still a Role for Complex Fractionated Atrial Electrogram Ablation in Addition to Pulmonary Vein Isolation in Patients With Paroxysmal and Persistent Atrial Fibrillation?. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 1017-1029.	2.1	76
678	Usefulness of intracardiac echocardiography during pulmonary vein isolation with the novel multipolar irrigated ablation catheter (nMARQTM). <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 39-45.	0.6	7
679	New Oral Anticoagulants: How Do We Use Them Wisely?. <i>Current Cardiology Reports</i> , 2015, 17, 626.	1.3	1
680	Management of stroke prevention in Bulgarian patients with non-valvular atrial fibrillation (BUL-AF) Tj ETQqO 0 0 rgBT./Overlock 10 Tf 50	0.8	2
681	Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II. <i>American Journal of Medicine</i> , 2015, 128, 1306-1313.e1.	0.6	135
682	The Case Against Using Hypertension as the Only Criterion for Oral Anticoagulation in Atrial Fibrillation. <i>Canadian Journal of Cardiology</i> , 2015, 31, 576-579.	0.8	7
683	2015 ACC/HRS/SCAI Left Atrial Appendage Occlusion Device Societal Overview. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1497-1513.	1.2	61
684	Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the Atrial Fibrillation Registry for Ankle-Brachial Index Prevalence Assessment-Collaborative Italian Study. <i>European Journal of Internal Medicine</i> , 2015, 26, e31-e33.	1.0	2
685	Triple Therapy – Can We Replace More With Better? –. <i>Journal of the American College of Cardiology</i> , 2015, 66, 628-630.	1.2	1
687	Postinterventional use of dabigatran in patients undergoing ablation therapy using an accelerated loading dose scheme – a single center experience. <i>Thrombosis Research</i> , 2015, 136, 486-487.	0.8	1
688	NT-proBNP in low risk patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2015, 179, 493-494.	0.8	2
689	A new mechanism links preamyloid oligomer formation in the myocyte stress response associated with atrial fibrillation. <i>Journal of Molecular and Cellular Cardiology</i> , 2015, 80, 110-113.	0.9	0
690	2015 ACC/HRS/SCAI left atrial appendage occlusion device societal overview. <i>Heart Rhythm</i> , 2015, 12, e122-e136.	0.3	17

#	ARTICLE	IF	CITATIONS
691	Atrial flutter and thromboembolic risk: a systematic review. <i>Heart</i> , 2015, 101, 1446-1455.	1.2	54
692	Treatment: special conditions. <i>Journal of the American Society of Hypertension</i> , 2015, 9, 313-317.	2.3	0
693	Atrial fibrillation and hypertrophic cardiomyopathy: who to anticoagulate?. <i>Clinical Research in Cardiology</i> , 2015, 104, 799-802.	1.5	7
694	Validation of a simple method for atrial fibrillation screening in patients with stroke. <i>Neurological Sciences</i> , 2015, 36, 1675-1678.	0.9	23
695	Prognostic value of CHA ₂ DS ₂ -VASc score in patients with non-valvular atrial fibrillation™ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. <i>European Heart Journal</i> , 2015, 36, 1822.2-1830.	1.0	53
696	Atrial fibrillation: prevalence in a large database of primary care patients in Brazil. <i>Europace</i> , 2015, 17, 1787-1790.	0.7	44
697	Atrial Fibrillation. <i>Emergency Medicine Clinics of North America</i> , 2015, 33, 597-612.	0.5	4
698	Determinants and consequences of differences in quality of anticoagulation therapy with vitamin K antagonists. <i>Thrombosis Research</i> , 2015, 136, 183-184.	0.8	1
699	Cost-effectiveness of mass screening for untreated atrial fibrillation using intermittent ECG recording. <i>Europace</i> , 2015, 17, 1023-1029.	0.7	128
700	Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2015, 17, 1169-1196.	0.7	138
701	Patient Outcomes According to Adherence to Treatment Guidelines for Rhythm Control of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	10
702	Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. <i>European Heart Journal</i> , 2015, 36, 1805-1811.	1.0	370
703	Infarct Topography and Detection of Atrial Fibrillation in Cryptogenic Stroke: Results from CRYSTAL AF. <i>Cerebrovascular Diseases</i> , 2015, 40, 91-96.	0.8	57
704	Incidence and predictors of dormant conduction after cryoballoon ablation incorporating a 30-min waiting period. <i>Europace</i> , 2015, 17, 1383-1390.	0.7	15
705	Atrial fibrillation, CHA ₂ DS ₂ -VASc score, antithrombotics and risk of traffic accidents: A population-based cohort study. <i>International Journal of Cardiology</i> , 2015, 197, 133-139.	0.8	5
706	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective Real-world™ Inception Cohort Study. <i>American Journal of Medicine</i> , 2015, 128, 1237-1243.	0.6	51
707	Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA). <i>Europace</i> , 2015, 17, 986-993.	0.7	38
708	Percutaneous left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation and contraindication for anticoagulation. <i>Revue Neurologique</i> , 2015, 171, 426-432.	0.6	13

#	ARTICLE	IF	CITATIONS
709	Non-vitamin K antagonist oral anticoagulants and atrial fibrillation guidelines in practice: barriers to and strategies for optimal implementation. <i>Europace</i> , 2015, 17, 1007-1017.	0.7	46
710	Left atrial appendage closure-indications, techniques, and outcomes: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2015, 17, 642-646.	0.7	77
711	Antithrombotic drugs, patient characteristics, and gastrointestinal bleeding: Clinical translation and areas of research. <i>Blood Reviews</i> , 2015, 29, 335-343.	2.8	24
712	New Oral Anticoagulants. <i>Medical Clinics of North America</i> , 2015, 99, 759-780.	1.1	5
713	Anaesthetic and sedative agents used for electrical cardioversion. <i>The Cochrane Library</i> , 2019, 2019, CD010824.	1.5	17
714	New oral anticoagulants: a practical guide for physicians. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 134-145.	1.4	54
715	Ablation of atrial fibrillation and esophageal injury: Role of bipolar and unipolar energy using a novel multipolar irrigated ablation catheter. <i>Heart Rhythm</i> , 2015, 12, 1120-1127.	0.3	9
717	Ablation de FA: quel coût de séjour pour quel tarif de remboursement?. <i>Pharmacien Hospitalier Et Clinicien</i> , 2015, 50, 105-113.	0.3	1
724	Narrow therapeutic index drugs: a clinical pharmacological consideration to flecainide. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 549-567.	0.8	166
725	Elevated M2-muscarinic and Î²1-adrenergic receptor autoantibody levels are associated with paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 226-233.	1.5	34
726	The APPLE score: a novel and simple score for the prediction of rhythm outcomes after catheter ablation of atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2015, 104, 871-876.	1.5	147
727	Pharmacists' role in handling problems with prescriptions for antithrombotic medication in Belgian community pharmacies. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 656-668.	1.0	9
728	Baseline NT-ProBNP level predicts success of cardioversion of atrial fibrillation with flecainide. <i>Netherlands Heart Journal</i> , 2015, 23, 182-189.	0.3	4
729	Therapeutic management in ambulatory elderly patients with atrial fibrillation: The S.AGES cohort. <i>Journal of Nutrition, Health and Aging</i> , 2015, 19, 219-227.	1.5	7
730	Who Gets Stroke Prevention? Stroke Prevention in Atrial Fibrillation Patients in the Inpatient Setting. <i>Heart Lung and Circulation</i> , 2015, 24, 488-494.	0.2	5
731	Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention. <i>Current Hypertension Reports</i> , 2015, 17, 553.	1.5	5
732	Intracranial Hemorrhage and Subsequent Ischemic Stroke in Patients With Atrial Fibrillation. <i>Chest</i> , 2015, 147, 1651-1658.	0.4	43
733	Optimizing stroke prevention in atrial fibrillation: better adherence and compliance from patients and physicians leads to better outcomes. <i>Europace</i> , 2015, 17, 507-508.	0.7	20

#	ARTICLE	IF	CITATIONS
734	Antazoline for termination of atrial fibrillation during the procedure of pulmonary veins isolation. <i>Advances in Medical Sciences</i> , 2015, 60, 231-235.	0.9	10
736	Status of oral anticoagulant treatment in patients with nonvalvular atrial fibrillation in Spain. REACT-AF study. <i>Revista Clínica Española</i> , 2015, 215, 73-82.	0.3	5
737	Optimizing Atrial Fibrillation Management. <i>Chest</i> , 2015, 148, 859-864.	0.4	43
738	A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark. <i>Pharmacoeconomics</i> , 2015, 33, 967-979.	1.7	15
739	2013 Korean Society of Hypertension guidelines for the management of hypertension: part III-hypertension in special situations. <i>Clinical Hypertension</i> , 2015, 21, 3.	0.7	11
740	Validation of the Adherence Barriers Questionnaire – an instrument for identifying potential risk factors associated with medication-related non-adherence. <i>BMC Health Services Research</i> , 2015, 15, 153.	0.9	41
741	Comparison of left atrial dimensions in CT and echocardiography as predictors of long-term success after catheter ablation of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 43, 237-244.	0.6	34
743	Oral Anticoagulation, Aspirin, or No Therapy in Patients With Nonvalvular AF With 0 or 1 Stroke Risk Factor Based on the CHA2DS2-VASc Score. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1385-1394.	1.2	141
744	Five-Year Follow-Up After Catheter Ablation of Persistent Atrial Fibrillation Using the Stepwise Approach and Prognostic Factors for Success. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2015, 8, 308-317.	2.1	141
745	In vivo contact force measurements and correlation with left atrial anatomy during catheter ablation of atrial fibrillation. <i>Europace</i> , 2015, 17, 1526.1-1532.	0.7	14
746	Digoxin-associated mortality: a systematic review and meta-analysis of the literature. <i>European Heart Journal</i> , 2015, 36, 1831-1838.	1.0	224
747	Safety of new oral anticoagulants. <i>BMJ</i> , 2015, 350, h1679-h1679.	3.0	10
748	Meta-Analysis of CHADS2 versus CHA2DS2-VASc for Predicting Stroke and Thromboembolism in Atrial Fibrillation Patients Independent of Anticoagulation. <i>Texas Heart Institute Journal</i> , 2015, 42, 6-15.	0.1	63
749	Real-World Observations with Dronedronone Compared to Other Anti-Arrhythmic Drugs in Recurrent Atrial Fibrillation. <i>British Journal of Medicine and Medical Research</i> , 2015, 5, 1088-1095.	0.2	1
750	The SAME-TT2R2 score and quality of anticoagulation in atrial fibrillation: a simple aid to decision-making on who is suitable (or not) for vitamin K antagonists. <i>Europace</i> , 2015, 17, 671-673.	0.7	16
751	High rate of durable pulmonary vein isolation after second-generation cryoballoon ablation: analysis of repeat procedures. <i>Europace</i> , 2015, 17, 725-731.	0.7	64
752	Holter monitoring to detect silent atrial fibrillation in high-risk subjects: the Perugia General Practitioner Study. <i>Internal and Emergency Medicine</i> , 2015, 10, 595-601.	1.0	12
753	Early detection of occult atrial fibrillation and stroke prevention. <i>Heart</i> , 2015, 101, 1097-1102.	1.2	37

#	ARTICLE	IF	CITATIONS
754	Long-term oral anticoagulation for patients after successful catheter ablation of atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2015, 30, 1-7.	0.8	15
756	Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2015, 20, 457-464.	1.0	2
757	The AFFORD Clinical Decision Aid to Identify Emergency Department Patients With Atrial Fibrillation at Low Risk for 30-Day Adverse Events. <i>American Journal of Cardiology</i> , 2015, 115, 763-770.	0.7	24
758	Heart failure in patients with atrial fibrillation in Europe: a report from the <scp>EURObservational</scp> Research Programme Pilot survey on Atrial Fibrillation. <i>European Journal of Heart Failure</i> , 2015, 17, 570-582.	2.9	68
759	Dabigatran for the prevention and treatment of thromboembolic disorders. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 529-540.	0.6	6
760	Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis. <i>Clinical Research in Cardiology</i> , 2015, 104, 418-429.	1.5	87
761	Periatrial epicardial adipose tissue thickness is an independent predictor of atrial fibrillation recurrence after cryoballoon-based pulmonary vein isolation. <i>Journal of Cardiovascular Computed Tomography</i> , 2015, 9, 295-302.	0.7	38
762	Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting. <i>Clinical Drug Investigation</i> , 2015, 35, 693-705.	1.1	6
763	Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation. <i>Europace</i> , 2015, 17, 1533-1540.	0.7	64
764	Cognitive Function: Is There More to Anticoagulation in Atrial Fibrillation Than Stroke?. <i>Journal of the American Heart Association</i> , 2015, 4, e001573.	1.6	20
765	Antiplatelet Therapy During PCI for Patients with Stable Angina and Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2015, 17, 64.	1.3	1
766	Direct Oral Anticoagulants for the Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Understanding Differences and Similarities. <i>Drugs</i> , 2015, 75, 1627-1644.	4.9	37
767	Improved outcomes with European Society of Cardiology guideline-adherent antithrombotic treatment in high-risk patients with atrial fibrillation: a report from the EORP-AF General Pilot Registry. <i>Europace</i> , 2015, 17, 1777-1786.	0.7	128
768	Relationship of Age With Stroke and Death in Anticoagulated Patients With Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 3202-3207.	1.0	13
769	Spectrum of digoxin-induced ocular toxicity: a case report and literature review. <i>BMC Research Notes</i> , 2015, 8, 368.	0.6	23
770	Stroke prevention in atrial fibrillation: Still room for practice improvement. <i>Archives of Cardiovascular Diseases</i> , 2015, 108, 541-543.	0.7	0
771	Net Clinical Benefits of Guidelines and Decision Tool Recommendations for Oral Anticoagulant Use among Patients with Atrial Fibrillation. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2845-2853.	0.7	6
772	Diabetes mellitus as risk factor for atrial fibrillation hospitalization: Incidence and outcomes over nine years in a region of Northern Italy. <i>Diabetes Research and Clinical Practice</i> , 2015, 109, 476-484.	1.1	27

#	ARTICLE	IF	CITATIONS
773	Stroke Risk Stratification in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1860-1863.	1.2	6
774	Use of vitamin K antagonists for secondary stroke prevention depends on the treating healthcare provider in Germany – results from the German AFNET registry. <i>BMC Neurology</i> , 2015, 15, 129.	0.8	22
775	Phased multipolar radiofrequency pulmonary vein isolation is as effective and safe as conventional irrigated point-to-point ablation. A prospective randomised 1-year implantable cardiac monitoring device follow-up trial. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 257-264.	0.6	7
776	Pulmonary vein stenosis after pulmonary vein isolation using duty-cycled unipolar/bipolar radiofrequency ablation guided by intracardiac echocardiography. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 44, 47-54.	0.6	5
778	Fibrillation atriale – facteurs de risque et conduite à tenir (podcast). <i>Praticien En Anesthésie Réanimation</i> , 2015, 19, 178-185.	0.0	0
779	Direct oral anticoagulants in atrial fibrillation: can data from randomized clinical trials be safely transferred to the general population? Yes. <i>Internal and Emergency Medicine</i> , 2015, 10, 641-645.	1.0	4
780	Comparative Performance of ATRIA, CHADS2, and CHA2DS2-VASc Risk Scores Predicting Stroke in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1851-1859.	1.2	162
781	Cost-Effectiveness of Novel Oral Anticoagulants for Stroke Prevention in Non-Valvular Atrial Fibrillation. <i>Current Cardiology Reports</i> , 2015, 17, 61.	1.3	11
782	Management of cardiovascular conditions in a cohort of patients with HIV: experience from a joint HIV/cardiology clinic. <i>Clinical Medicine</i> , 2015, 15, 442-446.	0.8	6
783	Atrial fibrillation screening in pharmacies using an iPhone ECG: a qualitative review of implementation. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1111-1120.	1.0	63
784	Role of Endovascular Closure of the Left Atrial Appendage in Stroke Prevention for Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2015, 17, 65.	2.0	3
786	Catheter ablation for atrial fibrillation: results from the first European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA) Part II. <i>Europace</i> , 2015, 17, 1727-1732.	0.7	36
787	Assessment of risk factors for bleeding in Japanese patients with non-valvular atrial fibrillation receiving warfarin treatment: A subanalysis of the J-RHYTHM Registry. <i>International Journal of Cardiology</i> , 2015, 201, 308-310.	0.8	4
788	Thirty-day mortality in ED patients with new onset atrial fibrillation and actively treated cancer. <i>American Journal of Emergency Medicine</i> , 2015, 33, 1483-1488.	0.7	14
789	Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2015, 17, 1467-1507.	0.7	951
790	Natriuretic peptides for the detection of paroxysmal atrial fibrillation. <i>Open Heart</i> , 2015, 2, e000182.	0.9	23
791	Will NOACs become the new standard of care in anticoagulation therapy?. <i>International Journal of the Cardiovascular Academy</i> , 2015, 1, 1-4.	0.1	19
792	Comparison of the Short-Term Risk of Bleeding and Arterial Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Newly Treated With Dabigatran or Rivaroxaban Versus Vitamin K Antagonists. <i>Circulation</i> , 2015, 132, 1252-1260.	1.6	161

#	ARTICLE	IF	CITATIONS
793	Stroke: Advances in Medical Therapy and Acute Stroke Intervention. <i>Current Cardiology Reports</i> , 2015, 17, 79.	1.3	11
794	NT-proBNP values in elderly heart failure patients with atrial fibrillation and diabetes. <i>Journal of Diabetes and Its Complications</i> , 2015, 29, 1119-1123.	1.2	12
795	Gastrointestinal haemorrhage in atrial fibrillation patients: impact of quality of anticoagulation control. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2015, 1, 265-272.	1.4	12
796	Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	30
797	Republished: Left atrial appendage occlusion. <i>Postgraduate Medical Journal</i> , 2015, 91, 527-534.	0.9	0
798	Reduction of radiation exposure during ablation of atrial fibrillation. <i>Herz</i> , 2015, 40, 883-891.	0.4	12
799	Amiodarone and risk of death in contemporary patients with atrial fibrillation: Findings from The Retrospective Evaluation and Assessment of Therapies in AF study. <i>American Heart Journal</i> , 2015, 170, 1033-1041.e1.	1.2	14
800	Increased Heart Rate Is Associated With Higher Mortality in Patients With Atrial Fibrillation (AF): Results From the Outcomes Registry for Better Informed Treatment of AF (ORBIT- ∞ AF). <i>Journal of the American Heart Association</i> , 2015, 4, e002031.	1.6	41
801	Effects of new class III antiarrhythmic drug niferidil on electrical activity in murine ventricular myocardium and their ionic mechanisms. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 1105-1112.	1.4	5
802	Stroke Risk Perception in Atrial Fibrillation Patients is not Associated with Clinical Stroke Risk. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2015, 24, 2527-2532.	0.7	3
803	Consideraciones sobre el tratamiento anticoagulante oral en pacientes con fibrilaci3n auricular no valvular en EspaA±a. <i>Revista Clinica Espanola</i> , 2015, 215, 542.	0.2	0
804	Satisfaction With Medical Care in Patients With Atrial Fibrillation Treated With Vitamin K Antagonists Versus New Oral Anticoagulants. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2015, 68, 537-539.	0.4	5
806	Long sheath filling defect during left atrial appendage occlusion device placement. <i>International Journal of Cardiology</i> , 2015, 199, 193-194.	0.8	2
807	APOLO I: controlo da hipocoagulaA±o na fibrilhaA±o auricular. <i>Revista Portuguesa De Cardiologia</i> , 2015, 34, 337-345.	0.2	2
808	Catheter ablation of atrial fibrillation in patients with diabetes mellitus: a systematic review and meta-analysis. <i>Europace</i> , 2015, 17, 1518-1525.	0.7	56
809	Identifying postoperative atrial fibrillation in cardiac surgical patients posthospital discharge, using iPhone ECG: a study protocol. <i>BMJ Open</i> , 2015, 5, e006849-e006849.	0.8	7
810	Stroke with atrial fibrillation or atrial flutter: a descriptive population-based study from the Brest stroke registry. <i>BMC Geriatrics</i> , 2015, 15, 63.	1.1	8
811	Gastrointestinal bleeding in patients receiving oral anticoagulation: Current treatment and pharmacological perspectives. <i>Thrombosis Research</i> , 2015, 136, 1074-1081.	0.8	25

#	ARTICLE	IF	CITATIONS
812	M2-muscarinic acetylcholine receptor autoantibody levels predict left atrial fibrosis severity in paroxysmal lone atrial fibrillation patients undergoing cryoablation. <i>Europace</i> , 2015, 17, 239-246.	0.7	27
813	Red blood cell distribution width predicts outcome of cryoballoon-based atrial fibrillation ablation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2015, 42, 51-58.	0.6	22
814	Left atrial appendage occlusion. <i>Heart</i> , 2015, 101, 834-841.	1.2	8
815	Effects of Persistent Atrial Fibrillation on Serum Galectin-3 Levels. <i>American Journal of Cardiology</i> , 2015, 115, 647-651.	0.7	54
816	Atrial Fibrillation Patients Categorized as "Not for Anticoagulation" According to the 2014 Canadian Cardiovascular Society Algorithm Are Not "Low Risk". <i>Canadian Journal of Cardiology</i> , 2015, 31, 24-28.	0.8	17
817	Cost Effectiveness of Rivaroxaban for Stroke Prevention in German Patients with Atrial Fibrillation. <i>Pharmacoeconomics</i> , 2015, 33, 271-283.	1.7	22
818	Oral anticoagulation after catheter ablation of atrial fibrillation: caught in the attribution trap?. <i>European Heart Journal</i> , 2015, 36, 267-269.	1.0	5
819	Selecting an oral anticoagulant for patients with nonvalvular atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 129-138.	1.0	2
820	GDF-15 and risk stratification in atrial fibrillation. <i>Nature Reviews Cardiology</i> , 2015, 12, 8-9.	6.1	18
822	Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naive atrial fibrillation patients. <i>Europace</i> , 2015, 17, 169-170.	0.7	0
824	Contact-force guided radiofrequency vs. second-generation balloon cryotherapy for pulmonary vein isolation in patients with paroxysmal atrial fibrillation--a prospective evaluation. <i>Europace</i> , 2015, 17, 225-231.	0.7	117
825	Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. <i>Herz</i> , 2015, 40, 18-26.	0.4	26
826	Efficacy and safety of remote magnetic catheter navigation vs. manual steerable sheath-guided ablation for catheter ablation of atrial fibrillation: a case-control study. <i>Europace</i> , 2015, 17, 232-238.	0.7	17
828	Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis. <i>European Heart Journal</i> , 2015, 36, 120-128.	1.0	104
829	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2015, 4, 386-386.	0.4	46
830	Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation. <i>Europace</i> , 2015, 17, 24-31.	0.7	164
831	Dissolution of large intracardiac thrombus, potential role of the emerging oral fibrinolytic agent. <i>Medical Journal of Indonesia</i> , 2016, 25, 62-6.	0.2	0
832	Traumatic events involving elderly patients treated with anticoagulants for atrial fibrillation: the downside of stroke prevention. <i>Emergency Care Journal</i> , 2016, 12, .	0.2	0

#	ARTICLE	IF	CITATIONS
833	Multimodality Echocardiographic Assessment of Patients Undergoing Atrial Fibrillation Ablation. , 0, , .		1
834	The dream comes true“start for the new beginning. Medical Journal of Indonesia, 2016, 25, 1-2.	0.2	1
835	Risk impact of edoxaban in the management of stroke and venous thromboembolism. Vascular Health and Risk Management, 2016, Volume 12, 329-335.	1.0	4
836	Percutaneous left atrial appendage closure devices: safety, efficacy, and clinical utility. Medical Devices: Evidence and Research, 2016, Volume 9, 309-316.	0.4	2
837	Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vascular Health and Risk Management, 2016, 12, 45.	1.0	4
839	Stroke Prevention in Atrial Fibrillation and Valvular Heart Disease. Open Cardiovascular Medicine Journal, 2016, 10, 110-116.	0.6	7
840	D-dimer and factor VIIa in atrial fibrillation “ prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis, 2016, 115, 921-930.	1.8	34
841	Dabigatran approaching the realm of heparin-induced thrombocytopenia. Blood Research, 2016, 51, 77.	0.5	8
842	Atrial fibrillation and silent stroke: links, risks, and challenges. Vascular Health and Risk Management, 2016, 12, 65.	1.0	42
843	Prevalence of unknown and untreated arrhythmias in an older outpatient population screened by wireless long-term recording ECG. Clinical Interventions in Aging, 2016, Volume 11, 1083-1090.	1.3	4
844	D-dimer and factor VIIa in atrial fibrillation “ prognostic values for cardiovascular events and effects of anticoagulation therapy. Thrombosis and Haemostasis, 2016, 115, 921-930.	1.8	34
845	SYNTAX score predicts postoperative atrial fibrillation in patients undergoing on-pump isolated coronary artery bypass grafting surgery. Anatolian Journal of Cardiology, 2016, 16, 892-893.	0.5	4
846	Beta-blockers or Digoxin for Atrial Fibrillation and Heart Failure?. Cardiac Failure Review, 2016, 2, 35.	1.2	8
847	Value of Implantable Loop Recorders in Monitoring Efficacy of Radiofrequency Catheter Ablation in Atrial Fibrillation. Medical Science Monitor, 2016, 22, 2846-2851.	0.5	7
848	Clinical Significance of Additional Ablation of Atrial Premature Beats after Catheter Ablation for Atrial Fibrillation. Yonsei Medical Journal, 2016, 57, 72.	0.9	13
849	Practical Guide to the New Oral Anticoagulants. Journal of General Practice (Los Angeles, Calif), 2016, 03, .	0.1	0
850	Individualising Anticoagulant Therapy in Atrial Fibrillation Patients. Arrhythmia and Electrophysiology Review, 2016, 5, 102.	1.3	5
851	Percutaneous left atrial appendage closure: here to stay. Journal of Thoracic Disease, 2016, 8, 2420-2423.	0.6	0

#	ARTICLE	IF	CITATIONS
852	The Need to Systematically Evaluate Clinical Practice Guidelines. <i>Journal of the American Board of Family Medicine</i> , 2016, 29, 644-648.	0.8	22
853	Developing a Complex Educational“Behavioural Intervention: The TREAT Intervention for Patients with Atrial Fibrillation. <i>Healthcare (Switzerland)</i> , 2016, 4, 10.	1.0	6
854	Stroke Prevention with Percutaneous Left Atrial Appendage Closure. <i>Clinical Medicine Insights Therapeutics</i> , 2016, 8, CMT.S18886.	0.4	0
855	Comparison between First- and Second-Generation Cryoballoon for Paroxysmal Atrial Fibrillation Ablation. <i>Cardiology Research and Practice</i> , 2016, 2016, 1-5.	0.5	24
856	Direct Oral Anticoagulants in Emergency Trauma Admissions. <i>Deutsches A&#x0308;rztblatt International</i> , 2016, 113, 575-82.	0.6	35
858	Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. <i>Tohoku Journal of Experimental Medicine</i> , 2016, 240, 259-268.	0.5	12
859	CHADS<sub>2</sub> score has a better predictive value than CHA<sub>2</sub>DS<sub>2</sub>-VASc score in elderly patients with atrial fibrillation. <i>Clinical Interventions in Aging</i> , 2016, Volume 11, 941-946.	1.3	8
860	New Direct Oral Anticoagulants (DOAC) and Their Use Today. <i>Dentistry Journal</i> , 2016, 4, 5.	0.9	36
861	The Use of Fish Oil with Warfarin Does Not Significantly Affect either the International Normalised Ratio or Incidence of Adverse Events in Patients with Atrial Fibrillation and Deep Vein Thrombosis: A Retrospective Study. <i>Nutrients</i> , 2016, 8, 578.	1.7	14
862	Accelerometry-Based Activity Recognition and Assessment in Rheumatic and Musculoskeletal Diseases. <i>Sensors</i> , 2016, 16, 2151.	2.1	9
863	Patients' Characteristics Affect the Survival Benefit of Warfarin Treatment for Hemodialysis Patients with Atrial Fibrillation. A Historical Cohort Study. <i>American Journal of Nephrology</i> , 2016, 44, 258-267.	1.4	24
864	Rivaroxaban for Periprocedural Anticoagulation Therapy in Japanese Patients Undergoing Catheter Ablation of Paroxysmal Non-Valvular Atrial Fibrillation. <i>International Heart Journal</i> , 2016, 57, 712-716.	0.5	5
865	The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective. <i>Hospital Pharmacy</i> , 2016, 51, 26-34.	0.4	0
866	Fluoroscopy-Free Pulmonary Vein Isolation in Patients with Atrial Fibrillation and a Patent Foramen Ovale Using Solely an Electroanatomic Mapping System. <i>PLoS ONE</i> , 2016, 11, e0148059.	1.1	16
867	Simulation of Daily Snapshot Rhythm Monitoring to Identify Atrial Fibrillation in Continuously Monitored Patients with Stroke Risk Factors. <i>PLoS ONE</i> , 2016, 11, e0148914.	1.1	20
868	Determinants and Time Trends for Ischaemic and Haemorrhagic Stroke in a Large Chinese Population. <i>PLoS ONE</i> , 2016, 11, e0163171.	1.1	4
869	Minimizing bleeding risk in patients receiving direct oral anticoagulants for stroke prevention. <i>International Journal of General Medicine</i> , 2016, Volume 9, 337-347.	0.8	12
870	Systematic review and network meta-analysis of stroke-prevention treatments in patients with atrial fibrillation. <i>Clinical Pharmacology: Advances and Applications</i> , 2016, Volume 8, 93-107.	0.8	35

#	ARTICLE	IF	CITATIONS
871	Management of Patients with Atrial Fibrillation: Focus on Treatment Options. <i>Journal of Atrial Fibrillation</i> , 2016, 9, 1450.	0.5	1
872	Atrial fibrillation septal pacing: translation of modelling results. <i>Europace</i> , 2016, 18, iv53-iv59.	0.7	3
873	Contact force-guided catheter ablation for the treatment of atrial fibrillation: a meta-analysis of randomized, controlled trials. <i>Brazilian Journal of Medical and Biological Research</i> , 2016, 49, .	0.7	2
874	Non-Vitamin K Antagonist Oral Anticoagulants, Clinical Use, Real-World Data, and Reversal of Anticoagulant Effect. , 2016, , .		0
875	Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. <i>Canadian Journal of Hospital Pharmacy</i> , 2016, 69, 280-5.	0.1	4
876	Atrial Fibrillation Increases the Risk of Peripheral Arterial Disease With Relative Complications and Mortality. <i>Medicine (United States)</i> , 2016, 95, e3002.	0.4	20
877	Clinical pre-test of a computerised antithrombotic risk assessment tool for stroke prevention in atrial fibrillation patients: giving consideration to NOACs. <i>Journal of Evaluation in Clinical Practice</i> , 2016, 22, 896-902.	0.9	3
878	Lessons From Drive-By Left Atrial Appendage Occlusion. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1384-1385.	1.1	0
879	Warfarin Treatment and All-Cause Mortality in Community-Dwelling Older Adults with Atrial Fibrillation: A Retrospective Observational Study. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1416-1424.	1.3	35
880	Catheter Ablation for Lone Atrial Fibrillation: Efficacy and Predictors of Recurrence. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 536-541.	0.8	10
881	Idarucizumab for Dabigatran Reversal Guideline. <i>Critical Pathways in Cardiology</i> , 2016, 15, 33-35.	0.2	2
882	Association of Increased Epicardial Adipose Tissue Thickness With Adverse Cardiovascular Outcomes in Patients With Atrial Fibrillation. <i>Medicine (United States)</i> , 2016, 95, e2874.	0.4	40
883	State-of-the-Art CT Imaging of the Left Atrium. <i>Current Radiology Reports</i> , 2016, 4, 1.	0.4	1
884	Smart detection of atrial fibrillation. <i>Europace</i> , 2016, 19, euw125.	0.7	79
885	Improvement of Atrial and Ventricular Remodeling with Low Atrial Fibrillation Burden after Hybrid Ablation of Persistent Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 216-224.	0.5	14
886	Intermittent drivers anchoring to structural heterogeneities as a major pathophysiological mechanism of human persistent atrial fibrillation. <i>Journal of Physiology</i> , 2016, 594, 2387-2398.	1.3	132
887	Documented atrial fibrillation recurrences after pulmonary vein isolation are associated with diminished quality of life. <i>Journal of Cardiovascular Medicine</i> , 2016, 17, 201-208.	0.6	5
888	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. <i>Europace</i> , 2016, 18, 1455-1490.	0.7	471

#	ARTICLE	IF	CITATIONS
889	Circulating Biomarkers Predictive of Postoperative Atrial Fibrillation. <i>Cardiology in Review</i> , 2016, 24, 76-87.	0.6	41
890	Anticoagulation in atrial fibrillation and chronic heart failure. <i>Current Opinion in Cardiology</i> , 2016, 31, 229-234.	0.8	9
891	Stroke risk assessment in atrial fibrillation: risk factors and markers of atrial myopathy. <i>Nature Reviews Cardiology</i> , 2016, 13, 549-559.	6.1	84
892	Strategies for prediction and early detection of atrial fibrillation: present and future. <i>Europace</i> , 2016, 19, euw131.	0.7	3
893	Predictors of sinus rhythm after electrical cardioversion of atrial fibrillation: results from a data mining project on the Flec-SL trial data set. <i>Europace</i> , 2017, 19, euw144.	0.7	7
894	The Total Incidence of Complications and the Impact of an Anticoagulation Regime on Adverse Events After Cryoballoon Ablation of Atrial Fibrillation: A Single-Center Study of 409 Patients. <i>Cardiovascular Therapeutics</i> , 2016, 34, 144-151.	1.1	11
895	Left Atrial Geometry Improves Risk Prediction of Thromboembolic Events in Patients With Atrial Fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, 804-810.	0.8	38
896	Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1054-1060.	1.3	19
897	One-Year Clinical Outcome of Pulmonary Vein Isolation Using the Second-Generation Cryoballoon: A Meta-Analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 182-189.	0.5	25
898	Stroke Prevention in Atrial Fibrillation: Current Strategies and Recommendations. <i>Cardiovascular Innovations and Applications</i> , 2016, 1, .	0.1	1
899	Safe automatic one-lead electrocardiogram analysis in screening for atrial fibrillation. <i>Europace</i> , 2017, 19, euw286.	0.7	32
900	Effectiveness, safety and costs of thromboembolic prevention in patients with non-valvular atrial fibrillation: phase I ESC-FA protocol study and baseline characteristics of a cohort from a primary care electronic database. <i>BMJ Open</i> , 2016, 6, e010144.	0.8	8
901	Detection of atrial fibrillation with seismocardiography. , 2016, 2016, 4369-4374.		5
902	Diagnostic Performance of a Smartphone-Based Photoplethysmographic Application for Atrial Fibrillation Screening in a Primary Care Setting. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	197
903	Efficacy and safety of warfarin in dialysis patients with atrial fibrillation: a systematic review and meta-analysis. <i>Open Heart</i> , 2016, 3, e000441.	0.9	41
904	Warfarin persistence among atrial fibrillation patients – why is treatment ended?. <i>Cardiovascular Therapeutics</i> , 2016, 34, 468-474.	1.1	7
905	Early real-world evidence of persistence on oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a cohort study in UK primary care. <i>BMJ Open</i> , 2016, 6, e011471.	0.8	52
906	Usefulness of CHA2DS2-VASc Scoring Systems for Predicting Risk of Perioperative Embolism in Patients of Cardiac Myxomas Underwent Surgical Treatment. <i>Scientific Reports</i> , 2016, 6, 39323.	1.6	12

#	ARTICLE	IF	CITATIONS
907	Sixteen-year nationwide trends in antithrombotic drug use in Denmark and its correlation with landmark studies. <i>Heart</i> , 2016, 102, 1883-1889.	1.2	45
908	CHA ₂ DS ₂ -VASc score, left atrial size and atrial fibrillation as stroke risk factors in the TromsÅ Study. <i>Open Heart</i> , 2016, 3, e000439.	0.9	16
909	Age-dependency of prescribing patterns of oral anticoagulant drugs in Austria during 2011â€“2014. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 447-451.	1.0	12
910	Direct new oral anticoagulants: follow-up, guidelines and bleeding complications in general practiceâ€”a survey of Swiss general internal medicine practitioners. <i>SpringerPlus</i> , 2016, 5, 2030.	1.2	12
911	QTc interval predicts outcome of catheter ablation in paroxysmal atrial fibrillation patients with type 2 diabetes mellitus. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2016, 36, 646-652.	1.0	6
912	A planning system of the implant size and position for minimally-invasive closure of the left atrial appendage. , 2016, , .		1
913	Stroke prevention in atrial fibrillation and â€œreal worldâ€™ adherence to guidelines in the Balkan Region: The BALKAN-AF Survey. <i>Scientific Reports</i> , 2016, 6, 20432.	1.6	40
914	Long-term outcomes after ablation of persistent atrial fibrillation: an observational study over 6â€¦years. <i>Open Heart</i> , 2016, 3, e000394.	0.9	27
915	The year in cardiology 2015: arrhythmias and device therapy. <i>Egyptian Heart Journal</i> , 2016, 68, 311-317.	0.4	0
916	â€œThe role of novel oral anticoagulants in patients undergoing cryoballoon ablation for atrial fibrillationâ€™. <i>Hellenic Journal of Cardiology</i> , 2016, 57, 331-337.	0.4	7
917	OUP accepted manuscript. <i>Europace</i> , 2016, 18, iv35-iv43.	0.7	29
919	Advanced Left Atrial Remodeling and Appendage Contractile Dysfunction in Women Than in Men Among the Patients With Atrial Fibrillation: Potential Mechanism for Stroke. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	25
920	Validation of satisfaction questionnaire ACTS in outpatients with atrial fibrillation treated with oral anticoagulants in Spain. ALADIN Study. <i>Medicina ClÃnica (English Edition)</i> , 2016, 147, 192-198.	0.1	11
921	Thoughts about anticoagulation in older patients. <i>Medicina ClÃnica (English Edition)</i> , 2016, 147, 151-153.	0.1	0
925	La fibrilaciÃ³n auricular en las guÃas de prÃctica clÃnica. <i>Revista Espanola De Cardiologia Suplementos</i> , 2016, 16, 52-54.	0.2	0
926	Opportunistic screening of atrial fibrillation by automatic blood pressure measurement in the community: TableA1. <i>BMJ Open</i> , 2016, 6, e010745.	0.8	22
927	Antithrombotic stewardship: a multidisciplinary team approach towards improving antithrombotic therapy outcomes during and after hospitalisation: a study protocol. <i>BMJ Open</i> , 2016, 6, e011537.	0.8	7
928	Cost-effectiveness analysis of left atrial appendage occlusion compared with pharmacological strategies for stroke prevention in atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 167.	0.7	14

#	ARTICLE	IF	CITATIONS
929	IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. <i>BMJ Open</i> , 2016, 6, e012241.	0.8	14
930	Major Bleeding in Patients with Non-Valvular Atrial Fibrillation: Impact of Time in Therapeutic Range on Contemporary Bleeding Risk Scores. <i>Scientific Reports</i> , 2016, 6, 24376.	1.6	49
931	Potassium Channel Remodeling in Heart Disease. <i>Cardiac Electrophysiology Clinics</i> , 2016, 8, 337-347.	0.7	5
932	Vernakalant is superior to ibutilide for achieving sinus rhythm in patients with recent-onset atrial fibrillation: a randomized controlled trial at the emergency department. <i>Europace</i> , 2017, 19, euw052.	0.7	32
933	Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA ₂ DS ₂ -VASc Score of 1. <i>Stroke</i> , 2016, 47, 1364-1367.	1.0	82
934	How to Manage Occult Atrial Fibrillation Detected on Long-Term Monitoring. <i>Circulation</i> , 2016, 133, 1290-1295.	1.6	7
936	Ultrasound-guided cannulation of the femoral vein in electrophysiological procedures: a systematic review and meta-analysis. <i>Europace</i> , 2017, 19, euw113.	0.7	38
937	Performance of a new atrial fibrillation detection algorithm in a miniaturized insertable cardiac monitor: Results from the Reveal LINQ Usability Study. <i>Heart Rhythm</i> , 2016, 13, 1425-1430.	0.3	130
938	Antithrombotic therapy in patients with non-valvular atrial fibrillation in Southern Sweden: A population-based cohort study. <i>Thrombosis Research</i> , 2016, 140, 94-99.	0.8	20
939	Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. <i>Clinical Pharmacokinetics</i> , 2016, 55, 641-655.	1.6	160
940	Utilidad de vernakalant en la estabilizaci3n del ritmo sinusal durante procedimientos de ablaci3n por cat3ter. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 708-709.	0.6	0
941	Plasma homocysteine levels predict early recurrence after catheter ablation of persistent atrial fibrillation. <i>Europace</i> , 2016, 19, euw081.	0.7	21
942	Electrical Isolation of Pulmonary Veins Using Laser Catheter in the Treatment of Paroxysmal and Persistent Atrial Fibrillation. One-year Results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 488-493.	0.4	8
943	Triple Oral Antithrombotic Therapy in Atrial Fibrillation and Coronary Artery Stenting: Searching for the Best Combination. <i>Seminars in Thrombosis and Hemostasis</i> , 2016, 42, 662-670.	1.5	12
944	Clinical Characteristics and Outcomes in Extreme Elderly (Age ≥ 85 Years) Japanese Patients With Atrial Fibrillation. <i>Chest</i> , 2016, 149, 401-412.	0.4	80
946	Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 671-679.	0.8	26
947	A Comparison of Oral Anticoagulant Use for Atrial Fibrillation in the Pre- and Post-DOAC Eras. <i>Drugs and Aging</i> , 2016, 33, 427-436.	1.3	28
948	Cost comparison of radiofrequency catheter ablation versus cryoablation for atrial fibrillation in hospitals using both technologies. <i>Journal of Medical Economics</i> , 2016, 19, 959-964.	1.0	14

#	ARTICLE	IF	CITATIONS
949	Real Data on Effectiveness, Tolerability and Safety of New Oral Anticoagulant Agents: Focus on Dabigatran. High Blood Pressure and Cardiovascular Prevention, 2016, 23, 115-122.	1.0	1
950	Stroke prevention for patients with atrial fibrillation: values and preferences of Canadian emergency medicine trainees. American Journal of Emergency Medicine, 2016, 34, 1685-1687.	0.7	7
951	Efficacy and Safety of Percutaneous Left Atrial Appendage Occlusion for Stroke Prevention in Nonvalvular Atrial Fibrillation: A Meta-analysis of Contemporary Studies. Heart Lung and Circulation, 2016, 25, 1107-1117.	0.2	10
952	â€œReal-worldâ€™ atrial fibrillation management in Europe: observations from the 2-year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase. Europace, 2016, 19, euw112.	0.7	55
953	Left atrial appendage morphology, echocardiographic characterization, procedural data and in-hospital outcome of patients receiving left atrial appendage occlusion device implantation: a prospective observational study. BMC Cardiovascular Disorders, 2016, 16, 25.	0.7	12
954	The impact of ischaemic stroke on atrial fibrillation-related healthcare cost: a systematic review. Europace, 2017, 19, euw093.	0.7	24
955	Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis. Nature Reviews Cardiology, 2016, 13, 321-332.	6.1	236
956	Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacological Research, 2016, 107, 1-18.	3.1	57
957	Can biomarkers balance stroke and bleeding risk?. Lancet, The, 2016, 387, 2266-2268.	6.3	4
958	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂) Tj ETQq1 1,0,784314,rgBT /Ove 1.6 33	1.6	33
959	Should Patients With Atrial Fibrillation and 1 Stroke Risk Factor (CHA ₂ DS ₂) Tj ETQq0 0,0,rgBT /Ove 1.6 15	1.6	15
960	Pharmacoepidemiological comparisons between acenocoumarol and dabigatran: interpretation of data reflecting clinical practice. Europace, 2016, 18, 1283-1284.	0.7	0
962	Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations. International Journal of Cardiology, 2016, 203, 465-473.	0.8	70
963	Multielectrode Pulmonary Vein Isolation Versus Single Tip Wide Area Catheter Ablation-Paroxysmal Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2016, 9, e004077.	2.1	1
964	The Risk of Hospital Admission Due to Traumatic Brain Injury IsÂIncreased in Older Persons With Severe Functional Limitations. Journal of the American Medical Directors Association, 2016, 17, 609-612.	1.2	11
966	CHA2DS2-Vasc score, age and body mass index as the main risk factors of hyperintense brain lesions in asymptomatic patients with paroxysmal non-valvular atrial fibrillation. International Journal of Cardiology, 2016, 215, 476-481.	0.8	8
967	Outcomes in a Warfarin-Treated Population With Atrial Fibrillation. JAMA Cardiology, 2016, 1, 172.	3.0	119
968	Left atrial thrombi and spontaneous echo contrast in patients with atrial fibrillation. Herz, 2016, 41, 706-714.	0.4	12

#	ARTICLE	IF	CITATIONS
969	Ablation of atrial fibrillation in patients ≥75 years: long-term clinical outcome and safety. <i>Europace</i> , 2016, 18, 543-549.	0.7	65
970	Electrocardiogram interpretation and arrhythmia management: a primary and secondary care survey. <i>British Journal of General Practice</i> , 2016, 66, e291-e296.	0.7	17
971	How to treat post-operative complications: An evidence-based approach. <i>Bailliere's Best Practice and Research in Clinical Anaesthesiology</i> , 2016, 30, 229-236.	1.7	1
972	Does left atrial appendage (LAA) occlusion device alter the echocardiography and electrocardiogram parameters in patients with atrial fibrillation?. <i>International Journal of Cardiology</i> , 2016, 215, 494-501.	0.8	3
973	Red blood cell distribution width and atrial fibrillation in patients with sick sinus syndrome. <i>Journal of Cardiology</i> , 2016, 67, 551-554.	0.8	12
974	Clinical and economic impact of rivaroxaban on the burden of atrial fibrillation: The case study of Japan. <i>Journal of Medical Economics</i> , 2016, 19, 889-899.	1.0	1
975	Evolving Treatments for Arterial and Venous Thrombosis. <i>Circulation Research</i> , 2016, 118, 1409-1424.	2.0	96
976	Left atrial posterior wall isolation reduces the recurrence of atrial fibrillation: a meta-analysis. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 267-274.	0.6	85
977	Use of a contact force-sensing ablation catheter with advanced catheter location significantly reduces fluoroscopy time and radiation dose in catheter ablation of atrial fibrillation. <i>Europace</i> , 2016, 18, 211-218.	0.7	41
978	The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , 2016, 29, 537-544.	1.2	29
979	The role of comprehensive geriatric assessment and functional status in evaluating the patterns of antithrombotic use among older people with atrial fibrillation. <i>Archives of Gerontology and Geriatrics</i> , 2016, 65, 248-254.	1.4	9
980	Atrial Fibrillation Ablation and Stroke. <i>Cardiology Clinics</i> , 2016, 34, 307-316.	0.9	3
981	Determination of rivaroxaban, apixaban and edoxaban in rat plasma by UPLC-MS/MS method. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 205-211.	1.0	40
982	The role of the Arrhythmia Team, an integrated, multidisciplinary approach to treatment of patients with cardiac arrhythmias: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2016, 18, 623-627.	0.7	25
983	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. <i>International Journal of Cardiology</i> , 2016, 217, 42-48.	0.8	6
984	Getting approval for new therapeutic medical devices versus drugs: are the differences justified?. <i>European Respiratory Review</i> , 2016, 25, 223-226.	3.0	3
985	Anti-arrhythmic strategies for atrial fibrillation. , 2016, 168, 126-142.		29
986	EHRA/HRS/APHRS/SOLAECE expert consensus on Atrial cardiomyopathies: Definition, characterisation, and clinical implication. <i>Journal of Arrhythmia</i> , 2016, 32, 247-278.	0.5	92

#	ARTICLE	IF	CITATIONS
987	Diagnosis and Management of Acute Intracerebral Hemorrhage. <i>Emergency Medicine Clinics of North America</i> , 2016, 34, 883-899.	0.5	89
988	Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience. <i>American Journal of Medicine</i> , 2016, 129, S33-S40.	0.6	74
989	Edoxaban Versus Warfarin in Atrial Fibrillation Patients at Risk of Falling. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1169-1178.	1.2	133
990	Screening for Atrial Fibrillation Using a Smartphone: Is There an App for That?. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	33
991	New Role of Biomarkers in Atrial Fibrillation. , 2016, , 507-539.		0
992	Unanswered Questions in Complex Fractionated Atrial Electrogram Ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1269-1278.	0.5	10
993	Total endoscopic ablation of patients with long-standing persistent atrial fibrillation: a randomized controlled study. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 23, 292-298.	0.5	6
994	Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2016, 175, 359-364.	1.2	25
995	Flutter auricular at pico tardio aps ablao de fibrilhao auricular. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 539.e1-539.e6.	0.2	2
996	Estudo HIPOGAIA: monitorizao da hipocoagulao oral com dicumarnicos no concelho de Gaia. <i>Revista Portuguesa De Cardiologia</i> , 2016, 35, 459-465.	0.2	4
997	The HIPOGAIA study: Monitoring of oral anticoagulation with vitamin K antagonists in the municipality of Gaia. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 459-465.	0.2	3
998	Use of the new contact force sensing ablation catheter dramatically reduces fluoroscopy time during atrial fibrillation ablation procedures. <i>Indian Pacing and Electrophysiology Journal</i> , 2016, 16, 83-87.	0.3	5
1000	Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal. <i>Critical Care</i> , 2016, 20, 273.	2.5	19
1002	Determinants of Time in Therapeutic Range in Patients Receiving Oral Anticoagulants (A Substudy of Tj ETQq1 1 0.784314 rgBT /Ovele	0.7	18
1003	Initial experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation: A single-centre registry. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 689-695.	0.7	0
1004	Cross-talk between macrophages and atrial myocytes in atrial fibrillation. <i>Basic Research in Cardiology</i> , 2016, 111, 63.	2.5	95
1005	Patient factors associated with quality of life in atrial fibrillation. <i>American Heart Journal</i> , 2016, 182, 135-143.	1.2	62
1006	Renal sympathetic denervation for treatment of patients with atrial fibrillation: Reappraisal of the available evidence. <i>Heart Rhythm</i> , 2016, 13, 2388-2394.	0.3	20

#	ARTICLE	IF	CITATIONS
1007	3D Printing for Left Atrial Appendage (LAA) Modeling Based on Transesophageal Echocardiography: A Step Forward in Closure with LAA Devices. <i>Cardiology</i> , 2016, 135, 249-254.	0.6	5
1008	Left Atrial Appendage Closure for Stroke Prevention in Atrial Fibrillation. <i>Current Atherosclerosis Reports</i> , 2016, 18, 65.	2.0	6
1009	New Oral Anticoagulants and Their Reversal Agents. <i>Current Treatment Options in Neurology</i> , 2016, 18, 47.	0.7	18
1010	Medication management strategy for older people with polypharmacy in general practice: a qualitative study on prescribing behaviour in primary care. <i>British Journal of General Practice</i> , 2016, 66, e540-e551.	0.7	26
1011	Cardiovascular Biomarker Score and Clinical Outcomes in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2016, 1, 999.	3.0	64
1012	Risk Prediction With Electronic Health Records. <i>JAMA Cardiology</i> , 2016, 1, 976.	3.0	25
1013	Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed. <i>American Journal of Emergency Medicine</i> , 2016, 34, 19-25.	0.7	3
1014	Late atypical atrial flutter after ablation of atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 539.e1-539.e6.	0.2	0
1017	Bleeding with direct oral anticoagulants vs warfarin: clinical experience. <i>American Journal of Emergency Medicine</i> , 2016, 34, 3-8.	0.7	25
1018	Place of non-vitamin K antagonist oral anticoagulants in anticoagulant+antiplatelet combinations in peripheral artery disease. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 634-640.	0.7	1
1019	30-year nationwide trends in incidence of atrial fibrillation in Denmark and associated 5-year risk of heart failure, stroke, and death. <i>International Journal of Cardiology</i> , 2016, 225, 30-36.	0.8	45
1020	New oral anticoagulants versus Warfarin in patients undergoing cardioversion of atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 225, 244-246.	0.8	5
1021	Is an Oral Anticoagulant Necessary for Young Atrial Fibrillation Patients With a CHA ₂ DS ₂ -VASc Score of 1 (Men) or 2 (Women)? <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	18
1022	Left Atrial Appendage Closure Under Intracardiac Echocardiographic Guidance: Feasibility and Comparison With Transesophageal Echocardiography. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	47
1023	New oral anticoagulants and dual antiplatelet therapy: Focus on apixaban. <i>International Journal of Cardiology</i> , 2016, 225, 154-158.	0.8	0
1024	Addition of TGF- β 21 to existing clinical risk scores does not improve prediction for arrhythmia recurrences after catheter ablation of atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 221, 52-54.	0.8	5
1025	Non-vitamin K oral anticoagulant treatment in elderly patients with atrial fibrillation and coronary heart disease. <i>International Journal of Cardiology</i> , 2016, 222, 1079-1083.	0.8	10
1026	Laserballoon and Cryoballoon Pulmonary Vein Isolation in Persistent and Longstanding Persistent Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 1099-1107.	0.5	8

#	ARTICLE	IF	CITATIONS
1027	Atrial Fibrillation Patients Treated With Long-Term Warfarin Anticoagulation Have Higher Rates of All Dementia Types Compared With Patients Receiving Long-Term Warfarin for Other Indications. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	43
1028	Prognostic Implications of Left Ventricular Scar Determined by Late Gadolinium Enhanced Cardiac Magnetic Resonance in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2016, 118, 991-997.	0.7	12
1029	Reversal agents for direct oral anticoagulants: A focused review. <i>International Journal of Cardiology</i> , 2016, 223, 244-250.	0.8	10
1030	Switching therapy from intravenous beta blocker to bisoprolol transdermal patch for atrial fibrillation tachycardia. <i>Journal of Anesthesia</i> , 2016, 30, 891-894.	0.7	8
1031	Factors associated with abrupt discontinuation of dabigatran therapy in patients with atrial fibrillation in Malaysia. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1182-1190.	1.0	5
1032	Anesthesia and Transesophageal Echocardiography for WATCHMAN Device Implantation. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , 2016, 30, 1685-1692.	0.6	13
1033	Tailored treatment strategies: a new approach for modern management of atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016, 279, 457-466.	2.7	9
1034	Safety and Long-Term Outcomes of Catheter Ablation of Atrial Fibrillation Using Magnetic Navigation versus Manual Conventional Ablation: A Propensity Score Analysis. <i>Journal of Cardiovascular Electrophysiology</i> , 2016, 27, S11-6.	0.8	21
1035	A tailored treatment strategy: a modern approach for stroke prevention in patients with atrial fibrillation. <i>Journal of Internal Medicine</i> , 2016, 279, 467-476.	2.7	13
1036	Relationship between smoking and adverse outcomes in patients with atrial fibrillation: A meta-analysis and systematic review. <i>International Journal of Cardiology</i> , 2016, 222, 289-294.	0.8	14
1037	Atrial Fibrillation in Transient Ischemic Attack Versus Ischemic Stroke. <i>Stroke</i> , 2016, 47, 2456-2461.	1.0	27
1038	Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. <i>Lancet</i> , The, 2016, 388, 1995-2003.	6.3	206
1040	Re-Initiation of Dabigatran and Direct Factor Xa Antagonists After a Major Bleed. <i>American Journal of Medicine</i> , 2016, 129, S54-S63.	0.6	9
1041	Concomitant Use of Single Antiplatelet Therapy With Edoxaban or Warfarin in Patients With Atrial Fibrillation: Analysis From the ENGAGE AF-TIMI48 Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	93
1042	Anticoagulation therapy in atrial fibrillation after intracranial hemorrhage. <i>Heart Rhythm</i> , 2016, 13, 1794-1802.	0.3	33
1043	Cardiology residents' anticoagulation preferences for stroke prophylaxis in atrial fibrillation patients. <i>International Journal of Cardiology</i> , 2016, 223, 63-64.	0.8	0
1044	Risk Stratification for Recurrence and Mortality in Embolic Stroke of Undetermined Source. <i>Stroke</i> , 2016, 47, 2278-2285.	1.0	69
1045	International normalised ratio stability in patients aged 80 years and over taking warfarin for non-valvular atrial fibrillation. <i>European Geriatric Medicine</i> , 2016, 7, 411-415.	1.2	0

#	ARTICLE	IF	CITATIONS
1046	Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: Real-world data from the GARFIELD-AF registry. <i>International Journal of Cardiology</i> , 2016, 223, 543-547.	0.8	71
1048	Rhythm control in atrial fibrillation. <i>Lancet, The</i> , 2016, 388, 829-840.	6.3	112
1049	Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints, and data collection requirements for clinical studies. <i>Europace</i> , 2017, 19, euw141.	0.7	120
1050	Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. <i>The Cochrane Library</i> , 2016, 2016, CD012088.	1.5	33
1051	Effects of Triple Therapy in Patients With Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention Regarding Thromboembolic Risk Stratification. <i>Circulation Journal</i> , 2016, 80, 354-362.	0.7	25
1052	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure—Subanalysis of the WARCEF Trial. <i>Circulation Journal</i> , 2016, 80, 619-626.	0.7	11
1053	Triple Antithrombotic Therapy—Always One Too Many? <i>Circulation Journal</i> , 2016, 80, 316-317.	0.7	1
1054	A prospective study investigating the causes of warfarin under-utilization in Chinese patients. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 1286-1293.	1.0	5
1055	Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm. <i>The Cochrane Library</i> , 2016, 9, CD003333.	1.5	11
1057	Dabigatran Versus Warfarin for Direct Current Cardioversion in Atrial Fibrillation. <i>Cardiology and Therapy</i> , 2016, 5, 215-221.	1.1	8
1058	Ablation of Atrial Fibrillation. <i>Circulation</i> , 2016, 134, 339-352.	1.6	46
1059	“One-Stop Shop”: <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1487-1495.	1.1	29
1060	Appropriate Apixaban Dosing. <i>JAMA Cardiology</i> , 2016, 1, 635.	3.0	16
1061	Valvular-CHADS-VASc as a safer alternative to CHADS-VASc score. <i>International Journal of Cardiology</i> , 2016, 221, 1051-1052.	0.8	1
1062	Imaging Techniques in Percutaneous Cardiac Structural Interventions: Atrial Septal Defect Closure and Left Atrial Appendage Occlusion. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 766-777.	0.4	2
1063	Association between Renal Function and Bleeding Risk for Dabigatran after Switching from Warfarin. <i>American Journal of Nephrology</i> , 2016, 44, 11-18.	1.4	9
1064	Impact of type 2 diabetes mellitus in hospitalizations for atrial fibrillation in Spain (2004–2013). <i>International Journal of Cardiology</i> , 2016, 221, 688-694.	0.8	10
1065	Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1705-1710.	0.7	55

#	ARTICLE	IF	CITATIONS
1066	Update on Echocardiographic Assessment in Diabetes Mellitus. <i>Current Cardiology Reports</i> , 2016, 18, 85.	1.3	12
1067	High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 558-565.	1.0	3
1068	Cost-effectiveness of screening for atrial fibrillation in primary care with a handheld, single-lead electrocardiogram device in the Netherlands. <i>Europace</i> , 2018, 20, euw285.	0.7	63
1069	Role of adenosine-guided pulmonary vein isolation in patients undergoing catheter ablation for atrial fibrillation: a meta-analysis. <i>Europace</i> , 2016, 19, euw201.	0.7	18
1073	DOACs "advances and limitations in real world. <i>Thrombosis Journal</i> , 2016, 14, 17.	0.9	69
1074	European Society of Cardiology Guideline-Adherent Antithrombotic Treatment and Risk of Mortality in Asian Patients with Atrial Fibrillation. <i>Scientific Reports</i> , 2016, 6, 30734.	1.6	14
1075	Electronic Alert System for Improving Stroke Prevention Among Hospitalized Oral Anticoagulation-Naïve Patients With Atrial Fibrillation: A Randomized Trial. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	29
1076	Applications of 3D printing in cardiovascular diseases. <i>Nature Reviews Cardiology</i> , 2016, 13, 701-718.	6.1	318
1077	Data mining experiments on the Angiotensin II-Antagonist in Paroxysmal Atrial Fibrillation (ANTIPAF-AFNET 2) trial: "exposing the invisible"™. <i>Europace</i> , 2016, 19, euw084.	0.7	2
1078	The rs6771157 C/G polymorphism in SCN10A is associated with the risk of atrial fibrillation in a Chinese Han population. <i>Scientific Reports</i> , 2016, 6, 35212.	1.6	2
1079	Cryoballoon ablation of persistent atrial fibrillation: feasibility and safety of left atrial roof ablation with generation of conduction block in addition to antral pulmonary vein isolation. <i>Europace</i> , 2016, 19, euw146.	0.7	41
1080	Poor anticoagulation relates to extended access times for cardioversion and is associated with long-term major cardiac and cerebrovascular events. <i>International Journal of Cardiology</i> , 2016, 225, 337-341.	0.8	1
1081	Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: Temporal trends 2011-2015 in Denmark. <i>Scientific Reports</i> , 2016, 6, 31477.	1.6	80
1082	Ranolazine reduces atrial fibrillatory wave frequency. <i>Europace</i> , 2016, 19, euw200.	0.7	7
1083	Stroke prevention strategies in patients with atrial fibrillation and heart valve abnormalities: perceptions of "valvular"™ atrial fibrillation: results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1593-1598.	0.7	13
1084	New antiarrhythmic drugs for atrial fibrillation. <i>Continuing Cardiology Education</i> , 2016, 2, 151-157.	0.4	3
1085	Primary prevention of atrial fibrillation with beta-blockers in patients with end-stage renal disease undergoing dialysis. <i>Scientific Reports</i> , 2016, 5, 17731.	1.6	8
1086	Stroke and thromboembolic event rates in atrial fibrillation according to different guideline treatment thresholds: A nationwide cohort study. <i>Scientific Reports</i> , 2016, 6, 27410.	1.6	67

#	ARTICLE	IF	CITATIONS
1087	Clinical events preceding switching and discontinuation of oral anticoagulant treatment in patients with atrial fibrillation. <i>Europace</i> , 2017, 19, euw241.	0.7	29
1088	Sex based subgroup differences in randomized controlled trials: empirical evidence from Cochrane meta-analyses. <i>BMJ, The</i> , 2016, 355, i5826.	3.0	56
1089	Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ, The</i> , 2016, 353, i3189.	3.0	351
1090	Prediction of rates of thromboembolic and major bleeding outcomes with dabigatran or warfarin among patients with atrial fibrillation: new initiator cohort study. <i>BMJ, The</i> , 2016, 353, i2607.	3.0	28
1091	The β 2 Adrenergic Receptor Agonist BRL37344 Exacerbates Atrial Structural Remodeling Through iNOS Uncoupling in Canine Models of Atrial Fibrillation. <i>Cellular Physiology and Biochemistry</i> , 2016, 38, 514-530.	1.1	12
1092	Burden of upper gastrointestinal symptoms in patients prescribed dabigatran for stroke prevention. <i>SAGE Open Medicine</i> , 2016, 4, 205031211666241.	0.7	5
1095	Presence of diabetic microvascular complications does not incrementally increase risk of ischemic stroke in diabetic patients with atrial fibrillation. <i>Medicine (United States)</i> , 2016, 95, e3992.	0.4	6
1096	Obey the first recommendation: start screening programmes for atrial fibrillation<xref ref-type="fn" rid="AN1" />. <i>Europace</i> , 2016, 18, 1753-1755.	0.7	2
1097	Left atrial appendage closure versus oral anticoagulation for preventing stroke in people with atrial fibrillation. <i>The Cochrane Library</i> , 0, , .	1.5	0
1098	A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. <i>Medicine (United States)</i> , 2016, 95, e4382.	0.4	8
1099	Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation. <i>Medicine (United States)</i> , 2016, 95, e5581.	0.4	15
1100	Light-based Approaches to Cardiac Arrhythmia Research: From Basic Science to Translational Applications. <i>Clinical Medicine Insights: Cardiology</i> , 2016, 10s1, CMC.S39711.	0.6	7
1101	Continuous Cardiac Monitoring around Atrial Fibrillation Ablation: Insights on Clinical Classifications and End Points. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2016, 39, 805-813.	0.5	12
1102	Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study. <i>Clinical Research in Cardiology</i> , 2016, 105, 912-920.	1.5	63
1103	Clinical trials with direct oral anticoagulants for stroke prevention in atrial fibrillation: how representative are they for real life patients?. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1125-1134.	0.8	18
1104	Rationale and design of the ODIn-AF Trial: randomized evaluation of the prevention of silent cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 95-105.	1.5	10
1105	Education and practice gaps on atrial fibrillation and anticoagulation: a survey of cardiovascular nurses. <i>BMC Medical Education</i> , 2016, 16, 9.	1.0	24
1106	Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. <i>European Heart Journal</i> , 2017, 38, ehw058.	1.0	203

#	ARTICLE	IF	CITATIONS
1107	Screening for atrial fibrillation in primary care: From recommendation to implementation. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 1880-1882.	0.8	3
1108	Resuming anticoagulant therapy after intracerebral bleeding. <i>Vascular Pharmacology</i> , 2016, 84, 15-24.	1.0	17
1109	Three-dimensional left atrial blood flow characteristics in patients with atrial fibrillation assessed by 4D flow CMR. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 1259-1268.	0.5	46
1110	Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. <i>Europace</i> , 2016, 18, 1514-1520.	0.7	104
1111	Can screening for atrial fibrillation be implemented at scale?. <i>Europace</i> , 2016, 18, 1449-1451.	0.7	6
1112	Increased risk of stroke and mortality following new-onset atrial fibrillation during hospitalization. <i>Europace</i> , 2017, 19, euw110.	0.7	9
1113	Defining nonvalvular atrial fibrillation: A quest for clarification. <i>American Heart Journal</i> , 2016, 178, 161-167.	1.2	17
1114	Interventional left atrial appendage occlusion: added value of 3D transesophageal echocardiography for device sizing. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 1363-1370.	0.7	12
1115	Evaluation of 5 Prognostic Scores for Prediction of Stroke, Thromboembolic and Coronary Events, All-Cause Mortality, and Major Adverse Cardiac Events in Patients With Atrial Fibrillation and Coronary Stenting. <i>American Journal of Cardiology</i> , 2016, 118, 700-707.	0.7	22
1116	How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?. <i>American Journal of Cardiology</i> , 2016, 118, 697-699.	0.7	9
1117	Response. <i>Chest</i> , 2016, 149, 1590-1591.	0.4	0
1118	Reduction of radiation exposure in cryoballoon ablation procedures: a single-centre study applying intracardiac echocardiography and other radioprotective measures. <i>Europace</i> , 2017, 19, euw139.	0.7	22
1119	Pacientes con anticoagulaci3n oral supervisados en consultas de atenci3n primaria: estudio en un centro de salud. <i>Medicina General Y De Familia</i> , 2016, 5, 91-96.	0.1	0
1120	The Usefulness of Vernakalant in Maintaining Sinus Rhythm During Ablation Procedures. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 708-709.	0.4	0
1121	Percutaneous management of periprocedural cardiac perforation during left atrial appendage closure. <i>Clinical Research in Cardiology</i> , 2016, 105, 463-466.	1.5	2
1122	The importance of catheter stability evaluated by VisitagTM during pulmonary vein isolation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 161-166.	0.6	12
1123	Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking. <i>Biochemical Pharmacology</i> , 2016, 113, 24-35.	2.0	34
1124	Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials. <i>EBioMedicine</i> , 2016, 8, 309-316.	2.7	31

#	ARTICLE	IF	CITATIONS
1125	Atrial fibrillation and gastroesophageal reflux disease: the cardiogastric interaction. <i>Europace</i> , 2016, 19, euw092.	0.7	37
1126	Learning to Make Decisions: Are Medical Postgraduate Trainees Getting With the Atrial Fibrillation Guidelines?. <i>Canadian Journal of Cardiology</i> , 2016, 32, 714-716.	0.8	0
1127	The utility of a CHA ₂ DS ₂ -VASc score in predicting the presence of significant stenosis and occlusion of veins with indwelling endocardial leads. <i>International Journal of Cardiology</i> , 2016, 218, 164-169.	0.8	4
1128	How much does the choice of new oral anticoagulant matter for reducing the burden of stroke in atrial fibrillation?. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 149-151.	0.2	0
1129	The arrhythmic burden in patients with sarcoidosis. Is it a real concern?. <i>The Egyptian Journal of Chest Diseases and Tuberculosis</i> , 2016, 65, 311-317.	0.1	3
1130	Association between peripheral plasma markers and left atrial anatomy in patients with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 621-623.	0.8	2
1132	Prevalence and associating factors of atrial fibrillation in patients with hypertension: a nation-wide study. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 57.	0.7	27
1133	Decision-making around antithrombotics for stroke prevention in atrial fibrillation: the health professionals' views. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 985-995.	1.0	11
1134	Reduced residual conduction gaps and favourable outcome in contact force-guided circumferential pulmonary vein isolation. <i>Europace</i> , 2016, 18, 531-537.	0.7	36
1135	Data on procedural handling and complications of pulmonary vein isolation using the pulmonary vein ablation catheter GOLD [®] . <i>Europace</i> , 2016, 18, 696.1-701.	0.7	19
1136	A population screening programme for atrial fibrillation: a report from the Belgian Heart Rhythm Week screening programme. <i>Europace</i> , 2016, 18, euw069.	0.7	55
1137	Results from a multicentre comparison of cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: is cryoablation more reproducible?. <i>Europace</i> , 2017, 19, euw080.	0.7	108
1138	- LAA Occluder View for post-implantation Evaluation (LOVE) - standardized imaging proposal evaluating implanted left atrial appendage occlusion devices by cardiac computed tomography. <i>BMC Medical Imaging</i> , 2016, 16, 25.	1.4	29
1140	Cryoballoon ablation for pulmonary vein isolation in patients with atrial fibrillation: preliminary results using novel short-tip cryoballoon. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 47, 91-98.	0.6	5
1141	Anticoagulation for Cardioversion of Acute Onset Atrial Fibrillation. <i>JACC: Clinical Electrophysiology</i> , 2016, 2, 495-497.	1.3	4
1142	Catheter Ablation as First-Line Therapy for Atrial Fibrillation: Ready for Prime-Time?. <i>Current Cardiology Reports</i> , 2016, 18, 71.	1.3	5
1143	Patients' experiences of communication and involvement in decision-making about atrial fibrillation treatment in consultations with nurses and physicians. <i>Scandinavian Journal of Caring Sciences</i> , 2016, 30, 535-546.	1.0	18
1144	Non-vitamin K oral anticoagulants in patients with atrial fibrillation after cardiac surgery: the results of the European Heart Rhythm Association Survey. <i>Europace</i> , 2016, 18, 1113-1116.	0.7	12

#	ARTICLE	IF	CITATIONS
1145	Comparison of international normalized ratio audit parameters in patients enrolled in GARFIELDâ€AF and treated with vitamin K antagonists. <i>British Journal of Haematology</i> , 2016, 174, 610-623.	1.2	13
1146	One-year follow-up after irrigated multi-electrode radiofrequency ablation of persistent atrial fibrillation. <i>Europace</i> , 2016, 18, 85-91.	0.7	9
1147	A porcine model of early atrial fibrillation using a custom-built, radio transmission-controlled pacemaker. <i>Journal of Electrocardiology</i> , 2016, 49, 124-131.	0.4	8
1148	Device-identified atrial fibrillation at pacing clinics. Should it guide anticoagulation?. <i>International Journal of Cardiology</i> , 2016, 207, 378-381.	0.8	7
1149	Respiratory gating algorithm helps to reconstruct more accurate electroanatomical maps during atrial fibrillation ablation performed under spontaneous respiration. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 153-159.	0.6	1
1150	Stroke Prevention in Atrial Fibrillation: A Clinical Perspective on Trials of the Novel Oral Anticoagulants. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 201-214.	1.3	18
1151	Values and Preferences of Physicians and Patients With Nonvalvular Atrial Fibrillation Who Receive Oral Anticoagulation Therapy for Stroke Prevention. <i>Canadian Journal of Cardiology</i> , 2016, 32, 747-753.	0.8	97
1152	One-year clinical outcome after ablation with a novel multipolar irrigated ablation catheter for treatment of atrial fibrillation: potential implications for clinical use. <i>Europace</i> , 2016, 18, 1170-1178.	0.7	17
1153	Individualized approaches to thromboprophylaxis in atrial fibrillation. <i>American Heart Journal</i> , 2016, 173, 143-158.	1.2	12
1154	Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 134-140.	0.4	4
1155	Adequacy of ESC atrial fibrillation guidelines in the elderly population: Analysis of practices from an internal medicine department. <i>European Geriatric Medicine</i> , 2016, 7, 23-27.	1.2	1
1156	Analysis of catheter contact force during atrial fibrillation ablation using the robotic navigation system: results from a randomized study. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2016, 46, 97-103.	0.6	24
1157	Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. <i>Cerebrovascular Diseases</i> , 2016, 41, 226-232.	0.8	4
1158	Cost-effectiveness of an insertable cardiac monitor to detect atrial fibrillation in patients with cryptogenic stroke. <i>International Journal of Stroke</i> , 2016, 11, 302-312.	2.9	64
1159	Impact of Complete Versus Incomplete Circumferential Lines Around the Pulmonary Veins During Catheter Ablation of Paroxysmal Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, e003337.	2.1	213
1160	Safety profile of multielectrode-phased radiofrequency pulmonary vein ablation catheter and irrigated radiofrequency catheter. <i>Europace</i> , 2016, 18, 78-84.	0.7	19
1161	Underuse of anticoagulation in patients with atrial fibrillation. <i>Postgraduate Medicine</i> , 2016, 128, 191-200.	0.9	30
1162	Factor Xa inhibitors: a novel therapeutic class for the treatment of nonvalvular atrial fibrillation. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2016, 10, 37-49.	1.0	13

#	ARTICLE	IF	CITATIONS
1163	Comorbidity of atrial fibrillation and heart failure. <i>Nature Reviews Cardiology</i> , 2016, 13, 131-147.	6.1	152
1164	Non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a call for action. <i>Europace</i> , 2016, 18, 1-3.	0.7	44
1165	Antithrombotic management in patients with atrial fibrillation undergoing coronary stent implantation: What is the impact of guideline adherence?. <i>International Journal of Cardiology</i> , 2016, 203, 987-994.	0.8	21
1166	Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. <i>European Heart Journal</i> , 2016, 37, 2465-2474.	1.0	410
1167	Treatment of stand-alone atrial fibrillation with a right thoracoscopic approach employing a microwave or monopolar radiofrequency energy source: long-term results. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2016, 22, 762-768.	0.5	9
1168	Cryoballoon ablation for persistent atrial fibrillation – Large single-center experience. <i>Journal of Cardiology</i> , 2016, 68, 492-497.	0.8	31
1169	Cost effectiveness of left atrial appendage closure with the Watchman device for atrial fibrillation patients with absolute contraindications to warfarin. <i>Europace</i> , 2016, 18, 979-986.	0.7	44
1170	How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. <i>Annals of Hematology</i> , 2016, 95, 437-449.	0.8	56
1171	Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. <i>Heart and Vessels</i> , 2016, 31, 2025-2034.	0.5	13
1172	Emerging Tools for Stroke Prevention in Atrial Fibrillation. <i>EBioMedicine</i> , 2016, 4, 26-39.	2.7	15
1173	Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VerT trial. <i>Europace</i> , 2016, 18, 184-190.	0.7	28
1174	Differences in attitude, education, and knowledge about oral anticoagulation therapy among patients with atrial fibrillation in Europe: result of a self-assessment patient survey conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 463-467.	0.7	49
1175	Regional differences in referral, procedures, and outcome after ablation for atrial fibrillation in Europe: a report from the Atrial Fibrillation Ablation Pilot Registry of the European Society of Cardiology. <i>Europace</i> , 2016, 18, 191-200.	0.7	13
1177	Drug Therapy for Rate and Rhythm Control in Nonvalvular Atrial Fibrillation: A Cross-sectional Study With Electronic Health Records in a Primary Care Cohort. <i>Clinical Therapeutics</i> , 2016, 38, 863-873.	1.1	0
1178	Budget Impact of Increasing Market Share of Patient Self-Testing and Patient Self-Management in Anticoagulation. <i>Value in Health</i> , 2016, 19, 383-390.	0.1	4
1179	Role of insertable cardiac monitors in anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding. <i>Europace</i> , 2016, 18, 799-806.	0.7	15
1180	Efficacy and safety of rivaroxaban compared with vitamin K antagonists for peri-procedural anticoagulation in catheter ablation of atrial fibrillation: a systematic review and meta-analysis. <i>Europace</i> , 2016, 18, euv408.	0.7	21
1181	Evaluation of SAME-TT ₂ R ₂ score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain. <i>Current Medical Research and Opinion</i> , 2016, 32, 1201-1207.	0.9	24

#	ARTICLE	IF	CITATIONS
1182	Prior bleeding, future bleeding and stroke risk with oral anticoagulation in atrial fibrillation: What new lessons can ARISTOTLE teach us?. <i>American Heart Journal</i> , 2016, 175, 168-171.	1.2	2
1184	Personalized and automated remote monitoring of atrial fibrillation. <i>Europace</i> , 2016, 18, 347-352.	0.7	26
1186	Why switch from warfarin to NOACs?. <i>Internal and Emergency Medicine</i> , 2016, 11, 289-293.	1.0	35
1187	A fortunate outcome after electrical cardioversion with a giant persistent left atrial thrombus. Is TOE-guided strategy more preferable in high risk patients?. <i>International Journal of Cardiology</i> , 2016, 208, 1-3.	0.8	0
1189	Recalibration of the HAS-BLED Score. <i>Chest</i> , 2016, 149, 311-314.	0.4	9
1191	Novel composite score to predict atrial Fibrillation in acute stroke patients. <i>International Journal of Cardiology</i> , 2016, 209, 184-189.	0.8	21
1192	Clinical Cardiology, Geriatric Cardiology, Heart Failure, and Transplantation 2015: A Selection of Topical Issues. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 159-166.	0.4	5
1193	Almanac 2015: atrial fibrillation research in Heart. <i>Heart</i> , 2016, 102, 573-580.	1.2	3
1194	Outcomes after cryoablation vs. radiofrequency in patients with paroxysmal atrial fibrillation: impact of pulmonary veins anatomy. <i>Europace</i> , 2016, 18, 1343-1351.	0.7	64
1195	Effectiveness of structured, hospital-based, nurse-led atrial fibrillation clinics: a comparison between a real-world population and a clinical trial population. <i>Open Heart</i> , 2016, 3, e000335.	0.9	24
1196	EACVI/EHRA Expert Consensus Document on the role of multi-modality imaging for the evaluation of patients with atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2016, 17, 355-383.	0.5	233
1197	Catheter ablation of atrial fibrillation in chronic heart failure: state-of-the-art and future perspectives. <i>Europace</i> , 2016, 18, 638-647.	0.7	30
1198	Update on Myocarditis and Inflammatory Cardiomyopathy: Reemergence of Endomyocardial Biopsy. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 178-187.	0.4	76
1199	Repercusiones en la posología de los anticoagulantes orales no antagonistas de la vitamina K por las variaciones de la función renal de los pacientes con fibrilación auricular e insuficiencia cardiaca aguda reciente. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 134-140.	0.6	9
1200	Selección de temas de actualidad en cardiología clínica, cardiología geriátrica e insuficiencia cardiaca y trasplante 2015. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 159-166.	0.6	9
1202	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. <i>European Heart Journal</i> , 2016, 38, ehv643.	1.0	69
1203	Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. <i>European Heart Journal</i> , 2017, 38, ehw069.	1.0	106
1204	Usefulness of the SAME-TT2R2 score to predict anticoagulation control on VKA in patients with atrial fibrillation and obstructive sleep apnea. <i>International Journal of Cardiology</i> , 2016, 204, 200-205.	0.8	10

#	ARTICLE	IF	CITATIONS
1205	Atrial fibrillation and risk of stroke: a nationwide cohort study. <i>Europace</i> , 2016, 18, 1689-1697.	0.7	45
1207	Effect of Frailty and Age on Platelet Aggregation and Response to Aspirin in Older Patients with Atrial Fibrillation: A Pilot Study. <i>Cardiology and Therapy</i> , 2016, 5, 51-62.	1.1	13
1208	Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	53
1210	Anticoagulation, CHA2DS2VASc Score, and Thromboembolic Risk of Cardioversion of Acute Atrial Fibrillation (from the FinCV Study). <i>American Journal of Cardiology</i> , 2016, 117, 1294-1298.	0.7	38
1211	Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review. <i>American Journal of Cardiovascular Drugs</i> , 2016, 16, 171-182.	1.0	4
1212	Novel oral anticoagulants in plastic surgery. <i>Journal of Plastic, Reconstructive and Aesthetic Surgery</i> , 2016, 69, 585-593.	0.5	8
1214	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , 2016, 18, 973-978.	0.7	19
1215	Effectiveness and safety of dabigatran versus acenocoumarol in "real-world" patients with atrial fibrillation. <i>Europace</i> , 2016, 18, 1319-1327.	0.7	32
1216	Outcomes and costs of left atrial appendage closure from randomized controlled trial and real-world experience relative to oral anticoagulation. <i>European Heart Journal</i> , 2016, 37, 3470-3482.	1.0	40
1217	Effect of Adherence to Oral Anticoagulants on Risk of Stroke and Major Bleeding Among Patients With Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	341
1218	Persistence and Discontinuation of Oral Anticoagulant: Remaining Issues Not Addressed by Phase III Clinical Trials. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	7
1219	Performance of handheld electrocardiogram devices to detect atrial fibrillation in a cardiology and geriatric ward setting. <i>Europace</i> , 2017, 19, euw025.	0.7	115
1220	Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. <i>American Heart Journal</i> , 2016, 176, 10-16.	1.2	9
1221	Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. <i>Heart Failure Clinics</i> , 2016, 12, 257-271.	1.0	8
1222	Markers for silent atrial fibrillation in esophageal long-term electrocardiography. <i>Journal of Electrocardiology</i> , 2016, 49, 496-503.	0.4	2
1223	Clinical and economic consequences of using dabigatran or rivaroxaban in patients with non-valvular atrial fibrillation. <i>Revista Portuguesa De Cardiologia (English Edition)</i> , 2016, 35, 141-148.	0.2	5
1224	Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 329-338.	0.8	103
1225	The year in cardiology 2015: arrhythmias and device therapy. <i>European Heart Journal</i> , 2016, 37, 587-593.	1.0	0

#	ARTICLE	IF	CITATIONS
1226	Risk of major bleeding in patients receiving vitamin K antagonists or low doses of aspirin. A systematic review and meta-analysis. <i>Thrombosis Research</i> , 2016, 138, 1-6.	0.8	13
1228	Reduction over time of QTc prolongation in patients with sotalol after cardioversion of atrial fibrillation. <i>Heart Rhythm</i> , 2016, 13, 661-668.	0.3	4
1229	Is hyperuricemia a recognizable biomarker for low risk of stroke in patients with atrial fibrillation?. <i>International Journal of Cardiology</i> , 2016, 203, 624-625.	0.8	2
1230	One-year follow-up after second-generation cryoballoon ablation for atrial fibrillation in a large cohort of patients: a single-centre experience. <i>Europace</i> , 2016, 18, 987-993.	0.7	43
1231	Risk of atrial fibrillation in diabetes mellitus: A nationwide cohort study. <i>European Journal of Preventive Cardiology</i> , 2016, 23, 621-627.	0.8	95
1232	A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in a real-world population with atrial fibrillation. <i>International Journal of Cardiology</i> , 2016, 203, 785-790.	0.8	1
1234	Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. <i>Clinical Chemistry and Laboratory Medicine</i> , 2016, 54, 275-83.	1.4	35
1235	Experience matters: long-term results of pulmonary vein isolation using a robotic navigation system for the treatment of paroxysmal atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 106-116.	1.5	14
1236	Paroxysmal atrial fibrillation and the hazards of under-treatment. <i>International Journal of Cardiology</i> , 2016, 202, 214-220.	0.8	14
1237	Preventing Thrombosis to Improve Outcomes in Heart Failure Patients. <i>Progress in Cardiovascular Diseases</i> , 2016, 58, 386-392.	1.6	6
1238	Ischaemic stroke in patients with atrial fibrillation with chronic kidney disease undergoing peritoneal dialysis. <i>Europace</i> , 2016, 18, 665.1-671.	0.7	39
1239	Enhanced FGF23 production in mice expressing PI3K-insensitive GSK3 is normalized by β -blocker treatment. <i>FASEB Journal</i> , 2016, 30, 994-1001.	0.2	29
1240	First-line catheter ablation of paroxysmal atrial fibrillation: outcome of radiofrequency vs. cryoballoon pulmonary vein isolation. <i>Europace</i> , 2016, 18, 368-375.	0.7	70
1241	A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. <i>Europace</i> , 2016, 18, 37-50.	0.7	121
1242	Evaluation of the HAS-BLED, ATRIA, and ORBIT Bleeding Risk Scores in Patients with Atrial Fibrillation Taking Warfarin. <i>American Journal of Medicine</i> , 2016, 129, 600-607.	0.6	101
1243	Physical activity, symptoms, medication and subjective health among veteran endurance athletes with atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 154-161.	1.5	24
1244	Impact of standardized MONitoring for Detection of Atrial Fibrillation in Ischemic Stroke (MonDAFIS): Rationale and design of a prospective randomized multicenter study. <i>American Heart Journal</i> , 2016, 172, 19-25.	1.2	35
1245	Patients' attitude and knowledge about oral anticoagulation therapy: results of a self-assessment survey in patients with atrial fibrillation conducted by the European Heart Rhythm Association. <i>Europace</i> , 2016, 18, 151-155.	0.7	50

#	ARTICLE	IF	CITATIONS
1246	Low P-wave amplitude (≤ 0.1 mV) in lead I is associated with displaced inter-atrial conduction and clinical recurrence of paroxysmal atrial fibrillation after radiofrequency catheter ablation. <i>Europace</i> , 2016, 18, 384-391.	0.7	62
1247	Current Antiarrhythmic Therapy for Nonvalvular Atrial Fibrillation in Spain. Data From the FANTASIA Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 54-60.	0.4	12
1249	Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial. <i>Europace</i> , 2016, 18, 6-11.	0.7	38
1250	Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 336-342.	1.0	8
1251	European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. <i>Europace</i> , 2016, 18, 12-36.	0.7	66
1252	Tratamiento antiarrítmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIA. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 54-60.	0.6	20
1253	Entropy at the right atrium as a predictor of atrial fibrillation recurrence outcome after pulmonary vein ablation. <i>Biomedizinische Technik</i> , 2016, 61, 29-36.	0.9	9
1254	Rationale and design of the RE-LATED AF™ AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus™ Effects of Dabigatran in patients with Atrial Fibrillation. <i>Clinical Research in Cardiology</i> , 2016, 105, 29-36.	1.5	33
1255	Predictors of left atrial volume index reduction following cryoballoon-based pulmonary vein isolation. <i>Europace</i> , 2016, 18, 392-397.	0.7	4
1256	Propafenone shows class Ic and class II antiarrhythmic effects. <i>Europace</i> , 2016, 18, 568-571.	0.7	27
1257	Catheter ablation of atrial fibrillation in patients with severely impaired left ventricular systolic function. <i>Heart and Vessels</i> , 2016, 31, 584-592.	0.5	15
1258	Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. <i>Europace</i> , 2016, 18, 955-964.	0.7	62
1259	Patient Characteristics and Antithrombotic Prescribing Patterns in Patients With Atrial Fibrillation in Tasmania. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 438-444.	0.7	5
1260	Higher CHA ₂ DS ₂ -VASc Score Is Associated With Increased Mortality in Acute Pulmonary Embolism. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 631-637.	0.7	19
1261	Apixaban to prevent stroke in patients with atrial fibrillation: a review. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2017, 11, 91-104.	1.0	10
1262	EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication. <i>Heart Rhythm</i> , 2017, 14, e3-e40.	0.3	442
1264	Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: Has Prescribing Improved?. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 573-578.	0.7	6
1265	Anticoagulation Control in Swiss Primary Care: Time in Therapeutic Range Percentages Exceed Benchmarks of Phase III Trials. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2017, 23, 685-695.	0.7	1

#	ARTICLE	IF	CITATIONS
1266	Catheter ablation in patients with persistent atrial fibrillation. <i>European Heart Journal</i> , 2017, 38, 20-26.	1.0	103
1267	Use of electronic healthcare records to identify complex patients with atrial fibrillation for targeted intervention. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2017, 24, 339-344.	2.2	31
1268	Efficacy and safety in pharmacological cardioversion of recent-onset atrial fibrillation: a propensity score matching to compare amiodarone vs class IC antiarrhythmic drugs. <i>Internal and Emergency Medicine</i> , 2017, 12, 853-859.	1.0	14
1269	Flecainide-induced wide complex QRS tachycardia: A case report and review of the literature. <i>European Geriatric Medicine</i> , 2017, 8, 8-9.	1.2	3
1270	Meta-analysis of major bleeding events on aspirin versus vitamin K antagonists in randomized trials. <i>International Journal of Cardiology</i> , 2017, 230, 572-576.	0.8	5
1271	Remote magnetic catheter navigation versus conventional ablation in atrial fibrillation ablation: Fluoroscopy reduction. <i>Journal of Arrhythmia</i> , 2017, 33, 167-171.	0.5	9
1272	Antithrombotic treatment in anticoagulated atrial fibrillation patients undergoing percutaneous coronary intervention. <i>European Journal of Internal Medicine</i> , 2017, 40, 1-7.	1.0	5
1273	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.	1.6	31
1274	Methods, accuracy and clinical implications of atrial fibrillation detection by cardiac implantable electronic devices. <i>International Journal of Cardiology</i> , 2017, 236, 262-269.	0.8	9
1275	Atrial fibrillation in patients hospitalized with acute myocardial infarction: analysis of the china acute myocardial infarction (CAMI) registry. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 2.	0.7	24
1276	Cardiac CT Angiography (CCTA) predicts left atrial appendage occluder device size and procedure outcome. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 739-747.	0.7	28
1277	Application of 3D printing technology to left atrial appendage occlusion. <i>International Journal of Cardiology</i> , 2017, 231, 258-263.	0.8	40
1278	New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 267-282.	0.6	45
1279	Cryoablation vs. radiofrequency ablation for treatment of paroxysmal atrial fibrillation: a systematic review and meta-analysis. <i>Europace</i> , 2017, 19, 784-794.	0.7	47
1280	Optimizing the use of oral anticoagulant therapy for atrial fibrillation in primary care: a pharmacist-led intervention. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 173-180.	1.0	16
1281	Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis. <i>Europace</i> , 2017, 19, 747-752.	0.7	75
1282	Quality of life with rivaroxaban in patients with non-valvular atrial fibrillation by therapeutic compliance. <i>Quality of Life Research</i> , 2017, 26, 647-654.	1.5	8
1283	Atrial Fibrillation, Type 2 Diabetes, and Non-Vitamin K Antagonist Oral Anticoagulants. <i>JAMA Cardiology</i> , 2017, 2, 442.	3.0	55

#	ARTICLE	IF	CITATIONS
1284	Risk Stratification Models in Atrial Fibrillation. <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 505-513.	1.5	9
1285	Clinical decision support for stroke prevention in atrial fibrillation (CDS-AF): Rationale and design of a cluster randomized trial in the primary care setting. <i>American Heart Journal</i> , 2017, 187, 45-52.	1.2	10
1286	Anticoagulation for atrial fibrillation in dialysis patients: What is known and what does the future hold?. <i>Heart Rhythm</i> , 2017, 14, 652-653.	0.3	0
1287	Routine 18F-FDG PET/CT does not detect inflammation in the left atrium in patients with atrial fibrillation. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1271-1276.	0.7	17
1288	Risk of major bleeding and stroke associated with the use of vitamin K antagonists, nonvitamin K antagonist oral anticoagulants and aspirin in patients with atrial fibrillation: a cohort study. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1844-1859.	1.1	17
1289	Major Bleeding Complications and Persistence With Oral Anticoagulation in Non-Valvular Atrial Fibrillation: Contemporary Findings in Real-Life Danish Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	109
1290	Use of three-dimensional computed tomography overlay for real-time cryoballoon ablation in atrial fibrillation reduces radiation dose and contrast dye. <i>Netherlands Heart Journal</i> , 2017, 25, 388-393.	0.3	5
1291	Outcomes Associated With Resuming Warfarin Treatment After Hemorrhagic Stroke or Traumatic Intracranial Hemorrhage in Patients With Atrial Fibrillation. <i>JAMA Internal Medicine</i> , 2017, 177, 563.	2.6	75
1292	Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism. <i>Hypertension</i> , 2017, 69, 545-550.	1.3	59
1293	Matrix Metalloproteinase Neutrophil Gelatinase-Associated Lipocalin Complex Predicts Atrial Fibrillation Recurrence after Electrical Cardioversion in Obese Patients. <i>CardioRenal Medicine</i> , 2017, 7, 11-20.	0.7	5
1294	Prestroke CHA2DS2-VASc Score and Severity of Acute Stroke in Patients with Atrial Fibrillation: Findings from RAF Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2017, 26, 1363-1368.	0.7	7
1295	Screening for Atrial Fibrillation using Economical and accurate Technology (SAFETY)â€”a pilot study. <i>BMJ Open</i> , 2017, 7, e013535.	0.8	15
1296	Pneumatic Burst Pressures After Inverted Closure of the Left Atrial Appendage: An Ex Vivo Model. <i>Annals of Thoracic Surgery</i> , 2017, 104, 116-121.	0.7	0
1297	Intracardiac thrombi during warfarin anticoagulation - A case report and a brief literature review. <i>Cor Et Vasa</i> , 2017, 59, e277-e281.	0.1	4
1298	Cardioembolic Stroke. <i>Circulation Research</i> , 2017, 120, 514-526.	2.0	273
1299	Stratification of cardiovascular risk in patients with atrial fibrillation and obstructive sleep apneaâ€”validity of the 2MACE score. <i>Sleep and Breathing</i> , 2017, 21, 601-606.	0.9	13
1300	Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation. <i>Heart</i> , 2017, 103, 307-314.	1.2	205
1301	Exercise-based cardiac rehabilitation for adults with atrial fibrillation. <i>The Cochrane Library</i> , 2017, 2, CD011197.	1.5	60

#	ARTICLE	IF	CITATIONS
1302	Cardiac Rhythm Disturbances. , 2017, , 95-103.		1
1303	Atrial Fibrillation and Stroke in Cancer Patients. , 2017, , 131-138.		0
1304	Time in Therapeutic Range and Outcomes After Warfarin Initiation in Newly Diagnosed Atrial Fibrillation Patients With Renal Dysfunction. Journal of the American Heart Association, 2017, 6, .	1.6	57
1305	Radiofrequency catheter ablation for redo procedures after pulmonary vein isolation with the cryoballoon technique. Herzschrittmachertherapie Und Elektrophysiologie, 2017, 28, 225-231.	0.3	6
1306	Anticoagulation in atrial fibrillation: NOAC prescribing in primary health care. International Journal of Clinical Pharmacy, 2017, 39, 478-482.	1.0	3
1307	Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart, 2017, 103, 672-678.	1.2	71
1308	Long-Term Follow-Up of Proband With Brugada Syndrome. American Journal of Cardiology, 2017, 119, 1392-1400.	0.7	23
1309	Catheter ablation of atrial fibrillation is associated with reduced risk of stroke and mortality: A propensity scoreâ€‘matched analysis. Heart Rhythm, 2017, 14, 635-642.	0.3	74
1310	Assessment of the atrial electromechanical properties of patients with human immunodeficiency virus. Journal of Infection and Public Health, 2017, 10, 721-724.	1.9	3
1311	Pulmonary Embolism and Atrial Fibrillation: Two Sides of the Same Coin? A Systematic Review. Seminars in Thrombosis and Hemostasis, 2017, 43, 849-863.	1.5	45
1313	Impact of gender on event rates at 1â€‘year in patients with newly diagnosed non-valvular atrial fibrillation: contemporary perspective from the GARFIELD-AF registry. BMJ Open, 2017, 7, e014579.	0.8	30
1315	Digoxin versus placebo, no intervention, or other medical interventions for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. Systematic Reviews, 2017, 6, 71.	2.5	5
1316	Unnecessary overuse. Study of â€‘inadvisable practicesâ€‘for patients with atrial fibrillation. Revista Clínica Espanõla, 2017, 217, 181-187.	0.3	1
1317	Efficacy and safety of antazoline in the rapid cardioversion of paroxysmal atrial fibrillation (the Tj ETQq1 1 0.784314 rgBT /Oyerlock 10 0.719	0.7	19
1318	Efficacy of Catheter Ablation for Nonparoxysmal Atrial Fibrillation. JAMA Cardiology, 2017, 2, 812.	3.0	6
1319	The short-term associations of weather and air pollution with emergency ambulance calls for paroxysmal atrial fibrillation. Environmental Science and Pollution Research, 2017, 24, 15031-15043.	2.7	21
1320	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm, 2017, 14, e275-e444.	0.3	1,671
1322	Vitamin K antagonist therapy: changes in the treated populations and in management results in Italian anticoagulation clinics compared with those recorded 20Â‘years ago. Internal and Emergency Medicine, 2017, 12, 1109-1119.	1.0	30

#	ARTICLE	IF	CITATIONS
1323	Catheter ablation of persistent atrial fibrillation. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2017, 28, 403-408.	0.3	1
1324	Screening for Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 1851-1867.	1.6	453
1325	Dabigatran plasma levels, aPTT and thromboelastography in patients with AF: implications for allowing early non-elective surgical procedures. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 9-13.	1.0	8
1327	Implications of CHA ₂ DS ₂ -VASc Score in Stroke Patients with Atrial Fibrillation: An Analysis of 938 Korean Patients. <i>European Neurology</i> , 2017, 77, 307-315.	0.6	5
1328	Incidence and predictors of silent cerebral thromboembolic lesions after catheter ablation for atrial fibrillation in patients treated with direct oral anticoagulants. <i>Heart and Vessels</i> , 2017, 32, 1227-1235.	0.5	7
1329	Comparative Effectiveness and Safety of Dabigatran and Rivaroxaban in Atrial Fibrillation Patients. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	23
1330	Is there an alternative treatment for patients intolerant to antiplatelet therapy if percutaneous left atrial appendage closure is considered?. <i>Netherlands Heart Journal</i> , 2017, 25, 510-515.	0.3	9
1331	Vitamin K antagonists: relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 365-379.	1.0	89
1332	Real-world outcomes, complications, and cost of catheter-based ablation for atrial fibrillation. <i>Current Opinion in Cardiology</i> , 2017, 32, 47-52.	0.8	14
1333	First insights into cryoballoon-based pulmonary vein isolation taking the individual time-to-isolation into account. <i>Europace</i> , 2017, 19, 1676-1680.	0.7	48
1334	Indications and appropriate selection of novel oral anticoagulants in patients with atrial fibrillation. <i>Heart</i> , 2017, 103, 1129-1137.	1.2	6
1335	Synergistic Effect of Dofetilide and Mexiletine on Prevention of Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	7
1336	Atrial fibrillation with a structurally normal heart in pregnancy: An international survey on current practice. <i>Obstetric Medicine</i> , 2017, 10, 74-78.	0.5	5
1337	Diagnostic performance of an automatic blood pressure measurement device, Microlife WatchBP Home A, for atrial fibrillation screening in a real-world primary care setting. <i>BMJ Open</i> , 2017, 7, e013685.	0.8	47
1339	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y Electrofisiologaa (SOLEACE). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 235-250.	1.4	50
1340	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Cardaca y Electrofisiologaa (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
1341	Electrical isolation of the left atrial appendage by Maze-like catheter substrate modification: A reproducible strategy for pulmonary vein isolation nonresponders?. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1006-1014.	0.8	28
1342	Transient ischemic attack and ischemic stroke patients with or without prior stroke. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 654-659.	1.0	5

#	ARTICLE	IF	CITATIONS
1344	Digoxin use in atrial fibrillation. American Journal of Emergency Medicine, 2017, 35, 1196.	0.7	1
1346	Contemporary Atrial Fibrillation Management: A Comparison of the Current AHA/ACC/HRS, CCS, and ESC Guidelines. Canadian Journal of Cardiology, 2017, 33, 965-976.	0.8	89
1347	Significant reduction in procedure duration in remote magnetic-guided catheter ablation of atrial fibrillation using the third-generation magnetic navigation system. Journal of Interventional Cardiac Electrophysiology, 2017, 49, 219-226.	0.6	12
1348	Safety of fluoroscopy-guided transseptal approach for ablation of left-sided arrhythmias. Europace, 2017, 19, 2023-2026.	0.7	20
1349	Viewpoint: Stroke Prevention in Recent Guidelines for the Management of Patients with Atrial Fibrillation: An Appraisal. American Journal of Medicine, 2017, 130, 773-779.	0.6	6
1351	Is new-onset postoperative atrial fibrillation a benign complication?. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 490-491.	0.4	2
1352	Scoring Systems for Estimating the Risk of Anticoagulant-Associated Bleeding. Seminars in Thrombosis and Hemostasis, 2017, 43, 514-524.	1.5	13
1353	Assessment of a personalized and distributed patient guidance system. International Journal of Medical Informatics, 2017, 101, 108-130.	1.6	61
1354	Apixaban Pharmacokinetics at Steady State in Hemodialysis Patients. Journal of the American Society of Nephrology: JASN, 2017, 28, 2241-2248.	3.0	171
1355	Serum galectin-3 level as a marker of thrombogenicity in atrial fibrillation. Journal of Clinical Laboratory Analysis, 2017, 31, .	0.9	10
1356	CHA 2 DS 2 -VASc Scores and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Who Are Receiving Rivaroxaban. Annals of Emergency Medicine, 2017, 69, 541-550.e1.	0.3	11
1357	Clinical implication of frailty assessment in older patients with atrial fibrillation. Archives of Gerontology and Geriatrics, 2017, 70, 1-7.	1.4	29
1358	Effect of left atrial volume and pulmonary vein anatomy on outcome of nMARQâ,¢ catheter ablation of paroxysmal atrial fibrillation. Journal of Interventional Cardiac Electrophysiology, 2017, 48, 201-207.	0.6	9
1359	Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design. Europace, 2017, 19, 297-302.	0.7	37
1360	Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: a report from the EURObservational research programme pilot survey on atrial fibrillation. Europace, 2017, 19, 1439-1448.	0.7	47
1361	Complication Rates of Catheter Ablation of Atrial Fibrillation in Patients Aged â‰¥75 Years versus <75 Yearsâ€”Results from the German Ablation Registry. Journal of Cardiovascular Electrophysiology, 2017, 28, 258-265.	0.8	31
1362	Decision-Making in Clinical Practice: Oral Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation and a Single Additional Stroke Risk Factor. Advances in Therapy, 2017, 34, 357-377.	1.3	14
1363	The Year in Cardiothoracic and Vascular Anesthesia: Selected Highlights From 2016. Journal of Cardiothoracic and Vascular Anesthesia, 2017, 31, 1-13.	0.6	4

#	ARTICLE	IF	CITATIONS
1364	Relationship between tissue Doppler measurements of left ventricular diastolic function and silent brain infarction in patients with non-valvular atrial fibrillation. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 1245-1252.	0.5	13
1365	Non-vitamin-K oral anticoagulants and laboratory testing: now and in the future. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 42-47.	1.4	47
1366	Adenosine-guided pulmonary vein isolation versus conventional pulmonary vein isolation in patients undergoing atrial fibrillation ablation: An updated meta-analysis. <i>International Journal of Cardiology</i> , 2017, 227, 151-160.	0.8	7
1367	Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 48, 223-233.	0.6	13
1368	Percutaneous closure of a left atrial appendage with relevant suture dehiscence. <i>Netherlands Heart Journal</i> , 2017, 25, 152-154.	0.3	0
1369	Top Ten Articles in Hospital Medicine 2016. <i>Hospital Medicine Clinics</i> , 2017, 6, 147-162.	0.2	0
1370	Predicted risk of stroke and bleeding and use of oral anticoagulants in atrial fibrillation: Danish nationwide temporal trends 2011-2016. <i>Thrombosis Research</i> , 2017, 160, 19-26.	0.8	3
1371	Catheter ablation for AF improves global thrombotic profile and enhances fibrinolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 44, 413-426.	1.0	8
1372	Underuse of Anticoagulation in Older Patients with Atrial Fibrillation and CHADS2 Score: Are We Doing Better Since the Marketing of Direct Oral Anticoagulants?. <i>Drugs and Aging</i> , 2017, 34, 841-850.	1.3	17
1373	Exercise for Cardiovascular Disease Prevention and Treatment. <i>Advances in Experimental Medicine and Biology</i> , 2017, , .	0.8	3
1374	Anticoagulation: The Successes and Pitfalls of Long-Term Management. <i>Physician Assistant Clinics</i> , 2017, 2, 603-622.	0.1	0
1376	Screening of older patients for atrial fibrillation in general practice: Current evidence and its implications for future practice. <i>European Journal of General Practice</i> , 2017, 23, 246-253.	0.9	15
1377	Evolving landscape of stroke prevention in atrial fibrillation within the UK between 2012 and 2016: a cross-sectional analysis study using CPRD. <i>BMJ Open</i> , 2017, 7, e015363.	0.8	38
1378	Demographics, treatment and outcomes of atrial fibrillation in a developing country: the population-based Turkish Atrial Fibrillation (TRAF) cohort. <i>Europace</i> , 2017, 19, 734-740.	0.7	7
1379	Mobile Health Technology for Atrial Fibrillation Management Integrating Decision Support, Education, and Patient Involvement: mAF App Trial. <i>American Journal of Medicine</i> , 2017, 130, 1388-1396.e6.	0.6	172
1380	Severity of Hypertension Correlates with Risk of Thromboembolic Stroke. <i>Journal of Cardiovascular Translational Research</i> , 2017, 10, 368-373.	1.1	1
1381	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
1383	Long-term antithrombotic treatment in intracranial hemorrhage survivors with atrial fibrillation. <i>Neurology</i> , 2017, 89, 687-696.	1.5	79

#	ARTICLE	IF	CITATIONS
1384	Dabigatran and vitamin K antagonists use in naïve patients with non-valvular atrial fibrillation: a cross-sectional study of primary care-based electronic health records. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1323-1330.	0.8	4
1385	2017 consensus of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation. <i>Journal of Arrhythmia</i> , 2017, 33, 345-367.	0.5	141
1386	Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1417-1425.	0.8	69
1387	Sobreutilización innecesaria. Estudio de los «no hacer» en pacientes con fibrilación auricular. <i>Revista Clinica Espanola</i> , 2017, 217, 181-187.	0.2	2
1390	Net clinical benefit of warfarin in individuals with atrial fibrillation across stroke risk and across primary and secondary care. <i>Heart</i> , 2017, 103, 210-218.	1.2	41
1391	Risk analysis of new oral anticoagulants for gastrointestinal bleeding and intracranial hemorrhage in atrial fibrillation patients: a systematic review and network meta-analysis. <i>Journal of Zhejiang University: Science B</i> , 2017, 18, 567-576.	1.3	18
1392	ANMCO Position Paper: direct oral anticoagulants for stroke prevention in atrial fibrillation: clinical scenarios and future perspectives. <i>European Heart Journal Supplements</i> , 2017, 19, D70-D88.	0.0	6
1393	Sex and Gender Differences in Thromboprophylactic Treatment of Patients With Atrial Fibrillation After the Introduction of Non-Vitamin K Oral Anticoagulants. <i>American Journal of Cardiology</i> , 2017, 120, 1302-1308.	0.7	24
1394	Natriuretic Peptides as Markers of Atrial Fibrillation Burden and Recurrence (from the AMIO-CAT) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5</i>	0.7	18
1395	The preference of the physicians in diagnosis and treatment of cardiovascular diseases. <i>International Journal of the Cardiovascular Academy</i> , 2017, 3, 11-15.	0.1	1
1396	Management of atrial fibrillation and concomitant coronary artery disease. <i>Continuing Cardiology Education</i> , 2017, 3, 47-55.	0.4	8
1397	Catheter ablation of persistent atrial fibrillation. <i>Herzschrmmachertherapie Und Elektrophysiologie</i> , 2017, 28, 328-334.	0.3	6
1398	Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2017, 92, 1203-1213.	1.4	34
1399	The Patterns of Non-vitamin K Antagonist Oral Anticoagulants (NOACs) Use in Patients with Atrial Fibrillation in Seven Balkan Countries: a Report from the BALKAN-AF Survey. <i>Advances in Therapy</i> , 2017, 34, 2043-2057.	1.3	17
1400	All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAf) Newly Treated with Dabigatran or Warfarin. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 481-492.	1.0	10
1401	Utilization of Standard and Target-Specific Oral Anticoagulants Among Adults in the United Kingdom With Incident Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 1820-1829.	0.7	11
1403	Laser Balloon or Wide-Area Circumferential Irrigated Radiofrequency Ablation for Persistent Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2017, 10, .	2.1	71
1404	Feasibility Testing of the Alert for AFib Intervention. <i>Western Journal of Nursing Research</i> , 2017, 39, 252-272.	0.6	4

#	ARTICLE	IF	CITATIONS
1405	Protocol for validating cardiovascular and cerebrovascular ICD-9-CM codes in healthcare administrative databases: the Umbria Data Value Project. <i>BMJ Open</i> , 2017, 7, e013785.	0.8	18
1406	Fluoroscopy-free AF ablation using transesophageal echocardiography and electroanatomical mapping technology. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 235-244.	0.6	15
1408	Effects of Exercise on Arrhythmia (and Viceversa): Lesson from the Greek Mythology. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1000, 85-93.	0.8	0
1409	Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. <i>European Heart Journal</i> , 2017, 38, ehw658.	1.0	142
1410	Right atrial diameter and outcome of catheter ablation of atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 49, 157-164.	0.6	12
1411	Assessment of the radiofrequency ablation dynamics of esophageal tissue with optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	1.4	11
1412	Stroke prediction with CHA2DS2-VASc score in patients with mesenteric ischemia without atrial fibrillation-insights from a nationwide cohort. <i>Journal of Clinical Neuroscience</i> , 2017, 45, 193-198.	0.8	2
1413	Real-life use of Rivaroxaban in the Netherlands: data from the Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation (XANTUS) registry. <i>Netherlands Heart Journal</i> , 2017, 25, 551-558.	0.3	26
1414	Underuse of Oral Anticoagulants and Inappropriate Prescription of Antiplatelet Therapy in Older Inpatients with Atrial Fibrillation. <i>Drugs and Aging</i> , 2017, 34, 701-710.	1.3	19
1415	Predictive value of CHADS2 and CHA2DS2-VASc scores for acute myocardial infarction in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 4730.	1.6	6
1416	Left atrial strain predicts recurrence of atrial arrhythmias after catheter ablation of persistent atrial fibrillation. <i>Open Heart</i> , 2017, 4, e000572.	0.9	36
1417	Auscultatory versus oscillometric blood pressure measurement in patients with atrial fibrillation and arterial hypertension. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 87.	0.7	12
1418	Aeroembolism in left atrium during catheter ablation of atrial fibrillation in a patient with dextrocardia: a case report and review of the literature. <i>BMC Cardiovascular Disorders</i> , 2017, 17, 143.	0.7	3
1419	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis. <i>Systematic Reviews</i> , 2017, 6, 47.	2.5	5
1420	Factors associated with antithrombotic treatment decisions for stroke prevention in atrial fibrillation in the Stockholm region after the introduction of NOACs. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1315-1322.	0.8	14
1421	Dealing With the Left Atrial Appendage for Stroke Prevention: Devices and Decision-Making. <i>Heart Lung and Circulation</i> , 2017, 26, 918-925.	0.2	2
1422	Drug therapy in anticoagulation: which drug for which patient?. <i>Clinical Medicine</i> , 2017, 17, 233-244.	0.8	9
1423	Magnetic resonance imaging guided transatrial electrophysiological studies in swine using active catheter tracking – experience with 14 cases. <i>European Radiology</i> , 2017, 27, 1954-1962.	2.3	13

#	ARTICLE	IF	CITATIONS
1424	Prognostic Value of Red Blood Cell Distribution Width on Bleeding Events in Nonvalvular Atrial Fibrillation Patients Taking Dabigatran (110 mg b.i.d.) after Catheter Ablation. <i>Cardiology</i> , 2017, 136, 215-221.	0.6	5
1425	Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence. <i>Therapeutic Advances in Drug Safety</i> , 2017, 8, 67-75.	1.0	40
1426	Durability of wide-area left atrial appendage isolation: Results from extensive catheter ablation for treatment of persistent atrial fibrillation. <i>Heart Rhythm</i> , 2017, 14, 314-319.	0.3	37
1427	The totally thoracoscopic maze procedure for the treatment of atrial fibrillation. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2017, 24, 102-111.	0.5	46
1428	Impact of valvular heart disease on oral anticoagulant therapy in non-valvular atrial fibrillation: results from the RAMSES study. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 157-165.	1.0	3
1429	Registries in Atrial Fibrillation: From Trials to Real-Life Clinical Practice. <i>American Journal of Medicine</i> , 2017, 130, 135-145.	0.6	40
1430	Association of serum chemerin concentrations with the presence of atrial fibrillation. <i>Annals of Clinical Biochemistry</i> , 2017, 54, 342-347.	0.8	15
1431	Prognosis in patients with atrial fibrillation and a presumed "temporary cause" in a community-based cohort study. <i>Clinical Research in Cardiology</i> , 2017, 106, 202-210.	1.5	24
1432	Atrial fibrillation in women: treatment. <i>Nature Reviews Cardiology</i> , 2017, 14, 113-124.	6.1	56
1433	Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. <i>Circulation</i> , 2017, 135, 208-219.	1.6	103
1434	Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 276-286.	0.8	3
1435	Safety of low-dose dabigatran in patients with atrial fibrillation and mild renal insufficiency. <i>Journal of Cardiology</i> , 2017, 69, 591-595.	0.8	7
1436	Risk factors associated with bleeding after multi antithrombotic therapy during implantation of cardiac implantable electronic devices. <i>Heart and Vessels</i> , 2017, 32, 333-340.	0.5	4
1437	Combined aspirin and anticoagulant therapy in patients with atrial fibrillation. <i>Journal of Thrombosis and Thrombolysis</i> , 2017, 43, 7-17.	1.0	31
1438	Atrial fibrillation: Therapeutic potential of atrial K + channel blockers. , 2017, 176, 13-21.		41
1439	Effects of policy interventions on the introduction of novel oral anticoagulants in Stockholm: an interrupted time series analysis. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 642-652.	1.1	39
1440	Clinical presentation, management, and outcomes in the Indian Heart Rhythm Society-Atrial Fibrillation (IHRS-AF) registry. <i>Indian Heart Journal</i> , 2017, 69, 43-47.	0.2	25
1441	Cryoballoon vs. radiofrequency ablation for paroxysmal atrial fibrillation: an updated meta-analysis of randomized and observational studies. <i>Europace</i> , 2017, 19, 378-384.	0.7	57

#	ARTICLE	IF	CITATIONS
1442	Antiarrhythmic effect of vernakalant in an experimental model of Long-QT-syndrome. <i>Europace</i> , 2017, 19, 866-873.	0.7	7
1443	A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 28-36.	1.4	93
1444	Immediate discontinuation of ablation during pulmonary vein isolation remarkably decreases the incidence of esophageal thermal lesions even when using steerable sheaths. <i>Journal of Arrhythmia</i> , 2017, 33, 23-27.	0.5	1
1445	Severe Spontaneous Echo Contrast/Auricular Thrombosis in "Nonvalvular" AF: Value of Thromboembolic Risk Scores. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2017, 40, 57-62.	0.5	6
1446	Comparisons of the underlying mechanisms of left atrial remodeling after repeat circumferential pulmonary vein isolation with or without additional left atrial linear ablation in patients with recurrent atrial fibrillation. <i>International Journal of Cardiology</i> , 2017, 228, 449-455.	0.8	9
1447	Assessment of Use vs Discontinuation of Oral Anticoagulation After Pulmonary Vein Isolation in Patients With Atrial Fibrillation. <i>JAMA Cardiology</i> , 2017, 2, 146.	3.0	54
1448	Incidence of severe renal dysfunction among individuals taking warfarin and implications for non-vitamin K oral anticoagulants. <i>American Heart Journal</i> , 2017, 184, 150-155.	1.2	18
1449	Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis. <i>International Journal of Cardiology</i> , 2017, 231, 73-77.	0.8	0
1450	Descending aortic mechanics and atrial fibrillation: a two-dimensional speckle tracking transesophageal echocardiography study. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 509-519.	0.7	3
1451	Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective. <i>American Journal of Cardiovascular Drugs</i> , 2017, 17, 123-133.	1.0	14
1452	The impact of digoxin on mortality in patients with chronic systolic heart failure: A propensity-matched cohort study. <i>International Journal of Cardiology</i> , 2017, 228, 214-218.	0.8	13
1453	Influence of Competing Risks on Estimating the Expected Benefit of Warfarin in Individuals with Atrial Fibrillation Not Currently Taking Anticoagulants: The Anticoagulation and Risk Factors in Atrial Fibrillation Study. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 35-41.	1.3	13
1454	Ibutilide protects against cardiomyocytes injury via inhibiting endoplasmic reticulum and mitochondrial stress pathways. <i>Heart and Vessels</i> , 2017, 32, 208-215.	0.5	13
1455	ANMCO/AIAC/SICI-GISE/SIC/SICCH Consensus Document: percutaneous occlusion of the left atrial appendage in non-valvular atrial fibrillation patients: indications, patient selection, staff skills, organisation, and training. <i>European Heart Journal Supplements</i> , 2017, 19, D333-D353.	0.0	32
1456	Atrial high-rate episodes and stroke prevention. <i>Europace</i> , 2017, 19, 169-179.	0.7	84
1457	Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología (SOLAECE). <i>Europace</i> , 2017, 19, 1589-1623.	0.7	208
1458	Antithrombotic therapy in atrial fibrillation associated with valvular heart disease: a joint consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology Working Group on Thrombosis, endorsed by the ESC Working Group on Valvular Heart Disease, Cardiac Arrhythmia Society of Southern Africa (CASSA), Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart (SA Heart) Association and Sociedad Latinoamericana de Estimulación Cardíaca y Electrofisiología. <i>Europace</i> , 2017, 19, 1757-1758.	0.7	107
1459	Two in one is better than one plus one: comparison of adverse events between combining electrophysiological examination and coronary angiography versus performing them consecutively. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2017, 50, 203-209.	0.6	0

#	ARTICLE	IF	CITATIONS
1460	Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation. <i>BMJ Open</i> , 2017, 7, e017157.	0.8	92
1461	Mild troponin elevation in patients admitted to the emergency department with atrial fibrillation: 30-day post-discharge prognostic significance. <i>Internal and Emergency Medicine</i> , 2018, 13, 333-341.	1.0	4
1462	NT-proBNP test with improved accuracy for the diagnosis of chronic heart failure. <i>Medicine (United States)</i> , 2017, 96, 24.	0.4	24
1463	Development and validation of hospital information system-generated indicators of the appropriateness of oral anticoagulant prescriptions in hospitalised adults: the PACHA study protocol. <i>BMJ Open</i> , 2017, 7, e016488.	0.8	2
1464	Atrial Fibrillation Detection using Stationary Wavelet Transform and Deep Learning. , 0, , .		12
1465	Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. <i>BMJ: British Medical Journal</i> , 2017, 356, j510.	2.4	275
1466	Effectiveness and safety of vitamin K antagonists and new anticoagulants in the prevention of thromboembolism in atrial fibrillation in older adults â€” a systematic review of reviews and the development of recommendations to reduce inappropriate prescribing. <i>BMC Geriatrics</i> , 2017, 17, 223.	1.1	19
1467	Use of CHA ₂ DS ₂ -VASc Score to Predict New-Onset Atrial Fibrillation in Chronic Obstructive Pulmonary Disease Patientsâ€”Large-Scale Longitudinal Study â€”. <i>Circulation Journal</i> , 2017, 81, 1792-1797.	0.7	6
1469	The Time in Therapeutic Range and Bleeding Complications of Warfarin in Different Geographic Regions of Turkey: A Subgroup Analysis of WARFARIN-TR Study. <i>Balkan Medical Journal</i> , 2017, 34, 349-355.	0.3	8
1470	Current Use of Oral Anticoagulants and Prognostic Analysis in Patients with Atrial Fibrillation Undergoing Coronary Stenting. <i>Chinese Medical Journal</i> , 2017, 130, 1418-1423.	0.9	2
1471	Value of Combining Left Atrial Diameter and Amino-terminal Pro-brain Natriuretic Peptide to the CHA ₂ DS ₂ -VASc Score for Predicting Stroke and Death in Patients with Sick Sinus Syndrome after Pacemaker Implantation. <i>Chinese Medical Journal</i> , 2017, 130, 1902-1908.	0.9	5
1472	Transcatheter Ablation of Atrial Fibrillation in Patients with Chronic Heart Failure. , 0, , .		0
1473	Oral Anticoagulants Initiation in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort. <i>Frontiers in Pharmacology</i> , 2017, 8, 63.	1.6	30
1474	Antithrombotic prophylaxis of atrial fibrillation in an Italian real-world setting: a retrospective study. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 239-246.	1.0	3
1475	Signal Reconstruction of Pulmonary Vein Recordings Using a Phenomenological Mathematical Model: Application to Pulmonary Vein Isolation Therapy. <i>Frontiers in Physiology</i> , 2017, 8, 496.	1.3	3
1476	SAMe-TT2R2 Score in the Outpatient Anticoagulation Clinic to Predict Time in Therapeutic Range and Adverse Events. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 108, 290-296.	0.3	9
1477	Loop Recorder Detected High Rate of Atrial Fibrillation Recurrence after a Single Balloon- or Basket-Based Ablation of Paroxysmal Atrial Fibrillation: Results of the MACPAF Study. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 4.	1.1	4
1478	Should We Maintain Anticoagulation after Successful Radiofrequency Catheter Ablation of Atrial Fibrillation? The Need for a Randomized Study. <i>Frontiers in Cardiovascular Medicine</i> , 2017, 4, 85.	1.1	12

#	ARTICLE	IF	CITATIONS
1479	Potential Roles of Serum Caveolin-3 Levels in Patients with Atrial Fibrillation. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 90.	1.7	2
1480	Mortality, stroke, and heart failure in atrial fibrillation cohorts after ablation versus propensity-matched cohorts. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 99-106.	1.1	12
1481	Factors influencing medication knowledge and beliefs on warfarin adherence among patients with atrial fibrillation in China. <i>Patient Preference and Adherence</i> , 2017, Volume 11, 213-220.	0.8	26
1482	Discordant Relationships between Systemic Inflammatory Markers and Burden of Oxidative Stress in Patients with Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2017, 47, 752.	0.7	5
1483	Cardiovascular exercise and burden of arrhythmia in patients with atrial fibrillation - A randomized controlled trial. <i>PLoS ONE</i> , 2017, 12, e0170060.	1.1	39
1484	Atrial fibrillation among patients under investigation for suspected obstructive sleep apnea. <i>PLoS ONE</i> , 2017, 12, e0171575.	1.1	25
1485	Elevated neutrophil to lymphocyte ratio and ischemic stroke risk in generally healthy adults. <i>PLoS ONE</i> , 2017, 12, e0183706.	1.1	52
1486	Alteration of Endothelin 1, MCP-1 and Chromogranin A in patients with atrial fibrillation undergoing pulmonary vein isolation. <i>PLoS ONE</i> , 2017, 12, e0184337.	1.1	6
1487	Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany. <i>PLoS ONE</i> , 2017, 12, e0185642.	1.1	30
1488	Opportunistic screening for atrial fibrillation in a real-life setting in general practice in Denmarkâ€”The Atrial Fibrillation Found On Routine Detection (AFFORD) non-interventional study. <i>PLoS ONE</i> , 2017, 12, e0188086.	1.1	12
1489	Validation of the R ₂ CHADS ₂ and CHADS ₂ Scores for Predicting Post-stroke Cognitive Impairment. <i>Internal Medicine</i> , 2017, 56, 2719-2725.	0.3	7
1490	Analysis of cardiovascular mortality, bleeding, vascular and cerebrovascular events in patients with atrial fibrillation vs. sinus rhythm undergoing transfemoral Transcatheter Aortic Valve Implantation (TAVR). <i>BMC Cardiovascular Disorders</i> , 2017, 17, 298.	0.7	5
1491	Atrial fibrillation is not uncommon among patients with ischemic stroke and transient ischemic stroke in China. <i>BMC Neurology</i> , 2017, 17, 207.	0.8	17
1492	PA-6 inhibits inward rectifier currents carried by V93I and D172N gain-of-function KIR2.1 channels, but increases channel protein expression. <i>Journal of Biomedical Science</i> , 2017, 24, 44.	2.6	14
1493	Antiarrhythmic drug therapy among patients presenting to emergency department with symptomatic atrial fibrillation â€” a prospective nationwide cohort. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2017, 25, 81.	1.1	5
1494	Self-detection of atrial fibrillation in an aged population: three-year follow-up of the LietoAF intervention study. <i>BMC Geriatrics</i> , 2017, 17, 218.	1.1	6
1495	Reliability of pulse palpation in the detection of atrial fibrillation in an elderly population. <i>Scandinavian Journal of Primary Health Care</i> , 2017, 35, 293-298.	0.6	10
1496	Comparison of the CHADS ₂ , CHA ₂ DS ₂ -VASc and R ₂ CHADS ₂ Scores in Japanese Patients with Non-valvular Paroxysmal Atrial Fibrillation Not Receiving Anticoagulation Therapy. <i>Internal Medicine</i> , 2017, 56, 2827-2836.	0.3	3

#	ARTICLE	IF	CITATIONS
1497	Atrial Fibrillation on Admission Is Related With Higher Mortality in ST-Segment Elevation Myocardial Infarction Patients. <i>International Heart Journal</i> , 2017, 58, 486-494.	0.5	17
1498	Current Status and Outcomes of Direct Oral Anticoagulant Use in Real-World Atrial Fibrillation Patientsâ€• Fushimi AF Registry â€•. <i>Circulation Journal</i> , 2017, 81, 1278-1285.	0.7	111
1499	Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. <i>Korean Circulation Journal</i> , 2017, 47, 555.	0.7	56
1500	Efficacy and Safety of the WATCHMAN Left Atrial Appendage System for Stroke Prevention in Chinese Patients with Nonvalvular Atrial Fibrillation. <i>Chinese Medical Journal</i> , 2017, 130, 434-438.	0.9	7
1501	Impact of contact force technology on reducing the recurrence and major complications of atrial fibrillation ablation: A systematic review and meta-analysis. <i>Anatolian Journal of Cardiology</i> , 2017, 17, 82-91.	0.5	15
1502	Validating Features for Atrial Fibrillation Detection from Photoplethysmogram under Hospital and Free-living Conditions. , 2017, , .		5
1503	The Short and Long-Term Efficacy of Pulmonary Vein Isolation as a Sole Treatment Strategy for Paroxysmal Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Current Cardiology Reviews</i> , 2017, 13, 199-208.	0.6	34
1504	Efficacy and safety of triple versus dual antithrombotic therapy in atrial fibrillation and ischemic heart disease: a systematic review and meta-analysis. <i>Oncotarget</i> , 2017, 8, 81154-81166.	0.8	7
1505	Novel stroke risk reduction in atrial fibrillation: left atrial appendage occlusion with a focus on the Watchman closure device. <i>Vascular Health and Risk Management</i> , 2017, Volume 13, 81-90.	1.0	3
1506	Incidence, type of atrial fibrillation and risk factors for stroke: a population-based cohort study. <i>Clinical Epidemiology</i> , 2017, Volume 9, 53-62.	1.5	19
1507	Increasing the Single-Procedure Success Rate of Pulmonary Vein Isolation. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 217.	1.3	7
1508	Effect of ramadan fasting on acenocoumarol-induced antocoagulant effect. <i>Annales De Biologie Clinique</i> , 2017, 75, 513-518.	0.2	1
1509	Stroke rates before and after ablation of atrial fibrillation and in propensity-matched controls in the UK. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 107-118.	1.1	8
1510	The significance of the left atrial volume index in prediction of atrial fibrillation recurrence after electrical cardioversion. <i>Journal of Cardiovascular and Thoracic Research</i> , 2017, 9, 54-59.	0.3	35
1511	First results of the Brazilian Registry of Percutaneous Left Atrial Appendage Closure. <i>Arquivos Brasileiros De Cardiologia</i> , 2017, 109, 440-447.	0.3	8
1512	Catheter Ablation versus Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation (CASA-AF): study protocol for a randomised controlled trial. <i>Trials</i> , 2018, 19, 117.	0.7	7
1513	A new clinical decision support tool for improving the adequacy of anticoagulant therapy and reducing the incidence of stroke in nonvalvular atrial fibrillation. <i>Medicine (United States)</i> , 2018, 97, e9578.	0.4	6
1514	Pulmonary vein orientation is independently associated with outcomes following cryoballoon-based atrial fibrillation ablation. <i>Journal of Cardiovascular Computed Tomography</i> , 2018, 12, 281-285.	0.7	11

#	ARTICLE	IF	CITATIONS
1515	Impact of the third generation cryoballoon on atrial fibrillation ablation: An useful tool?. Indian Pacing and Electrophysiology Journal, 2018, 18, 127-132.	0.3	3
1516	Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection. Journal of Thrombosis and Thrombolysis, 2018, 45, 423-431.	1.0	9
1517	New-onset atrial fibrillation: an update. Journal of Anesthesia, 2018, 32, 414-424.	0.7	8
1518	Annual costs attributed to atrial fibrillation management: cross-sectional study of primary healthcare electronic records. European Journal of Health Economics, 2018, 19, 1129-1136.	1.4	6
1519	The New 2016 European Society of Cardiology/European Association for Cardio-Thoracic Surgery Guidelines: Enough Guidance? Enough Evidence?. European Journal of Cardio-thoracic Surgery, 2018, 53, i9-i13.	0.6	1
1520	Gender Differences in Antithrombotic Treatment for Newly Diagnosed Atrial Fibrillation: The GLORIA-AF Registry Program. American Journal of Medicine, 2018, 131, 945-955.e3.	0.6	27
1521	A double-blind, randomised, placebo-controlled, cross-over study assessing the use of XEN-D0103 in patients with paroxysmal atrial fibrillation and implanted pacemakers allowing continuous beat-to-beat monitoring of drug efficacy. Journal of Interventional Cardiac Electrophysiology, 2018, 51, 191-197.	0.6	20
1522	Pharmacists detecting atrial fibrillation (PDAF) in primary care during the influenza vaccination season: a multisite, cross-sectional screening protocol. BMJ Open, 2018, 8, e021121.	0.8	11
1524	Use of Direct Oral Anticoagulants in Patients with Cancer: Practical Considerations for the Management of Patients with Nausea or Vomiting. Oncologist, 2018, 23, 822-839.	1.9	24
1525	Association between modified CHA2DS2-VASc Score with Ankle-Brachial index–0.9. Scientific Reports, 2018, 8, 1175.	1.6	7
1526	A Pilot Study for Left Atrial Appendage Occlusion Guided by 3-Dimensional Rotational Angiography Alone. JACC: Cardiovascular Interventions, 2018, 11, 223-224.	1.1	16
1527	Update on the Treatment of Spontaneous Intraparenchymal Hemorrhage: Medical and Interventional Management. Current Treatment Options in Neurology, 2018, 20, 1.	0.7	26
1528	2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace, 2018, 20, e1-e160.	0.7	767
1529	Current Readings: An Update on Prevention and Management of Atrial Fibrillation Post Cardiac Surgery. Seminars in Thoracic and Cardiovascular Surgery, 2018, 30, 256-261.	0.4	2
1530	Residual rivaroxaban exposure after discontinuation of anticoagulant therapy in patients undergoing cardiac catheterization. European Journal of Clinical Pharmacology, 2018, 74, 611-618.	0.8	5
1531	Impact of left atrial appendage morphology on thrombus formation after successful left atrial appendage occlusion: Assessment with cardiac-computed-tomography. Scientific Reports, 2018, 8, 1670.	1.6	19
1532	Influence of stroke and bleeding risk on prescribing of oral anticoagulants in older inpatients; has the availability of direct oral anticoagulants changed prescribing?. Therapeutic Advances in Drug Safety, 2018, 9, 113-121.	1.0	6
1533	Alcohol-related hospitalization is associated with increased risk of ischaemic stroke among low-risk patients with atrial fibrillation. Europace, 2018, 20, 19-24.	0.7	4

#	ARTICLE	IF	CITATIONS
1534	Antiarrhythmic drugsâ€“clinical use and clinical decision making: a consensus document from the European Heart Rhythm Association (EHRA) and European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and International Society of Cardiovascular Pharmacotherapy (ISCP). <i>Europace</i> , 2018, 20, 731-732an.	0.7	144
1536	Quantifying Time in Atrial Fibrillation and the Need for Anticoagulation. <i>Progress in Cardiovascular Diseases</i> , 2018, 60, 537-541.	1.6	7
1537	Oral anticoagulation therapy upon discharge in hospitalized patients with nonvalvular atrial fibrillation: a retrospective cohort study. <i>Hospital Practice (1995)</i> , 2018, 46, 22-29.	0.5	0
1539	Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations. <i>American Journal of Transplantation</i> , 2018, 18, 30-42.	2.6	105
1540	Results of the first investigator-initiated randomized clinical trial of nMARQ TM , PVACT TM , and thoracoscopic ablation for paroxysmal atrial fibrillation. <i>Europace</i> , 2018, 20, f384-f391.	0.7	9
1541	Concomitant atrial fibrillation surgery: worth the effort?. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, i14-i18.	0.6	2
1542	The CHA ₂ DS ₂ -VASc score strongly correlates with glomerular filtration rate and predicts renal function decline over time in elderly patients with atrial fibrillation and chronic kidney disease. <i>International Journal of Cardiology</i> , 2018, 253, 71-77.	0.8	24
1543	Is There a Preferred Stroke Prevention Strategy for Diabetic Patients with Non-Valvular Atrial Fibrillation? Comparing Warfarin, Dabigatran and Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, 072-081.	1.8	21
1544	The womenâ€™s heart health programme: a pilot trial of sex-specific cardiovascular management. <i>BMC Women's Health</i> , 2018, 18, 56.	0.8	9
1545	Percutaneous left atrial appendage closure with complex anatomy by using the staged â€“kissing-Watchmanâ€™ technology with double devices. <i>International Journal of Cardiology</i> , 2018, 265, 58-61.	0.8	16
1546	Role of CHA ₂ DS ₂ -VASc score in predicting new-onset atrial fibrillation in patients with type 2 diabetes mellitus with and without hyperosmolar hyperglycaemic state: real-world data from a nationwide cohort. <i>BMJ Open</i> , 2018, 8, e020065.	0.8	11
1547	Functional consequences of genetic variation in sodium channel modifiers in early onset lone atrial fibrillation. <i>Personalized Medicine</i> , 2018, 15, 93-102.	0.8	4
1548	Dynamic Changes of CHA ₂ DS ₂ -VASc Score and the Risk of Ischaemic Stroke in Asian Patients with Atrial Fibrillation: A Nationwide Cohort Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1296-1304.	1.8	97
1549	Comparison of uninterrupted anticoagulation with dabigatran etexilate or warfarin in the periprocedural period for atrial fibrillation catheter ablation: Results of the Japanese subgroup of the REâ€“CIRCUIT trial. <i>Journal of Arrhythmia</i> , 2018, 34, 148-157.	0.5	4
1550	Design and baseline characteristics of the Xarelto Postâ€“Authorization Safety & Effectiveness Study in Japanese Patients with Atrial Fibrillation (XAPASS). <i>Journal of Arrhythmia</i> , 2018, 34, 167-175.	0.5	13
1551	Atrial fibrillation in the Middle East: unmapped, underdiagnosed, undertreated. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 341-348.	0.6	17
1552	Patterns of direct oral anticoagulant drug prescription in France in 2010â€“2013: a study in the Midi-PyrÃ©nÃ©es area. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 945-951.	0.8	5
1553	High rate of persistent iatrogenic atrial septal defect after single transeptal puncture for cryoballoon pulmonary vein isolation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 141-148.	0.6	17

#	ARTICLE	IF	CITATIONS
1554	Trends in initiation of direct oral anticoagulant therapies for atrial fibrillation in a national population-based cross-sectional study in the French health insurance databases. <i>BMJ Open</i> , 2018, 8, e018180.	0.8	44
1555	Left Atrial Appendage Occlusion, Shared Decision-Making, and Comprehensive Atrial Fibrillation Management. <i>Interventional Cardiology Clinics</i> , 2018, 7, 267-283.	0.2	0
1556	Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2018, 118, S34-S44.	1.8	1
1557	Arrhythmias in congenital heart disease: a position paper of the European Heart Rhythm Association (EHRA), Association for European Paediatric and Congenital Cardiology (AEPC), and the European Society of Cardiology (ESC) Working Group on Grown-up Congenital heart disease, endorsed by HRS, PACES, APHRS, and SOLAECE. <i>Europace</i> , 2018, 20, 1719-1753.	0.7	210
1558	Impact of chronic kidney disease on Watchman implantation: experience with 300 consecutive left atrial appendage closures at a single center. <i>Heart and Vessels</i> , 2018, 33, 1068-1075.	0.5	25
1559	Anticoagulation in atrial fibrillation with heart failure. <i>Heart Failure Reviews</i> , 2018, 23, 563-571.	1.7	17
1560	Percutaneous Left Atrial Appendage Closure with WATCHMAN [®] device: peri-procedural and mid-term outcomes from the TRAPS Registry. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2018, 52, 47-52.	0.6	8
1561	Major knowledge gaps and system barriers to guideline implementation among European physicians treating patients with atrial fibrillation: a European Society of Cardiology international educational needs assessment. <i>Europace</i> , 2018, 20, 1919-1928.	0.7	37
1562	Catheter ablation of atrial fibrillation in very young adults: a 5-year follow-up study. <i>Europace</i> , 2018, 20, 58-64.	0.7	24
1563	CHA2DS2-VASc score for ischaemic stroke risk stratification in patients with chronic obstructive pulmonary disease with and without atrial fibrillation: a nationwide cohort study. <i>Europace</i> , 2018, 20, 575-581.	0.7	16
1564	Catheter ablation of persistent atrial fibrillation. <i>Herzschrittmachertherapie Und Elektrophysiologie</i> , 2018, 29, 133-140.	0.3	6
1565	Non-vitamin K-dependent oral anticoagulants have a positive impact on ischaemic stroke severity in patients with atrial fibrillation. <i>Europace</i> , 2018, 20, 569-574.	0.7	37
1566	Safety of cardioversion in atrial fibrillation lasting less than 48h without post-procedural anticoagulation in patients at low cardioembolic risk. <i>Internal and Emergency Medicine</i> , 2018, 13, 87-93.	1.0	16
1567	The Utilization of Antithrombotic Therapy in Older Patients in Aged Care Facilities With Atrial Fibrillation. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 519-524.	0.7	11
1568	Long-term outcome of pulmonary vein isolation in patients with paroxysmal atrial fibrillation and Brugada syndrome. <i>Europace</i> , 2018, 20, 548-554.	0.7	8
1569	Diagnosis-to-ablation time as a predictor of success: early choice for pulmonary vein isolation and long-term outcome in atrial fibrillation: results from the Middelheim-PVI Registry. <i>Europace</i> , 2018, 20, 589-595.	0.7	36
1570	Stroke and bleeding with non-vitamin K antagonist oral anticoagulant or warfarin treatment in patients with non-valvular atrial fibrillation: a population-based cohort study. <i>Europace</i> , 2018, 20, 420-428.	0.7	46
1571	Rate vs. rhythm control and adverse outcomes among European patients with atrial fibrillation. <i>Europace</i> , 2018, 20, 243-252.	0.7	33

#	ARTICLE	IF	CITATIONS
1572	Shifting to a non-vitamin K antagonist oral anticoagulation agent from vitamin K antagonist in atrial fibrillation. <i>Europace</i> , 2018, 20, e78-e86.	0.7	22
1573	Temporal pattern/episode duration-based classification of atrial fibrillation as paroxysmal vs. persistent: is it time to develop a more integrated prognostic score to optimize management?. <i>Europace</i> , 2018, 20, f288-f298.	0.7	14
1574	Comparing volume-clamp method and intra-arterial blood pressure measurements in patients with atrial fibrillation admitted to the intensive or medium care unit. <i>Journal of Clinical Monitoring and Computing</i> , 2018, 32, 439-446.	0.7	29
1575	The electrocardiogram as a predictor of successful pharmacological cardioversion and progression of atrial fibrillation. <i>Europace</i> , 2018, 20, e96-e104.	0.7	17
1577	Epicardial left atrial appendage AtriClip occlusion reduces the incidence of stroke in patients with atrial fibrillation undergoing cardiac surgery. <i>Europace</i> , 2018, 20, e105-e114.	0.7	68
1578	Usefulness of the CHA2DS2-VASc Score in Predicting In-Stent Restenosis Among Patients Undergoing Revascularization With Bare-Metal Stents. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 589-595.	0.7	10
1579	Association of P wave duration index with atrial fibrillation recurrence after cryoballoon catheter ablation. <i>Journal of Electrocardiology</i> , 2018, 51, 182-187.	0.4	15
1580	CHA2DS2-VASc score predicts short- and long-term outcomes in patients with acute ischemic stroke treated with intravenous thrombolysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2018, 45, 122-129.	1.0	2
1581	Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 22-32.	0.7	11
1582	Atrial Fibrillation and Central Nervous Complications in Liver Transplanted Hereditary Transthyretin Amyloidosis Patients. <i>Transplantation</i> , 2018, 102, e59-e66.	0.5	14
1583	Evaluation of the predictive performance of bleeding risk scores in patients with nonvalvular atrial fibrillation on oral anticoagulants. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2018, 43, 209-219.	0.7	8
1584	Effects of hyperoxia on myocardial injury following cardioversion—A randomized clinical trial. <i>American Heart Journal</i> , 2018, 196, 97-104.	1.2	2
1585	Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 74-84.	0.7	21
1586	Definition of indicators of the appropriateness of oral anticoagulant prescriptions in hospitalized adults: Literature review and consensus (PACHA study). <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 155-171.	0.7	1
1587	Shared Decision-Making as the Future of Emergency Cardiology. <i>Canadian Journal of Cardiology</i> , 2018, 34, 117-124.	0.8	31
1588	Prevention of Stroke in Atrial Fibrillation. , 2018, , 1092-1100.		0
1589	Cardiac Sarcoidosis: A Review of Contemporary Challenges in Diagnosis and Treatment. <i>American Journal of the Medical Sciences</i> , 2018, 355, 113-125.	0.4	18
1590	Decision Algorithms for Direct Oral Anticoagulant Use in Patients With Nonvalvular Atrial Fibrillation: A Practical Guide for Neurologists. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2018, 24, 396-404.	0.7	2

#	ARTICLE	IF	CITATIONS
1591	Editorial commentary: What can lung transplantation teach us about the mechanisms of atrial arrhythmias?. <i>Trends in Cardiovascular Medicine</i> , 2018, 28, 62-63.	2.3	0
1592	Safety and efficacy analysis of one-stop intervention for treating nonvalvular atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2018, 41, 28-34.	0.5	6
1593	Evaluating the potential for pharmacists to prescribe oral anticoagulants for atrial fibrillation. <i>Canadian Pharmacists Journal</i> , 2018, 151, 51-61.	0.4	5
1594	Higher contact force, energy setting, and impedance rise during radiofrequency ablation predicts charring: New insights from contact force-guided <i>in vivo</i> ablation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 227-235.	0.8	22
1595	Changes in Cognitive Function after Left Atrial Appendage Occlusion. <i>Journal of Neurology and Neuroscience</i> , 2018, 09, .	0.4	2
1596	Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Thrombocytopenia. <i>Journal of Cardiovascular Pharmacology</i> , 2018, 72, 153-160.	0.8	19
1597	Study on the incidence and risk factor of silent cerebrovascular disease in young adults with first-ever stroke. <i>Medicine (United States)</i> , 2018, 97, e13311.	0.4	16
1598	A review and analysis of strategies for prediction, prevention and management of post-operative atrial fibrillation after non-cardiac thoracic surgery. <i>Journal of Thoracic Disease</i> , 2018, 10, S3799-S3808.	0.6	32
1599	Clinical Utility of Intravenous Nifekalant Injection during Radiofrequency catheter Ablation for Persistent Atrial Fibrillation. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 1839.	0.5	10
1600	Arrhythmogenic Substrates for Atrial Fibrillation in Obesity. <i>Frontiers in Physiology</i> , 2018, 9, 1482.	1.3	17
1601	The Impact of Obesity on the Cardiovascular System. <i>Journal of Diabetes Research</i> , 2018, 2018, 1-12.	1.0	274
1602	Patterns of adipose tissue fatty acids and the risk of atrial fibrillation: A case-cohort study. <i>PLoS ONE</i> , 2018, 13, e0208833.	1.1	3
1603	Long term outcomes after left atrial appendage closure with the LARIAT device—Stroke risk reduction over five years follow-up. <i>PLoS ONE</i> , 2018, 13, e0208710.	1.1	28
1604	Bleeding Risk of Warfarin and Direct Oral Anticoagulants in Younger Population: A Historical Cohort Study Using a Japanese Claims Database. <i>International Journal of Medical Sciences</i> , 2018, 15, 1686-1693.	1.1	26
1605	Relation of left atrial appendage closure devices to topographic neighboring structures using standardized imaging by cardiac computed tomography angiography. <i>Clinical Cardiology</i> , 2019, 42, 264-269.	0.7	12
1606	Efficacy of Wenxin Keli Plus Amiodarone versus Amiodarone Monotherapy in Treating Recent-Onset Atrial Fibrillation. <i>Cardiology Research and Practice</i> , 2018, 2018, 1-7.	0.5	5
1607	Relation between health literacy, self-care and adherence to treatment with oral anticoagulants in adults: a narrative systematic review. <i>BMC Public Health</i> , 2018, 18, 1157.	1.2	27
1608	Management of Thrombosis Risk in a Carrier of Hemophilia A with Low Factor VIII Levels with Atrial Fibrillation: A Clinical Case and Literature Review. <i>Case Reports in Hematology</i> , 2018, 2018, 1-4.	0.3	5

#	ARTICLE	IF	CITATIONS
1609	Staged hybrid procedure versus radiofrequency catheter ablation in the treatment of atrial fibrillation. PLoS ONE, 2018, 13, e0205431.	1.1	10
1610	Connexins and Atrial Fibrillation in Obstructive Sleep Apnea. Current Sleep Medicine Reports, 2018, 4, 300-311.	0.7	8
1611	Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy. Therapeutics and Clinical Risk Management, 2018, Volume 14, 1907-1914.	0.9	4
1612	Association Between Family History and Early-Onset Atrial Fibrillation Across Racial and Ethnic Groups. JAMA Network Open, 2018, 1, e182497.	2.8	23
1613	Left atrial appendage isolation in atrial fibrillation catheter ablation: A meta-analysis. Journal of Arrhythmia, 2018, 34, 478-484.	0.5	11
1614	Has the Catheter Become Mightier Than the Sword?. Circulation: Arrhythmia and Electrophysiology, 2018, 11, e006867.	2.1	3
1615	Sympathetic and Parasympathetic Coactivation Induces Perturbed Heart Rate Dynamics in Patients with Paroxysmal Atrial Fibrillation. Medical Science Monitor, 2018, 24, 2164-2172.	0.5	12
1616	The Significance of Drug-Drug and Drug-Food Interactions of Oral Anticoagulation. Arrhythmia and Electrophysiology Review, 2018, 7, 55.	1.3	96
1617	Stroke Risk and Treatment in Patients with Atrial Fibrillation and Low CHA ₂ DS ₂ -VASc Scores: Findings From the ORBIT-AF I and II Registries. Journal of the American Heart Association, 2018, 7, e008764.	1.6	9
1618	Plasma markers of myocardial inflammation at isolated atrial fibrillation. Journal of Arrhythmia, 2018, 34, 493-500.	0.5	7
1619	Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database. Therapie, 2018, 73, 449-460.	0.6	2
1620	Revisiting Atrial Fibrillation in the Transcatheter Aortic Valve Replacement Era. Interventional Cardiology Clinics, 2018, 7, 459-469.	0.2	4
1621	Rivaroxaban prescribing in a Saudi tertiary care teaching hospital. Saudi Pharmaceutical Journal, 2018, 26, 775-779.	1.2	7
1622	A new model to predict major bleeding in patients with atrial fibrillation using warfarin or direct oral anticoagulants. PLoS ONE, 2018, 13, e0203599.	1.1	20
1623	Serum neuron-specific enolase, a marker of neuronal injury, increases after catheter ablation of atrial fibrillation. Journal of International Medical Research, 2018, 46, 4518-4526.	0.4	5
1624	Withdrawal of oral anticoagulants 3 months after successful radiofrequency catheter ablation in patients with atrial fibrillation: A meta-analysis. PACE - Pacing and Clinical Electrophysiology, 2018, 41, 1391-1400.	0.5	13
1625	Anticancer Therapy-Induced Atrial Fibrillation: Electrophysiology and Related Mechanisms. Frontiers in Pharmacology, 2018, 9, 1058.	1.6	47
1626	Risk Factor Management in Atrial Fibrillation. Arrhythmia and Electrophysiology Review, 2018, 7, 118.	1.3	95

#	ARTICLE	IF	CITATIONS
1627	Sex Differences in Atrial Fibrillation—Update on Risk Assessment, Treatment, and Long-Term Risk. Current Treatment Options in Cardiovascular Medicine, 2018, 20, 79.	0.4	2
1628	Trend of Prevalence of Atrial Fibrillation and use of Oral Anticoagulation Therapy in Patients With Atrial Fibrillation in South Korea (2002–2013). Journal of Epidemiology, 2018, 28, 81-87.	1.1	17
1629	Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation. JAMA Network Open, 2018, 1, e180171.	2.8	25
1630	Obesity is associated with impaired long-term success of pulmonary vein isolation: a plea for risk factor management before ablation. Open Heart, 2018, 5, e000771.	0.9	25
1631	Disturbi del ritmo cardiaco. EMC - Urgenze, 2018, 22, 1-14.	0.0	0
1632	Radiofrequency Ablation versus Cryoablation in the Treatment of Paroxysmal Atrial Fibrillation: A Meta-Analysis. Cardiology Research and Practice, 2018, 2018, 1-10.	0.5	22
1634	Apelin and Atrial Fibrillation: The Role in the Arrhythmia Recurrence Prognosis. Disease Markers, 2018, 2018, 1-8.	0.6	8
1635	Thromboprophylaxis for Patients with High-risk Atrial Fibrillation and Flutter Discharged from the Emergency Department. Western Journal of Emergency Medicine, 2018, 19, 346-360.	0.6	11
1636	NOAC in "real world" patients with atrial fibrillation in Italy: results from the ISPAF-2 (Indagine Sicoa) Tj ETQq0,0,0 rgBT /Overlock 1	1.0	12
1637	Atrial Fibrillation in Athletes. , 2018, , 241-256.		0
1638	Selection of essential medicines for the prevention and treatment of cardiovascular diseases in low and middle income countries. BMC Cardiovascular Disorders, 2018, 18, 126.	0.7	8
1639	Although non-stroke outcomes are more common, stroke risk scores can be used for prediction in patients with atrial fibrillation. International Journal of Cardiology, 2018, 269, 145-151.	0.8	5
1640	Relationship between Impairment of the Vascular Endothelial Function and the CHA ₂ DS ₂ -VASc Score in Patients with Sinus Rhythm and Non-valvular Atrial Fibrillation. Internal Medicine, 2018, 57, 2131-2139.	0.3	14
1641	Atrial Fibrillation Recurrence and Peri-Procedural Complication Rates in nMARQ vs. Conventional Ablation Techniques: A Systematic Review and Meta-Analysis. Frontiers in Physiology, 2018, 9, 544.	1.3	5
1643	Atrial fibrillation in aging population. Aging Medicine (Milton (N S W)), 2018, 1, 67-74.	0.9	11
1644	CHA ₂ DS ₂ -VASc score as a predictor of long-term cardiac outcomes in elderly patients with or without atrial fibrillation. Clinical Interventions in Aging, 2018, Volume 13, 497-504.	1.3	14
1645	Associations between illness beliefs, medication beliefs, anticoagulation-related quality of life, and INR control: Insights from the Switching Study. Research and Practice in Thrombosis and Haemostasis, 2018, 2, 497-507.	1.0	17
1646	Incidence of complications related to catheter ablation of atrial fibrillation and atrial flutter: a nationwide in-hospital analysis of administrative data for Germany in 2014. European Heart Journal, 2018, 39, 4020-4029.	1.0	108

#	ARTICLE	IF	CITATIONS
1647	Differential Association of Cx37 and Cx40 Genetic Variants in Atrial Fibrillation with and without Underlying Structural Heart Disease. <i>International Journal of Molecular Sciences</i> , 2018, 19, 295.	1.8	15
1648	Anticoagulation therapy in patients with stroke and atrial fibrillation: a registry-based study of acute stroke care in Surrey, UK. <i>BMJ Open</i> , 2018, 8, e022558.	0.8	17
1649	Screening for atrial fibrillation using smartphone-based technology and layperson volunteers: High-tech meets community participatory research for the best of both worlds. <i>Heart Rhythm</i> , 2018, 15, 1312-1313.	0.3	2
1650	Reducing age bias in decision analyses of anticoagulation for patients with nonvalvular atrial fibrillation – A microsimulation study. <i>PLoS ONE</i> , 2018, 13, e0199593.	1.1	3
1651	Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2018, 13, 1144-1152.	2.2	50
1652	Variations in clinical management of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation according to different equations for estimating renal function. <i>Internal and Emergency Medicine</i> , 2018, 13, 1059-1067.	1.0	17
1653	Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 11.	0.7	11
1654	Cardiac computed tomography in patients with symptomatic new-onset atrial fibrillation, rule-out acute coronary syndrome, but with intermediate pretest probability for coronary artery disease admitted to a chest pain unit. <i>European Journal of Medical Research</i> , 2018, 23, 6.	0.9	3
1655	Health economic evaluation of rivaroxaban in elective cardioversion of atrial fibrillation. <i>European Journal of Health Economics</i> , 2018, 19, 957-965.	1.4	9
1656	Periprocedural anticoagulation in atrial fibrillation: Update on electrical cardioversion and ablation. <i>Netherlands Heart Journal</i> , 2018, 26, 352-360.	0.3	1
1657	Risk of incident atrial fibrillation in patients presenting with retinal artery or vein occlusion: a nationwide cohort study. <i>BMC Cardiovascular Disorders</i> , 2018, 18, 91.	0.7	21
1658	Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry: protocol for a prospective, observational nationwide cohort study. <i>BMJ Open</i> , 2018, 8, e020191.	0.8	14
1659	Real-World Health Care Costs Based on Medication Adherence and Risk of Stroke and Bleeding in Patients Treated with Novel Anticoagulant Therapy. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2018, 24, 430-439.	0.5	33
1660	Risk factors for stroke and choice of oral anticoagulant in atrial fibrillation. <i>European Journal of Clinical Pharmacology</i> , 2018, 74, 1653-1662.	0.8	5
1661	Non-vitamin K antagonist oral anticoagulants in patients with an increased risk of bleeding. <i>Wiener Klinische Wochenschrift</i> , 2018, 130, 722-734.	1.0	4
1662	Atrial Fibrillation, Cognitive Decline, and Dementia: an Epidemiologic Review. <i>Current Epidemiology Reports</i> , 2018, 5, 252-261.	1.1	42
1663	CHA ₂ DS ₂ -VASc Score in the Prediction of Ischemic Stroke in Patients after Radiofrequency Catheter Ablation of Typical Atrial Flutter. <i>Yonsei Medical Journal</i> , 2018, 59, 236.	0.9	11
1664	Patient and facility variation in costs of catheter ablation for atrial fibrillation. <i>Journal of Cardiovascular Electrophysiology</i> , 2018, 29, 1081-1088.	0.8	9

#	ARTICLE	IF	CITATIONS
1665	Multiple spontaneous hemorrhages after commencing warfarin therapy. SAGE Open Medical Case Reports, 2018, 6, 2050313X1877838.	0.2	2
1666	Silent Cerebral Infarction in East Asian vs. Non-Asian Atrial Fibrillation Patients – Meta-Analysis. Circulation Journal, 2018, 82, 672-676.	0.7	5
1667	Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?. Archives of Cardiovascular Diseases, 2018, 111, 357-369.	0.7	22
1668	The safety and efficacy of non-vitamin K antagonist oral anticoagulants in atrial fibrillation in the elderly. International Journal of Cardiology, 2018, 265, 118-124.	0.8	18
1669	Non-vitamin K antagonist oral anticoagulants for the treatment of intracardiac thrombosis. Journal of Thrombosis and Thrombolysis, 2018, 46, 332-338.	1.0	11
1670	L'anticoagulation orale en prévention du risque thromboembolique dans la fibrillation atriale. Actualites Pharmaceutiques, 2018, 57, 15-19.	0.0	0
1671	Trends in warfarin use and its associations with thromboembolic and bleeding rates in a population with atrial fibrillation between 1996 and 2011. PLoS ONE, 2018, 13, e0194295.	1.1	14
1672	Methodologic Differences Across Studies of Patients With Atrial Fibrillation Lead to Varying Estimates of Stroke Risk. Journal of the American Heart Association, 2018, 7, .	1.6	5
1673	A clinical decision support tool for improving adherence to guidelines on anticoagulant therapy in patients with atrial fibrillation at risk of stroke: A cluster-randomized trial in a Swedish primary care setting (the CDS-AF study). PLoS Medicine, 2018, 15, e1002528.	3.9	74
1674	Assessment of the clinical efficacy of the heart spectrum blood pressure monitor for diagnosis of atrial fibrillation: An unblinded clinical trial. PLoS ONE, 2018, 13, e0198852.	1.1	3
1676	Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. European Journal of Epidemiology, 2019, 34, 173-190.	2.5	51
1677	Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS. Europace, 2019, 21, 421-427.	0.7	10
1678	Editorial commentary: Sex, strokes and atrial fibrillation. Trends in Cardiovascular Medicine, 2019, 29, 153-154.	2.3	1
1679	Regional collaboration to improve atrial fibrillation care: Preliminary data from the Netherlands heart network. Journal of Arrhythmia, 2019, 35, 604-611.	0.5	3
1680	Understanding the Beat-to-Beat Variations of P-Waves Morphologies in AF Patients During Sinus Rhythm: A Scoping Review of the Atrial Simulation Studies. Frontiers in Physiology, 2019, 10, 742.	1.3	4
1681	CHA2DS2-VASc score performance to predict stroke after acute decompensated heart failure with and without reduced ejection fraction. Europace, 2019, 21, 1639-1645.	0.7	6
1682	2018 Korean society of hypertension guidelines for the management of hypertension: part III-hypertension in special situations. Clinical Hypertension, 2019, 25, 19.	0.7	31
1683	Prospective evaluation of iatrogenic atrial septal defect after cryoballoon or radiofrequency catheter ablation of atrial fibrillation – EVITA study. Journal of Interventional Cardiac Electrophysiology, 2019, 56, 19-27.	0.6	5

#	ARTICLE	IF	CITATIONS
1684	Predicting stroke and death in patients with heart failure using CHA2DS2-VASc score in Asia. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 193.	0.7	12
1685	Profiling of patients with non-valvular atrial fibrillation and moderate-to-high risk of stroke not receiving oral anticoagulation in Spain. <i>Semergen</i> , 2019, 45, 396-405.	0.2	6
1686	A diagnostic accuracy study validating cardiovascular ICD-9-CM codes in healthcare administrative databases. The Umbria Data-Value Project. <i>PLoS ONE</i> , 2019, 14, e0218919.	1.1	58
1687	Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. <i>Europace</i> , 2019, 21, 1764-1775.	0.7	20
1688	Vernakalant in Atrial Fibrillation: A Relatively New Weapon in the Armamentarium Against an Old Enemy. <i>Drug Target Insights</i> , 2019, 13, 117739281986111.	0.9	5
1689	Stroke Risk in Atrial Fibrillation: Beyond the CHA2DS2-VASc Score. <i>Current Cardiology Reports</i> , 2019, 21, 95.	1.3	19
1690	Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. <i>Clinical Pharmacokinetics</i> , 2019, 58, 1517-1532.	1.6	6
1691	Alternative Facts. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1053-1054.	1.1	0
1692	Reply. <i>Journal of the American College of Cardiology</i> , 2019, 73, 3362-3363.	1.2	0
1693	Mortality risk in atrial fibrillation: the role of aspirin, vitamin K and non-vitamin K antagonists. <i>International Journal of Clinical Pharmacy</i> , 2019, 41, 1536-1544.	1.0	4
1694	CHA2DS2-VASC Score Predicts Risk of Contrast-Induced Nephropathy in Non-ST Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Interventions. <i>Kidney Diseases (Basel)</i> , 2019, 10, 337-344.	1.0	0
1695	Antithrombotic therapy in acute coronary syndrome and stable coronary artery disease patients with atrial fibrillation: a 3-year retrospective cohort study. <i>Personalized Medicine</i> , 2019, 16, 399-407.	0.8	0
1696	Applying the Capability, Opportunity, and Motivation Behaviour Model (COM-B) to Guide the Development of Interventions to Improve Early Detection of Atrial Fibrillation. <i>Clinical Medicine Insights: Cardiology</i> , 2019, 13, 117954681988513.	0.6	12
1697	Safety of cataract surgery in patients treated with the new oral anticoagulants (NOACs). <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2019, 257, 2671-2676.	1.0	5
1698	Ischemic and Bleeding Outcomes in Patients With Atrial Fibrillation and Contraindications to Oral Anticoagulation. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 1384-1392.	1.3	12
1699	Comparison of bleeding risks among non-vitamin K antagonist oral anticoagulants using the Korea adverse event reporting system database. <i>Therapeutic Advances in Drug Safety</i> , 2019, 10, 204209861987673.	1.0	4
1700	Current Status and Clinical Outcomes of Oral Anticoagulant Discontinuation After Ablation for Atrial Fibrillation in Japan—Findings From the AF Frontier Ablation Registry. <i>Circulation Journal</i> , 2019, 83, 2418-2427.	0.7	16
1701	Comparative effectiveness of warfarin, dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation: A nationwide pharmacoepidemiological study. <i>PLoS ONE</i> , 2019, 14, e0221500.	1.1	19

#	ARTICLE	IF	CITATIONS
1702	The Value of the CHADS2 and CHA2DS2-VASc Score for Predicting the Prognosis in Lacunar Stroke with or without Atrial Fibrillation Patients. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2019, 28, 104143.	0.7	5
1703	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1901-1919.	1.8	57
1704	Cost-effectiveness of apixaban compared to other anticoagulants in patients with atrial fibrillation in the real-world and trial settings. <i>PLoS ONE</i> , 2019, 14, e0222658.	1.1	21
1705	Percutaneous left atrial appendage closure in a patient with haemophilia and atrial fibrillation: a case report. <i>European Heart Journal - Case Reports</i> , 2019, 3, .	0.3	7
1706	Asleep at the Switch? Are We Failing to Recognize Obstructive Sleep Apnea in Patients with Atrial Fibrillation and Heart Failure?. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1426-1429.	0.8	1
1707	Direct results of a prospective randomized study comparing ablation with the nMARQ catheter and the PVAC catheter used with and without a 3D system (MAPER 3D Study). <i>Archives of Medical Science</i> , 2019, 15, 78-85.	0.4	4
1708	Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy. <i>Thrombosis and Haemostasis</i> , 2019, 119, 576-585.	1.8	8
1709	Antithrombotic treatment patterns in patients with atrial fibrillation in Italy pre- and post-DOACs: the REPAIR study. <i>Future Cardiology</i> , 2019, 15, 109-118.	0.5	3
1710	FDG atrial uptake is associated with an increased prevalence of stroke in patients with atrial fibrillation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1268-1275.	3.3	14
1711	Oral anticoagulation in very elderly patients with atrial fibrillation: Results from the prospective multicenter START2-REGISTER study. <i>PLoS ONE</i> , 2019, 14, e0216831.	1.1	19
1712	Prediction of acute coronary syndrome, ischemic stroke, and mortality in patients with heart failure: a comparison of CHA2DS2-VASc and AHEAD scores. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 225-231.	0.6	4
1713	Risk of Atrial Fibrillation in Patients with Congenital Heart Disease: Results of a Propensity Score-Matched, Nationwide Cohort Study. <i>Journal of Atherosclerosis and Thrombosis</i> , 2019, 26, 670-677.	0.9	8
1714	External Validation of the Model of Thromboembolic Risk in Hypertrophic Cardiomyopathy Patients. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1800-1806.	0.8	14
1715	Efficacy and safety of left atrial appendage closure in non-valvular atrial fibrillation in patients over 75 years. <i>Heart and Vessels</i> , 2019, 34, 1858-1865.	0.5	9
1716	Patients on NOACs in the Emergency Room. <i>Current Neurology and Neuroscience Reports</i> , 2019, 19, 40.	2.0	4
1717	Patient involvement in consultation for atrial fibrillation – the cardiologists’ perspective. <i>International Journal of Health Care Quality Assurance</i> , 2019, 32, 765-776.	0.2	4
1718	Cost-Effectiveness of Cryoballoon Ablation Versus Radiofrequency Ablation for Paroxysmal Atrial Fibrillation in China: Results Based on Real-World Data. <i>Value in Health</i> , 2019, 22, 863-870.	0.1	7
1719	Management of Myocarditis-Related Cardiomyopathy in Adults. <i>Circulation Research</i> , 2019, 124, 1568-1583.	2.0	179

#	ARTICLE	IF	CITATIONS
1720	Prevalence and risk factors for atrial fibrillation and its anticoagulant requirement in adults aged 40 in Jimma Town, Southwest Ethiopia: A community based cross-sectional study. <i>IJC Heart and Vasculature</i> , 2019, 22, 199-204.	0.6	16
1721	Evaluation of a clinical score for predicting atrial fibrillation in cryptogenic stroke patients with insertable cardiac monitors: results from the CRYSTAL AF study. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641984269.	1.5	24
1722	Should we abandon the term " lone atrial fibrillation"? <i>Hellenic Journal of Cardiology</i> , 2019, 60, 216-223.	0.4	4
1723	Long-term safety and efficacy of combined percutaneous LAA and PFO/ASD closure: a single-center experience (LAAC combined PFO/ASD closure). <i>Expert Review of Medical Devices</i> , 2019, 16, 429-435.	1.4	9
1724	Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. <i>BMJ Open</i> , 2019, 9, e026645.	0.8	48
1725	CHA2DS2-Vasc score and CHA2DS2-Vasc-HS score are poor predictors of in-stent restenosis among patients with coronary drug-eluting stents. <i>Journal of International Medical Research</i> , 2019, 47, 2533-2544.	0.4	4
1726	A novel atrial fibrillation prediction model for Chinese subjects: a nationwide cohort investigation of 682,237 study participants with random forest model. <i>Europace</i> , 2019, 21, 1307-1312.	0.7	21
1727	Anticoagulation Management With Coumarinic Drugs in Chilean Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2019, 25, 107602961983434.	0.7	3
1728	Evidence for a Heritable Contribution to Atrial Fibrillation Associated With Fibrosis. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 493-500.	1.3	8
1729	MRI-detected brain lesions in AF patients without further stroke risk factors undergoing ablation - a retrospective analysis of prospective studies. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 58.	0.7	8
1730	Exposure to vitamin k antagonists and kidney function decline in patients with atrial fibrillation and chronic kidney disease. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 207-216.	1.0	20
1731	Antithrombotic Treatment May Reduce Mortality Among New-Onset Atrial Fibrillation Patients with Gray-Zone Risk of Stroke. <i>International Heart Journal</i> , 2019, 60, 303-309.	0.5	3
1732	Cost-Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation. <i>Korean Circulation Journal</i> , 2019, 49, 252.	0.7	94
1733	Patient characteristics as predictors of recurrence of atrial fibrillation following cryoballoon ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2019, 42, 694-704.	0.5	24
1734	Cost-effectiveness analysis of case management for optimized antithrombotic treatment in German general practices compared to usual care " results from the PICANT trial. <i>Health Economics Review</i> , 2019, 9, 4.	0.8	2
1735	ECG Diagnosis: Ibutilide-induced Torsade de Pointes. , 2019, 23, .		1
1736	Recurrent ischemic stroke in atrial fibrillation with non-vitamin K antagonist oral anticoagulation. <i>Journal of Clinical Neuroscience</i> , 2019, 64, 127-133.	0.8	5
1737	Serum relaxin level predicts recurrence of atrial fibrillation after radiofrequency catheter ablation. <i>Heart and Vessels</i> , 2019, 34, 1543-1551.	0.5	8

#	ARTICLE	IF	CITATIONS
1738	CHA2DS2-VASC score as a preprocedural predictor of contrast-induced nephropathy among patients with chronic total occlusion undergoing percutaneous coronary intervention: a single-center experience. <i>BMC Cardiovascular Disorders</i> , 2019, 19, 74.	0.7	6
1739	High CHA2DS2-VASc score without atrial fibrillation: “NAO yes, NAO no”™. <i>European Heart Journal Supplements</i> , 2019, 21, B67-B68.	0.0	4
1740	Effectiveness and Safety of Off-Label Dose-Reduced Direct Oral Anticoagulants in Atrial Fibrillation. <i>American Journal of Medicine</i> , 2019, 132, 847-855.e3.	0.6	67
1741	Shorter hospital stays in epistaxis patients with atrial fibrillation when taking rivaroxaban or apixaban versus phenprocoumon. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 384-391.	1.0	7
1742	Factors affecting general practitioners’™ decisions to adopt new prescription drugs “ cohort analyses using Australian longitudinal physician survey data. <i>BMC Health Services Research</i> , 2019, 19, 94.	0.9	14
1743	Predictive value of interatrial block for atrial fibrillation in elderly subjects enrolled in the PREDICTOR study. <i>Journal of Electrocardiology</i> , 2019, 54, 22-27.	0.4	10
1744	Early differentiation of long-standing persistent atrial fibrillation using the characteristics of fibrillatory waves in surface ECG multi-leads. <i>Scientific Reports</i> , 2019, 9, 2746.	1.6	9
1745	<p>Screening of novel HSP-inducing compounds to conserve cardiomyocyte function in experimental atrial fibrillation</p>. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 345-364.	2.0	17
1746	Ablation of atrial fibrillation in patients with Brugada syndrome: A systematic review of the literature. <i>Journal of Arrhythmia</i> , 2019, 35, 18-24.	0.5	5
1747	Peripheral blood metabolite profiles associated with new onset atrial fibrillation. <i>American Heart Journal</i> , 2019, 211, 54-59.	1.2	9
1748	Atrial Fibrillation and Stroke in Patients with Hypertrophic Cardiomyopathy: Important New Insights. <i>Thrombosis and Haemostasis</i> , 2019, 119, 355-357.	1.8	12
1749	Twelve-month outcome in patients with stroke and atrial fibrillation not suitable to oral anticoagulant strategy: the WATCH-AF registry. <i>Open Heart</i> , 2019, 6, e001187.	0.9	6
1750	Comparison of the Efficacy of Cryoballoon Ablation for Paroxysmal and Persistent Atrial Fibrillation. <i>Journal of the Nihon University Medical Association</i> , 2019, 78, 21-25.	0.0	0
1751	Incidence of atrial fibrillation in different major cancer subtypes: a Nationwide population-based 12%year follow up study. <i>BMC Cancer</i> , 2019, 19, 1105.	1.1	68
1752	Young-onset atrial fibrillation: Sex differences in clinical profile, progression rate and cardiovascular outcome. <i>IJC Heart and Vasculature</i> , 2019, 25, 100429.	0.6	5
1754	Imbalance of ER and Mitochondria Interactions: Prelude to Cardiac Ageing and Disease?. <i>Cells</i> , 2019, 8, 1617.	1.8	35
1755	Assessment of agreement and time in therapeutic range of capillary versus venous international normalised ratio in frail elderly people in a nursing home. <i>Internal Medicine Journal</i> , 2019, 49, 1442-1446.	0.5	1
1756	A Pilot Randomized Controlled Trial Testing the Feasibility and Acceptability of a SystemCHANGE Intervention to Improve Medication Adherence in Older Adult Stroke Survivors. <i>Journal of Neuroscience Nursing</i> , 2019, 51, 259-265.	0.7	5

#	ARTICLE	IF	CITATIONS
1757	Mitral annular calcification is associated with atrial fibrillation and major cardiac adverse events in atrial fibrillation patients. <i>Medicine (United States)</i> , 2019, 98, e17548.	0.4	8
1758	Non-contrast enhanced simultaneous 3D whole-heart bright-blood pulmonary veins visualization and black-blood quantification of atrial wall thickness. <i>Magnetic Resonance in Medicine</i> , 2019, 81, 1066-1079.	1.9	20
1759	The 4q25 variant rs13143308T links risk of atrial fibrillation to defective calcium homeostasis. <i>Cardiovascular Research</i> , 2019, 115, 578-589.	1.8	37
1760	An overview of current and emerging devices for percutaneous left atrial appendage closure. <i>Trends in Cardiovascular Medicine</i> , 2019, 29, 228-236.	2.3	11
1761	Bleeding risk score in Japanese patients on antiplatelets plus an anticoagulant. <i>Journal of Cardiology</i> , 2019, 73, 466-467.	0.8	2
1762	Comparison between blood coagulability in the intra-atrial and peripheral regions during the acute phase after rapid atrial pacing. <i>Experimental Animals</i> , 2019, 68, 137-146.	0.7	5
1763	Double factor single shot to diminish complications in cryoballoon ablation procedures for atrial fibrillation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2019, 55, 17-26.	0.6	6
1764	Assessment of peri-device leaks after interventional left atrial appendage closure using standardized imaging by cardiac computed tomography angiography. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 725-731.	0.7	17
1765	Comparing the delay with different anticoagulants before elective electrical cardioversion for atrial fibrillation/flutter. <i>PLoS ONE</i> , 2019, 14, e0210170.	1.1	1
1766	Direct comparison of prognostic ability of cardiac biomarkers for cardiogenic stroke and clinical outcome in patients with stroke. <i>Heart and Vessels</i> , 2019, 34, 1178-1186.	0.5	15
1767	Direct oral anticoagulants vs non-vitamin K antagonist in atrial fibrillation: A prospective, propensity score adjusted cohort study. <i>European Journal of Internal Medicine</i> , 2019, 62, 9-16.	1.0	13
1768	Prevalencia e implicaci3n pron3stica de la enfermedad valvular en pacientes con fibrilaci3n auricular que inician anticoagulantes orales. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 935-943.	0.6	0
1769	Levels of and Changes in Childhood Body Mass Index in Relation to Risk of Atrial Fibrillation and Atrial Flutter in Adulthood. <i>American Journal of Epidemiology</i> , 2019, 188, 684-693.	1.6	9
1771	Abnormally high risk of stroke in Brugada syndrome. <i>Journal of Cardiovascular Medicine</i> , 2019, 20, 59-65.	0.6	10
1772	Atrial flutter and embolic risk: The relationship between atrial flutter cycle length and left atrial appendage function. <i>Journal of Electrocardiology</i> , 2019, 52, 11-16.	0.4	2
1773	Thoracoscopic Left Atrial Appendage Occlusion for Stroke Prevention Compared with Long-Term Warfarin Therapy in Patients With Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2019, 123, 50-56.	0.7	3
1774	Catheter ablation in elderly patients. <i>Current Opinion in Cardiology</i> , 2019, 34, 29-34.	0.8	0
1775	Prevalence and Prognostic Implications of Valve Disease in Patients With Atrial Fibrillation Initiating Direct Oral Anticoagulants. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 935-943.	0.4	3

#	ARTICLE	IF	CITATIONS
1776	Comparison of CHA2DS2-VASc and AHEAD scores for the prediction of incident dementia in patients hospitalized for heart failure: a nationwide cohort study. <i>Internal and Emergency Medicine</i> , 2019, 14, 395-402.	1.0	4
1777	Risk of new-onset atrial fibrillation among heart, kidney and liver transplant recipients: insights from a national cohort study. <i>Internal and Emergency Medicine</i> , 2019, 14, 71-76.	1.0	8
1778	Oral Anticoagulation in the Elderly: New Oral Anticoagulantsâ€“Innovative Solution for an Old Problem?. <i>American Journal of Therapeutics</i> , 2019, 26, e133-e142.	0.5	5
1779	Hyponatremia is associated with occurrence of atrial fibrillation in outpatients with heart failure and reduced ejection fraction. <i>Hellenic Journal of Cardiology</i> , 2019, 60, 117-121.	0.4	23
1780	Left Atrial Appendage Exclusion Using the AtriClip Device: A Case Series. <i>Heart Lung and Circulation</i> , 2019, 28, 430-435.	0.2	6
1781	Female sex and stroke in atrial fibrillation: an intriguing relationship. <i>Internal and Emergency Medicine</i> , 2020, 15, 175-179.	1.0	3
1782	Determinants of anticoagulant therapy in atrial fibrillation at discharge from a geriatric ward: cross sectional study. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 49, 18-26.	1.0	11
1783	Efficacy and safety of catheter ablation combined with left atrial appendage occlusion for nonvalvular atrial fibrillation: A systematic review and metaâ€“analysis. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2020, 43, 123-132.	0.5	14
1784	Epidemiology of atrial fibrillation in northeast China: a cross-sectional study, 2017â€“2019. <i>Heart</i> , 2020, 106, 590-595.	1.2	28
1785	Reduction of radiation and contrast agent exposure in a cryoballoon ablation procedure with integration of electromagnetic mapping and intracardiac echocardiography: a single center experience. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2020, 59, 545-550.	0.6	14
1786	CHA2DS2-Vasc score and saphenous vein graft disease in patients with coronary artery bypass graft surgery. <i>Coronary Artery Disease</i> , 2020, 31, 243-247.	0.3	4
1787	Cerebrovascular Dysfunction in Atrial Fibrillation. <i>Frontiers in Physiology</i> , 2020, 11, 1066.	1.3	12
1788	Appropriate Dosing Regimens of Non-Vitamin K Antagonist Oral Anticoagulants for Treatment of Patients With Non-Valvular Atrial Fibrillation: An Evidence-Based Consideration. <i>Frontiers in Pharmacology</i> , 2020, 11, 1293.	1.6	3
1789	Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials. <i>European Heart Journal Supplements</i> , 2020, 22, 11-112.	0.0	4
1790	Female Sex as a Thromboembolic Risk Factor in the Era of Nonvitamin K Antagonist Oral Anticoagulants. <i>Cardiovascular Therapeutics</i> , 2020, 2020, 1-9.	1.1	11
1791	Inhibition of the NFATc4/ERK/AKT Pathway and Improvement of Thiol-Specific Oxidative Stress by Dronedarone Possibly Secondary to the Reduction of Blood Pressure in an Animal Model of Ventricular Hypertrophy. <i>Frontiers in Physiology</i> , 2020, 11, 967.	1.3	0
1792	Patient perception of anticoagulant treatment for stroke prevention (RE-SONANCE study). <i>Open Heart</i> , 2020, 7, e001202.	0.9	7
1793	Treatment Complications of Atrial Fibrillation and Their Management. <i>International Journal of Angiology</i> , 2020, 29, 098-107.	0.2	0

#	ARTICLE	IF	CITATIONS
1794	High incidence of (ultra)low oesophageal temperatures during cryoballoon pulmonary vein isolation for atrial fibrillation. <i>Netherlands Heart Journal</i> , 2020, 28, 662-669.	0.3	2
1795	Effectiveness and Safety of Apixaban Compared With Rivaroxaban for Patients With Atrial Fibrillation in Routine Practice. <i>Annals of Internal Medicine</i> , 2020, 172, 463.	2.0	72
1796	The possibility to have 1 mm positioning accuracy of intracardiac catheter via electrical measurement. , 2020, , .		0
1797	Evaluation of the Long-Term Impact on Quality After the End of Pharmacist-Driven Warfarin Therapy Management in Patients With Poor Quality of Anticoagulation Therapy. <i>Frontiers in Pharmacology</i> , 2020, 11, 1056.	1.6	1
1798	Prescription of oral anticoagulants and antiplatelets for stroke prophylaxis in atrial fibrillation: nationwide time series ecological analysis. <i>Europace</i> , 2020, 22, 1311-1319.	0.7	21
1799	A two-part model to estimate inpatient, outpatient, prescribing and care home costs associated with atrial fibrillation in Scotland. <i>BMJ Open</i> , 2020, 10, e028575.	0.8	13
1800	Management of Anticoagulation and Antiplatelet Therapy in Glaucoma Surgery. <i>Journal of Glaucoma</i> , 2020, 29, 732-741.	0.8	3
1801	Relationship between coarse F waves and thromboembolic events in patients with permanent atrial fibrillation. <i>Journal of Arrhythmia</i> , 2020, 36, 1025-1031.	0.5	2
1802	Optimal Antithrombotic Treatment of Patients with Atrial Fibrillation Early after an Acute Coronary Syndrome—Triple Therapy, Dual Antithrombotic Therapy with an Anticoagulant—Or, Rather, Temporary Dual Antiplatelet Therapy?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2673.	1.0	5
1803	Cardioversion Safety — Are We Doing Enough?. <i>Cardiology</i> , 2020, 145, 740-745.	0.6	1
1804	Cost-effectiveness of direct oral anticoagulants versus vitamin K antagonist in atrial fibrillation. <i>Medicine (United States)</i> , 2020, 99, e22054.	0.4	3
1805	Psychological aspects of atrial fibrillation: A systematic narrative review. <i>Current Cardiology Reports</i> , 2020, 22, 137.	1.3	32
1806	Revisiting Antiarrhythmic Drug Therapy for Atrial Fibrillation: Reviewing Lessons Learned and Redefining Therapeutic Paradigms. <i>Frontiers in Pharmacology</i> , 2020, 11, 581837.	1.6	29
1807	Serum and Echocardiographic Markers May Synergistically Predict Adverse Cardiac Remodeling after ST-Segment Elevation Myocardial Infarction in Patients with Preserved Ejection Fraction. <i>Diagnostics</i> , 2020, 10, 301.	1.3	11
1808	A Delphi consensus on the management of oral anticoagulation in patients with non-valvular atrial fibrillation in Spain: ACOPREFERENCE study. <i>PLoS ONE</i> , 2020, 15, e0231565.	1.1	12
1809	Comparison of HAS-BLED with other risk models for predicting the bleeding risk in anticoagulated patients with atrial fibrillation. <i>Medicine (United States)</i> , 2020, 99, e20782.	0.4	7
1810	The CHA2DS2-VASc score predicts chronic kidney disease among patients with atrial fibrillation. <i>International Urology and Nephrology</i> , 2020, 52, 1523-1531.	0.6	5
1811	Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation. <i>Stroke</i> , 2020, 51, 2066-2075.	1.0	41

#	ARTICLE	IF	CITATIONS
1813	Serum microRNA in patients undergoing atrial fibrillation ablation. <i>Scientific Reports</i> , 2020, 10, 4424.	1.6	13
1814	Digoxin-amiodarone Combination is Associated With Excess All-cause Mortality in Patients With Atrial Fibrillation. <i>Scientific Reports</i> , 2020, 10, 4101.	1.6	6
1816	A cost-effectiveness analysis model of Preventicus atrial fibrillation screening from the point of view of statutory health insurance in Germany. <i>Health Economics Review</i> , 2020, 10, 16.	0.8	13
1817	A self-management support intervention for patients with atrial fibrillation: a randomized controlled pilot trial. <i>Pilot and Feasibility Studies</i> , 2020, 6, 87.	0.5	6
1818	A risk stratification scoring system for new-onset atrial fibrillation after ischemic stroke. <i>Medicine (United States)</i> , 2020, 99, e20881.	0.4	3
1819	Atrial Fibrillation and Surgical Patients with Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2020, 67, 411-416.	0.4	2
1820	The Tasmanian Atrial Fibrillation Study (TAFS): Differences in Stroke Prevention According to Sex. <i>Annals of Pharmacotherapy</i> , 2020, 54, 837-845.	0.9	10
1821	Antithrombotic therapy in patients with non-traumatic intracerebral haemorrhage and atrial fibrillation: A retrospective study. <i>Heliyon</i> , 2020, 6, e03219.	1.4	0
1822	Cardiovascular drug use among people with cognitive impairment living in nursing homes in northern Sweden. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 525-537.	0.8	3
1823	Current status and factors influencing oral anticoagulant therapy among patients with non-valvular atrial fibrillation in Jiangsu province, China: a multi-center, cross-sectional study. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 22.	0.7	16
1824	Global research productions pertaining to atrial fibrillation from 2004 to 2018. <i>Medicine (United States)</i> , 2020, 99, e20881.	0.4	6
1825	Serum N-Acetylneuraminic Acid Is Associated with Atrial Fibrillation and Left Atrial Enlargement. <i>Cardiology Research and Practice</i> , 2020, 2020, 1-6.	0.5	10
1826	Clinical characteristics and antithrombotic prescription in elderly hospitalized atrial fibrillation patients. <i>IJC Heart and Vasculature</i> , 2020, 27, 100505.	0.6	6
1827	Prognostic indicators of new onset atrial fibrillation in patients with acute coronary syndrome. <i>Clinical Cardiology</i> , 2020, 43, 647-651.	0.7	7
1828	Functionally Significant Coumarin-Related Variant Alleles and Time to Therapeutic Range in Chilean Cardiovascular Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2020, 26, 107602962090915.	0.7	5
1829	Impact of re-definition of paroxysmal and persistent atrial fibrillation in the 2012 and 2016 European Society of Cardiology atrial fibrillation guidelines on outcomes after pulmonary vein isolation. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 115-123.	0.6	4
1830	Renal sympathetic denervation in addition to pulmonary vein isolation reduces the recurrence rate of atrial fibrillation: an updated meta-analysis of randomized control trials. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2021, 60, 459-467.	0.6	2
1831	Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis. <i>Journal of Nephrology</i> , 2021, 34, 63-73.	0.9	38

#	ARTICLE	IF	CITATIONS
1832	Anticoagulation for atrial fibrillation patients with the CHA2DS2-VASc score =1 (beyond sex). <i>Acta Cardiologica</i> , 2021, 76, 258-264.	0.3	1
1833	Edoxaban for stroke prevention in atrial fibrillation in routine clinical care: 1-year follow-up of the prospective observational ETNA-AF-Europe study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, f30-f39.	1.4	33
1834	Comparison of the efficacy and safety of different doses of nifekalant in the instant cardioversion of persistent atrial fibrillation during radiofrequency ablation. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, 128, 430-439.	1.2	2
1835	Blood-based 8-hydroxy-2-â€²-deoxyguanosine level: A potential diagnostic biomarker for atrial fibrillation. <i>Heart Rhythm</i> , 2021, 18, 271-277.	0.3	18
1836	Association of adipocytokines serum levels with left atrial thrombus formation in atrial fibrillation patients on oral anticoagulation (Alert) â€“ A cross-sectional study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 860-868.	1.1	3
1837	Mitochondrial genetic effect on atrial fibrillation: A case-control study. <i>Mitochondrion</i> , 2021, 56, 15-24.	1.6	2
1838	Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). <i>Europace</i> , 2021, 23, 362-369a.	0.7	91
1839	Oral anticoagulant use in patients with atrial fibrillation and mitral valve repair. <i>American Heart Journal</i> , 2021, 232, 1-9.	1.2	6
1840	The role of biomarkers and neuroimaging in ischemic/hemorrhagic risk assessment for cardiovascular/cerebrovascular disease prevention. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2021, 177, 345-357.	1.0	3
1842	Nonâ€“Vitamin K Antagonist Oral Anticoagulants in Elderly (â‰¥85 years) Patients With Newly Diagnosed Atrial Fibrillation. <i>Mayo Clinic Proceedings</i> , 2021, 96, 52-65.	1.4	21
1843	Assessment of a new algorithm to detect atrial fibrillation in home blood pressure monitoring device among healthy adults and patients with atrial fibrillation. <i>Journal of Clinical Hypertension</i> , 2021, 23, 1085-1088.	1.0	9
1844	The Echocardiographic Findings in Patients with Atrial Fibrillation in a Tertiary Care Center of Nepal: A Descriptive Cross-sectional Study. <i>Journal of the Nepal Medical Association</i> , 2021, 59, 46-50.	0.1	1
1845	Atrial Fibrillation is Associated with Femoropopliteal Totally Occlusive In-Stent Restenosis: A Single-Center, Retrospective, Observational Study. <i>Journal of Interventional Cardiology</i> , 2021, 2021, 1-8.	0.5	1
1846	Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: results of the multicenter RIF-CHF register. <i>Russian Journal of Cardiology</i> , 2021, 26, 4200.	0.4	7
1847	Lenient rate control versus strict rate control for atrial fibrillation: a protocol for the Danish Atrial Fibrillation (DanAF) randomised clinical trial. <i>BMJ Open</i> , 2021, 11, e044744.	0.8	3
1848	Efficacy and Safety of Clinically Driven Low-Dose Treatment with Direct Oral Anticoagulants in Asians with Atrial Fibrillation: a Systematic Review and Meta-analysis. <i>Cardiovascular Drugs and Therapy</i> , 2022, 36, 333-345.	1.3	5
1849	Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney function. <i>European Heart Journal</i> , 2021, 42, 1476-1485.	1.0	26
1850	Using Artificial Intelligence With Natural Language Processing to Combine Electronic Health Recordâ€™s Structured and Free Text Data to Identify Nonvalvular Atrial Fibrillation to Decrease Strokes and Death: Evaluation and Case-Control Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e28946.	2.1	16

#	ARTICLE	IF	CITATIONS
1851	Ten-Year Trends in the Use of Oral Anticoagulants in Australian General Practice Patients With Atrial Fibrillation. <i>Frontiers in Pharmacology</i> , 2021, 12, 586370.	1.6	20
1852	Prevalence and Resolution of Resistant Left Atrial Appendage Thrombus in Non-Valvular Atrial Fibrillation Patients Submitted to Percutaneous Interventions. <i>Clinical Cardiology and Cardiovascular Interventions</i> , 2021, 4, 01-09.	0.1	0
1853	Screening and management of atrial fibrillation in primary care. <i>BMJ, The</i> , 2021, 373, n379.	3.0	9
1854	Left Atrial Myopathy in Atrial Fibrillation and Heart Failure: Clinical Implications, Mechanisms, and Therapeutic Targets. <i>Current Heart Failure Reports</i> , 2021, 18, 85-98.	1.3	19
1855	The year in cardiovascular medicine 2020: arrhythmias. <i>Cardiologia Croatica</i> , 2021, 16, 107-116.	0.0	3
1856	Ablation Versus Drug Therapy for Atrial Fibrillation in Heart Failure. <i>Circulation</i> , 2021, 143, 1377-1390.	1.6	223
1857	The Role of the Contextual Cohort to Resolve Some Challenges and Limitations of Comparisons in Pharmacoepidemiology. <i>Drug Safety</i> , 2021, 44, 835-841.	1.4	1
1858	2020 Clinical practice guidelines for Hypertrophic cardiomyopathy. <i>Russian Journal of Cardiology</i> , 2021, 26, 4541.	0.4	20
1859	Management of Atrial Fibrillation in 2021: An Updated Comparison of the Current CCS/CHRS, ESC, and AHA/ACC/HRS Guidelines. <i>Canadian Journal of Cardiology</i> , 2021, 37, 1607-1618.	0.8	48
1860	Galectin-3 in patients with atrial fibrillation and restored sinus rhythm. <i>Folia Medica</i> , 2021, 63, 329-336.	0.2	3
1861	3D Printing in Modern Cardiology. <i>Current Pharmaceutical Design</i> , 2021, 27, 1918-1930.	0.9	27
1862	Effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in atrial fibrillation: a Scandinavian population-based cohort study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2022, 8, 577-587.	1.8	7
1863	Kardia Mobile applicability in clinical practice: A comparison of Kardia Mobile and standard 12-lead electrocardiogram records in 100 consecutive patients of a tertiary cardiovascular care center. <i>Cardiology Journal</i> , 2021, 28, 543-548.	0.5	50
1864	Neurologists's attitudes and options for anticoagulation therapy in central China. <i>International Journal of Clinical Practice</i> , 2021, 75, e14305.	0.8	1
1865	Warfarin: time in therapeutic range, a single centre study on patients using warfarin for stroke prevention in non-valvular atrial fibrillation and prosthetic heart valves. <i>SA Heart Journal</i> , 2021, 18, .	0.0	1
1866	Effect of Evidence-Based Pharmacy Care on Satisfaction and Cognition in Patients with Non-Valvular Atrial Fibrillation Taking Rivaroxaban. <i>Patient Preference and Adherence</i> , 2021, Volume 15, 1661-1670.	0.8	2
1867	Association of atrial fibrillation and various cancer subtypes. <i>Journal of Arrhythmia</i> , 2021, 37, 1205-1214.	0.5	8
1868	Analysis of risk factors for thrombosis of the left atrium/left atrial appendage in patients with non-valvular atrial fibrillation. <i>Cardiovascular Journal of Africa</i> , 2021, 32, 6-12.	0.2	2

#	ARTICLE	IF	CITATIONS
1869	Convenience and satisfaction in direct oral anticoagulant-treated patients with atrial fibrillation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12577.	1.0	1
1870	One-year Follow-up Results of the Optimal Thromboprophylaxis in Elderly Chinese Patients with Atrial Fibrillation (ChiOTEAF) registry. <i>Journal of Arrhythmia</i> , 2021, 37, 1227-1239.	0.5	7
1871	Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST - AFNET 4 trial. <i>Europace</i> , 2022, 24, 552-564.	0.7	22
1872	Subclinical thyroid function and cardiovascular events in patients with atrial fibrillation. <i>European Journal of Endocrinology</i> , 2021, 185, 375-385.	1.9	8
1873	New Strategies for the Treatment of Atrial Fibrillation. <i>Pharmaceuticals</i> , 2021, 14, 926.	1.7	6
1874	Comparing Patient Preferences for Antithrombotic Treatment During the Acute and Chronic Phases of Myocardial Infarction: A Discrete-Choice Experiment. <i>Patient</i> , 2022, 15, 255-266.	1.1	8
1875	Preintervention imaging and intraoperative management care of the hypertrophic obstructive cardiomyopathy patient. <i>Asian Cardiovascular and Thoracic Annals</i> , 2022, 30, 35-42.	0.2	1
1876	The year in cardiovascular medicine 2020: arrhythmias. <i>European Heart Journal</i> , 2021, 42, 499-507.	1.0	4
1877	Heart Drugs and Influences on TH Metabolism. , 2020, , 311-325.		4
1878	Antithrombotika und Antihämorrhagika. , 2016, , 351-368.		2
1879	Analysis of Risk Factors Independently Associated with Cognitive Impairment in Patients with Permanent Atrial Fibrillation: A Cross-sectional Observational Study. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2020, 29, 104895.	0.7	2
1880	A Novel Loss-of-Function Variant in the Chloride Ion Channel Gene <i>Clcn2</i> Associates with Atrial Fibrillation. <i>Scientific Reports</i> , 2020, 10, 1453.	1.6	10
1881	Efficacy and Safety of Oral Anticoagulants in Patients with Systolic Heart Failure in Sinus Rhythm: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Cohort Studies. <i>TH Open</i> , 2020, 04, e383-e392.	0.7	3
1882	Publisher's note. <i>European Heart Journal</i> , 2015, 36, 2880-5.	1.0	25
1883	Two-year outcomes of patients with newly diagnosed atrial fibrillation: results from GARFIELD-AF. <i>European Heart Journal</i> , 2016, 37, 2882-2889.	1.0	222
1884	Emergency reversal of dabigatran for emergency surgery. <i>BMJ Case Reports</i> , 2015, 2015, bcr2014209057-bcr2014209057.	0.2	6
1885	Real-world evaluation of perception, convenience and anticoagulant treatment satisfaction of patients with atrial fibrillation switched from long-term vitamin K antagonist treatment to dabigatran. <i>Open Heart</i> , 2020, 7, e001343.	0.9	6
1886	SUPPORT-AF II: Supporting Use of Anticoagulants Through Provider Profiling of Oral Anticoagulant Therapy for Atrial Fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005871.	0.9	18

#	ARTICLE	IF	CITATIONS
1887	Clinical outcomes of catheter ablation of paroxysmal atrial fibrillation in very young population compared to older population: a prospective study. <i>Egyptian Heart Journal</i> , 2019, 71, 11.	0.4	6
1888	Atrial fibrillation: the current epidemic. <i>Journal of Geriatric Cardiology</i> , 2017, 14, 195-203.	0.2	208
1890	Management of atrial fibrillation. <i>F1000prime Reports</i> , 2014, 6, 22.	5.9	4
1891	Expanding use of new oral anticoagulants. <i>F1000prime Reports</i> , 2014, 6, 93.	5.9	15
1892	Apixaban in the prevention of stroke and systemic embolism in nonvalvular atrial fibrillation. <i>Drugs of Today</i> , 2013, 49, 425.	0.7	3
1893	Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease. <i>PLoS ONE</i> , 2014, 9, e94420.	1.1	35
1894	The Association of CHA2DS2-VASc Score and Blood Biomarkers with Ischemic Stroke Outcomes: The Belgrade Stroke Study. <i>PLoS ONE</i> , 2014, 9, e106439.	1.1	16
1895	Cardiovascular Complications Secondary to Graves's Disease: A Prospective Study from Ukraine. <i>PLoS ONE</i> , 2015, 10, e0122388.	1.1	20
1896	The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. <i>PLoS ONE</i> , 2015, 10, e0122520.	1.1	69
1897	Risk of Bleeding and Stroke with Oral Anticoagulation and Antiplatelet Therapy in Patients with Atrial Fibrillation in Taiwan: A Nationwide Cohort Study. <i>PLoS ONE</i> , 2015, 10, e0125257.	1.1	26
1898	Multiscale Entropy of the Heart Rate Variability for the Prediction of an Ischemic Stroke in Patients with Permanent Atrial Fibrillation. <i>PLoS ONE</i> , 2015, 10, e0137144.	1.1	30
1899	Young Male Patients with Atrial Fibrillation and CHA2DS2-VASc Score of 1 May Not Need Anticoagulants: A Nationwide Population-Based Study. <i>PLoS ONE</i> , 2016, 11, e0151485.	1.1	17
1900	Shensongyangxin Capsules for Paroxysmal Atrial Fibrillation: A Systematic Review of Randomized Clinical Trials. <i>PLoS ONE</i> , 2016, 11, e0151880.	1.1	9
1901	Screening for Atrial Fibrillation – A Cross-Sectional Survey of Healthcare Professionals in Primary Care. <i>PLoS ONE</i> , 2016, 11, e0152086.	1.1	19
1902	Prediction of Mortality in Incident Hemodialysis Patients: A Validation and Comparison of CHADS2, CHA2DS2, and CCI Scores. <i>PLoS ONE</i> , 2016, 11, e0154627.	1.1	20
1903	Chronic Kidney Disease and the Risk of New-Onset Atrial Fibrillation: A Meta-Analysis of Prospective Cohort Studies. <i>PLoS ONE</i> , 2016, 11, e0155581.	1.1	30
1904	Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. <i>PLoS ONE</i> , 2016, 11, e0164076.	1.1	118
1905	Patient-Reported Treatment Satisfaction with Rivaroxaban for Stroke Prevention in Atrial Fibrillation. A French Observational Study, the SAFARI Study. <i>PLoS ONE</i> , 2016, 11, e0166218.	1.1	29

#	ARTICLE	IF	CITATIONS
1906	Prediction of Thromboembolic Events in Heart Failure Patients in Sinus Rhythm: The Hong Kong Heart Failure Registry. PLoS ONE, 2016, 11, e0169095.	1.1	8
1907	Effectiveness and usage of a decision support system to improve stroke prevention in general practice: A cluster randomized controlled trial. PLoS ONE, 2017, 12, e0170974.	1.1	56
1908	The effects of rhythm control strategies versus rate control strategies for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and Trial Sequential Analysis. PLoS ONE, 2017, 12, e0186856.	1.1	43
1909	Temporal trends of antithrombotic therapy for stroke prevention in Korean patients with non-valvular atrial fibrillation in the era of non-vitamin K antagonist oral anticoagulants: A nationwide population-based study. PLoS ONE, 2017, 12, e0189495.	1.1	71
1910	Non-vitamin K antagonist oral anticoagulants versus warfarin for the prevention of spontaneous echo-contrast and thrombus in patients with atrial fibrillation or flutter undergoing cardioversion: A trans-esophageal echocardiography study. PLoS ONE, 2018, 13, e0191648.	1.1	14
1911	Nonsteroidal anti-inflammatory drug choice and adverse outcomes in clopidogrel users: A retrospective cohort study. PLoS ONE, 2018, 13, e0193800.	1.1	7
1912	Digoxin for atrial fibrillation and atrial flutter: A systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. PLoS ONE, 2018, 13, e0193924.	1.1	37
1913	Efficacy of Oral Anticoagulation in Stroke Prevention among Sinus-Rhythm Patients Who Lack Left Atrial Mechanical Contraction after Cryoablation. Texas Heart Institute Journal, 2015, 42, 430-437.	0.1	4
1914	Underuse of Oral Anticoagulants for Nonvalvular Atrial Fibrillation: Past, Present, and Future. Texas Heart Institute Journal, 2016, 43, 287-290.	0.1	10
1915	Minimally Symptomatic Atrial Fibrillation Patients Derive Significant Symptom Relief Following Rate Control or Rhythm Control Therapy. Journal of Clinical Medicine Research, 2015, 7, 690-693.	0.6	2
1916	ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study). Anatolian Journal of Cardiology, 2016, 16, 734-741.	0.5	17
1917	The influence of the vegetative balance in the development of atrial fibrillation in patients with chronic obstructive pulmonary disease. Annaly Aritmologii, 2014, 11, 24-31.	0.1	1
1918	Echocardiography predictors of the left atrial appendage thrombus in patients with persistent atrial fibrillation. Annaly Aritmologii, 2014, 11, 160-176.	0.1	3
1919	Increased cardiovascular risk in thyroid cancer patients taking levothyroxine: a nationwide cohort study in Korea. European Journal of Endocrinology, 2019, 180, 11-20.	1.9	36
1920	Does Deficiency of Vitamin D Increase New Onset Atrial Fibrillation after Coronary Artery Bypass Grafting Surgery?. Heart Surgery Forum, 2016, 19, 180.	0.2	16
1921	The Potential Role of Edoxaban in Stroke Prevention Guidelines. Arrhythmia and Electrophysiology Review, 2014, 3, 40-43.	1.3	2
1922	Relevance of Monitoring Atrial Fibrillation in Clinical Practice. Arrhythmia and Electrophysiology Review, 2012, 1, 54.	1.3	5
1923	Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion. Arrhythmia and Electrophysiology Review, 2013, 2, 109.	1.3	12

#	ARTICLE	IF	CITATIONS
1924	The European Heart Rhythm Association Practical Guide on the Use of New Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation – A Brief Summary. <i>Arrhythmia and Electrophysiology Review</i> , 2013, 2, 115.	1.3	2
1925	Stroke Prevention in Atrial Fibrillation – Outcomes and Future Directions. <i>Arrhythmia and Electrophysiology Review</i> , 2014, 3, 194.	1.3	2
1926	Balloon Devices for Atrial Fibrillation Therapy. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 4, 58.	1.3	17
1927	Upstream Treatment of Atrial Fibrillation with n-3 Polyunsaturated Fatty Acids: Myth or Reality?. <i>Arrhythmia and Electrophysiology Review</i> , 2015, 4, 163.	1.3	6
1928	Pharmacological Therapy of Tachyarrhythmias During Pregnancy. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 41.	1.3	10
1929	Pharmacological Tests in Atrial Fibrillation Ablation. <i>Arrhythmia and Electrophysiology Review</i> , 2016, 5, 170.	1.3	11
1930	Management of Complications in Anticoagulated Patients with Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 167.	1.3	1
1931	Practical Implementation of Anticoagulation Strategy for Patients Undergoing Cardioversion of Atrial Fibrillation. <i>Arrhythmia and Electrophysiology Review</i> , 2017, 6, 50.	1.3	7
1932	Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation: Assessment, Monitoring and Treatment Reversal. <i>European Cardiology Review</i> , 2016, 11, 118.	0.7	5
1933	Real World Outcomes of Left Atrial Appendage Occlusion. <i>Interventional Cardiology Review</i> , 2015, 10, 109.	0.7	2
1934	Standardy badaÅ„ ultrasonografi cznych Polskiego Towarzystwa Ultrasonografi cznego – aktualizacja. Badanie ultrasonografi czne tarczycy oraz biopsja tarczycy pod kontrolÅ… ultrasonografi i. , 2014, 14, 49-60.		14
1936	The role of obesity in the development of atrial fibrillation: current problem status. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2019, 18, 109-114.	0.4	8
1937	Association between gastroesophageal reflux disease and atrial fibrillation: a systematic review and meta-analysis. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 874-879.	0.1	7
1938	Clinical Experience of Dabigatran and Rivaroxaban in Electrical Cardioversion of Atrial Fibrillation. <i>International Cardiovascular Forum Journal</i> , 0, 4, 71.	1.1	9
1939	Old age, high risk medication, polypharmacy: a trilogy of risks in older patients with atrial fibrillation. <i>Pharmacy Practice</i> , 2016, 14, 706-706.	0.8	30
1940	Impact of atrial fibrillation on the development of ischemic stroke among cancer patients classified by CHA2DS2-VASc score-a nationwide cohort study. <i>Oncotarget</i> , 2018, 9, 7623-7630.	0.8	12
1941	Homocysteine as a prognostic marker of atrial remodeling and clinical picture in patients with paroxysmal and persistent forms of atrial fibrillation. <i>Klinicheskaia Meditsina</i> , 2016, 94, 16-22.	0.2	3
1942	A Nurse-led Approach to Improving Cardiac Lifestyle Modification in an Atrial Fibrillation Population. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2019, 10, 3826-3835.	0.2	5

#	ARTICLE	IF	CITATIONS
1943	Practical aspects of new oral anticoagulant use in atrial fibrillation. Polish Archives of Internal Medicine, 2014, 124, 124-135.	0.3	11
1944	The burden of cardiac arrhythmias in sarcoidosis: a population-based inpatient analysis. Annals of Translational Medicine, 2018, 6, 330-330.	0.7	28
1945	Novel oral anticoagulants for stroke prevention in atrial fibrillation: a focus on the older patient. International Journal of General Medicine, 2013, 6, 167.	0.8	16
1946	Biomarkers Associated with Bleeding Risk in the Setting of Atrial Fibrillation. Current Medicinal Chemistry, 2019, 26, 824-836.	1.2	4
1947	Atrial Fibrillation: Biomarkers Determining Prognosis. Current Medicinal Chemistry, 2019, 26, 909-915.	1.2	9
1948	Pathophysiology of Idiopathic Atrial Fibrillation - Prognostic and Treatment Implications. Current Pharmaceutical Design, 2014, 21, 551-572.	0.9	7
1949	The Role of Dronedaron in the Treatment of Atrial Fibrillation/Flutter in the Aftermath of PALLAS. Current Cardiology Reviews, 2014, 10, 303-308.	0.6	13
1950	Left Atrial Appendage Closure –The WATCHMAN Device. Current Cardiology Reviews, 2015, 11, 334-340.	0.6	15
1951	The Role of Atrial Fibrosis Detected by Delayed - Enhancement MRI in Atrial Fibrillation Ablation. Current Medical Imaging, 2020, 16, 135-144.	0.4	7
1952	Evolution of Implantable Cardiac Monitors: A Comparison of Reveal XT and LINQ Patient Selection, Arrhythmia Detection, and Clinical Outcomes. Journal of the Minneapolis Heart Institute Foundation, 2017, 1, 130-135.	0.0	3
1953	A Web-Based Clinical System for Cohort Surveillance of Specific Clinical Effectiveness and Safety Outcomes: A Cohort Study of Non-Vitamin K Antagonist Oral Anticoagulants and Warfarin. JMIR Medical Informatics, 2019, 7, e13329.	1.3	1
1954	Healthcare Resource Utilization among Non-Valvular Atrial Fibrillation Patients Who Switched from Warfarin to a Novel Oral Anti-Coagulant. Journal of Cardiology and Cardiovascular Sciences, 2019, 3, 36-46.	0.4	1
1955	Anticoagulation Management in Patients with Pacemaker-Detected Atrial Fibrillation. Open Access Macedonian Journal of Medical Sciences, 2016, 4, 243-247.	0.1	1
1956	DOACs vs Vitamin K Antagonists: a Comparison of Phase III Clinical Trials and a Prescriber Support Tool. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1226-1232.	0.1	10
1957	Selecting antithrombotic therapy for patients with atrial fibrillation. Cleveland Clinic Journal of Medicine, 2015, 82, 49-63.	0.6	5
1958	Fall risk and anticoagulation for atrial fibrillation in the elderly: A delicate balance. Cleveland Clinic Journal of Medicine, 2017, 84, 35-40.	0.6	30
1959	CHADS2 versus CHA2DS2-VASc score in assessing the stroke and thromboembolism risk stratification in patients with atrial fibrillation: a systematic review and meta-analysis. Journal of Geriatric Cardiology, 2013, 10, 258-66.	0.2	88
1960	Practical issues in the management of novel oral anticoagulants-cardioversion and ablation. Journal of Thoracic Disease, 2015, 7, 115-31.	0.6	8

#	ARTICLE	IF	CITATIONS
1961	Percutaneous left atrial appendage closure-An alternative strategy for anticoagulation in atrial fibrillation and hereditary hemorrhagic telangiectasia?. Cardiovascular Diagnosis and Therapy, 2015, 5, 49-53.	0.7	12
1962	Management Of Atrial Fibrillation In Patients With Heart Failure. Journal of Atrial Fibrillation, 2014, 7, 1105.	0.5	1
1963	Non-Invasive Estimation Of Left Atrial Dominant Frequency In Atrial Fibrillation From Different Electrode Sites: Insight From Body Surface Potential Mapping. Journal of Atrial Fibrillation, 2014, 7, 1131.	0.5	4
1964	Electroanatomical mapping of atrial fibrillation: Review of the current techniques and advances. Journal of Atrial Fibrillation, 2014, 7, 1140.	0.5	20
1965	Cryptogenic Stroke And Role Of Loop Recorder. Journal of Atrial Fibrillation, 2014, 7, 1178.	0.5	5
1966	Diagnosis and Therapy of Atrial Fibrillation: The Past, The Present and The Future. Journal of Atrial Fibrillation, 2015, 8, 1216.	0.5	16
1967	Phased RF Ablation: Results and Concerns. Journal of Atrial Fibrillation, 2015, 8, 1240.	0.5	5
1968	Review Of Obesity And Atrial Fibrillation: Exploring The Paradox. Journal of Atrial Fibrillation, 2015, 8, 1259.	0.5	6
1969	Atrial Fibrillation Ablation Using Magnetic Navigation Comparison With Conventional Approach During Long-Term Follow-Up. Journal of Atrial Fibrillation, 2015, 8, 1276.	0.5	7
1970	Advanced Mapping Systems To Guide Atrial Fibrillation Ablation: Electrical Information That Matters. Journal of Atrial Fibrillation, 2016, 8, 1337.	0.5	19
1971	Safety of The Direct Oral Anticoagulant Edoxaban for Atrial Fibrillation After Cardiac Surgery: Pilot Study. Journal of Atrial Fibrillation, 2016, 9, 1456.	0.5	12
1972	Incorporating Stroke and Bleeding Risk Stratification Tools into Atrial Fibrillation Management Making Sense of the Alphabet Soup. Journal of Atrial Fibrillation, 2017, 9, 1497.	0.5	3
1973	Bonus vs No Bonus Cryoballoon Isolation for Paroxysmal Atrial Fibrillation Ablation. Journal of Atrial Fibrillation, 2017, 9, 1513.	0.5	4
1974	Left Atrial Strain Predicts Pro-Thrombotic State in Patients with Non-Valvular Atrial Fibrillation. Journal of Atrial Fibrillation, 2017, 10, 1641.	0.5	17
1975	Predictors of Short and Long Term Recurrences of Paroxysmal AF after Radiofrequency Ablation. Is Blanking Period Really Benign?. Journal of Atrial Fibrillation, 2018, 11, 2012.	0.5	6
1976	Comparative Study of Cryoballoon versus Radiofrequency for Pulmonary Vein Isolation when Combined with vein of Marshall Ethanol Infusion for Paroxysmal Atrial Fibrillation. Journal of Atrial Fibrillation, 2020, 12, 2253.	0.5	3
1977	Omega-3 Polyunsaturated Fatty Acid Supplementation: Mechanism and Current Evidence in Atrial Fibrillation. Journal of Atrial Fibrillation, 2012, 5, 718.	0.5	8
1978	Warfarinbehandling ved atrieflimmer i allmennpraksis - "undervurderes blÅdningsrisikoen?". Tidsskrift for Den Norske Laegeforening, 2014, 134, 175-179.	0.2	2

#	ARTICLE	IF	CITATIONS
1979	Different transseptal puncture for different procedures: Optimization of left atrial catheterization guided by transesophageal echocardiography. <i>Annals of Cardiac Anaesthesia</i> , 2016, 19, 589.	0.3	27
1980	Clinicians-related determinants of anticoagulation therapy and prophylaxis in Nigeria. <i>Annals of African Medicine</i> , 2017, 16, 164.	0.2	3
1981	Cardiac tachyarrhythmias and anaesthesia: General principles and focus on atrial fibrillation. <i>Indian Journal of Anaesthesia</i> , 2017, 61, 712.	0.3	10
1982	Guideline-based Decision Support for the Mobile Patient Incorporating Data Streams from a Body Sensor Network. , 2014, , .		3
1983	Detection and Determination of Protein Network Associated with Atrial Fibrillation Phenotypes. <i>Journal of Clinical & Experimental Cardiology</i> , 2015, 6, .	0.0	1
1984	Non-Vitamin K Antagonist Oral Anticoagulants: Redefining the Role of the Nurse to Improve Patient Care. <i>Open Journal of Nursing</i> , 2015, 05, 1142-1157.	0.2	1
1985	Cardiac Radiosurgery for the Treatment of Atrial Fibrillation. <i>World Journal of Cardiovascular Diseases</i> , 2016, 06, 143-155.	0.0	1
1986	Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement. <i>EuroIntervention</i> , 2015, 10, 1015-1021.	1.4	21
1987	Percutaneous left atrial appendage occlusion in 2016. <i>EuroIntervention</i> , 2016, 11, e1576-e1578.	1.4	5
1988	Antithrombotic and antiplatelet therapy in TAVI patients: a fallow field?. <i>EuroIntervention</i> , 2013, 9, S43-S47.	1.4	11
1989	Cardiac arrhythmias in acute coronary syndromes: position paper from the joint EHRA, ACCA, and EAPCI task force. <i>EuroIntervention</i> , 2015, 10, 1095-1108.	1.4	29
1990	EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion. <i>EuroIntervention</i> , 2015, 10, 1109-1125.	1.4	76
1991	Catheter ablation of atrial fibrillation: Radiofrequency catheter ablation for redo procedures after cryoablation. <i>World Journal of Cardiology</i> , 2013, 5, 280.	0.5	8
1992	Hypertrophic cardiomyopathy in 2013: Current speculations and future perspectives. <i>World Journal of Cardiology</i> , 2014, 6, 26.	0.5	35
1993	Surgical perspectives in the management of atrial fibrillation. <i>World Journal of Cardiology</i> , 2016, 8, 41.	0.5	9
1994	Update on the status of new oral anticoagulants for stroke prevention in patients with atrial fibrillation. <i>Cardiovascular Medicine(Switzerland)</i> , 2013, 16, 103-114.	0.1	7
1995	Advanced ECG in 2016: is there more than just a tracing?. <i>Swiss Medical Weekly</i> , 2016, 146, w14303.	0.8	17
1996	Atrial fibrillation and the 4P medicine. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2013, 49, 247-8.	0.2	5

#	ARTICLE	IF	CITATIONS
1997	Dissolution of an apical thrombus by apixaban in a patient with old anteroseptal myocardial infarction. <i>Anatolian Journal of Cardiology</i> , 2015, 15, 671-672.	0.5	10
1998	The awareness, efficacy, safety, and time in therapeutic range of warfarin in the Turkish population: warfarin -tr. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 595-600.	0.5	18
1999	A review of the fixed dose use of new oral anticoagulants in obese patients: Is it really enough?. <i>Anatolian Journal of Cardiology</i> , 2015, 15, 1020-1029.	0.5	20
2000	The rs6817105 polymorphism on chromosome 4q25 is associated with the risk of atrial fibrillation in the Chinese Han population. <i>Anatolian Journal of Cardiology</i> , 2015, 16, 662-666.	0.5	1
2001	Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome in the real world: Data from the Berlin AFibACS Registry. <i>Cardiology Journal</i> , 2014, 21, 465-473.	0.5	12
2002	Learning curve in circular multipolar phased radiofrequency ablation of atrial fibrillation. <i>Cardiology Journal</i> , 2015, 22, 260-265.	0.5	12
2003	Can thromboembolic risk be associated with erectile dysfunction in atrial fibrillation patients?. <i>Cardiology Journal</i> , 2015, 22, 446-452.	0.5	7
2004	Predictors of early and late left atrial tachycardia and left atrial flutter after catheter ablation of atrial fibrillation: Long-term follow-up. <i>Cardiology Journal</i> , 2015, 22, 557-566.	0.5	10
2005	New concepts in the therapy of atrial fibrillation. <i>Cardiology Journal</i> , 2016, 23, 3-11.	0.5	5
2008	Obstructive sleep apnoea in patients with atrial fibrillation: prevalence, determinants and clinical characteristics of patients in Polish population. <i>Kardiologia Polska</i> , 2014, 72, 716-724.	0.3	34
2009	The effect of strict rate control on B-type natriuretic peptide values and echocardiographic parameters in chronic atrial fibrillation. <i>Kardiologia Polska</i> , 2014, 72, 934-940.	0.3	5
2010	Influence of left atrial size on the outcome of pulmonary vein isolation in patients with atrial fibrillation. <i>Kardiologia Polska</i> , 2014, 72, 1135-1140.	0.3	3
2011	New oral anticoagulants for the prevention of thromboembolic complications in atrial fibrillation: a single centre experience. <i>Kardiologia Polska</i> , 2015, 73, 85-93.	0.3	2
2012	Antithrombotic Management of Patients with Nonvalvular Atrial Fibrillation and Ischemic Stroke or Transient Ischemic Attack: Executive Summary of the Korean Clinical Practice Guidelines for Stroke. <i>Journal of Stroke</i> , 2015, 17, 210.	1.4	7
2013	How and When to Screen for Atrial Fibrillation after Stroke: Insights from Insertable Cardiac Monitoring Devices. <i>Journal of Stroke</i> , 2016, 18, 121-128.	1.4	10
2014	Il Diretrizes Brasileiras de Fibrilação Atrial. <i>Arquivos Brasileiros De Cardiologia</i> , 2016, 106, .	0.3	24
2015	Prevalence of oral anticoagulation in atrial fibrillation. <i>Clinics</i> , 2014, 69, 615-620.	0.6	14
2016	Diagnosed, undiagnosed and overall atrial fibrillation research on population over 60 year-old. AFABE study. <i>Cardiovascular System</i> , 2014, 2, 2.	1.0	2

#	ARTICLE	IF	CITATIONS
2017	Atrial fibrillation. <i>Journal of Biomedical Research</i> , 2014, 28, 1.	0.7	49
2018	Telemonitoring Boosts Atrial Fibrillation Detection in Cryptogenic Stroke Patients – Preliminary Findings. <i>Cardiology and Angiology</i> , 2013, 1, 47-57.	0.0	3
2019	Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation Treatment: Rural and Urban Trends in Medicare Beneficiaries. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 207-217.	1.0	8
2020	Remote magnetic navigation versus manual catheter ablation of atrial fibrillation: A single center long-term comparison. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 14-22.	0.5	5
2022	Atrial Fibrillation Ablation by Use of Electroanatomical Mapping: Efficacy and Recurrence Factors. <i>Arquivos Brasileiros De Cardiologia</i> , 2013, 102, 30-8.	0.3	2
2023	Recent Atrial Fibrillation Guidelines – Looking at Both Sides of the Atlantic. <i>Arrhythmia and Electrophysiology Review</i> , 2013, 2, 8.	1.3	0
2025	Stroke in Atrial Fibrillation – Long-term Follow-up of Cardiovascular Events. <i>Arrhythmia and Electrophysiology Review</i> , 2013, 2, 105.	1.3	4
2026	Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves. , 2013, , 786-799.		0
2028	Dabigatran, electrical cardioversion and measuring the aPTT. A safety measure or an unnecessary assessment?. <i>BMJ Case Reports</i> , 2013, 2013, bcr2013010090-bcr2013010090.	0.2	0
2030	Anticoagulation in Atrial Fibrillation. <i>Deutsches A&#x0308;rztblatt International</i> , 2013, 110, 523-4.	0.6	6
2031	Diastolic Echocardiographic Parameters in Predicting Outcome of Radiofrequency Catheter Ablation of Atrial Fibrillation. <i>The Open Pacing, Electrophysiology & Therapy Journal</i> , 2013, 5, 1-5.	0.7	0
2032	First Macedonian Registry on Atrial Fibrillation. <i>Cardiologia Croatica</i> , 2013, 8, 298-298.	0.0	0
2033	Anticoagulation management in nonvalvular atrial fibrillation: current and future directions. <i>Polish Archives of Internal Medicine</i> , 2013, 123, 623-634.	0.3	7
2035	The Prevalence of Atrial Fibrillation and Related Factors Including Anthropometric, Hemodynamic and Echocardiographic Parameters in Patients with Hemodialysis. <i>KoÅyuyolu Heart Journal</i> , 2013, 16, 229-232.	0.0	1
2036	Cardiac embolism after implantable cardiac defibrillator shock in non-anticoagulated atrial fibrillation: The role of left atrial appendage occlusion. <i>World Journal of Cardiology</i> , 2014, 6, 213.	0.5	0
2037	Aging, Diabetic Nephropathy and Multiple Macrovascular Involvement are Associated with Atrial Fibrillation in Type 2 Diabetes Mellitus. <i>British Journal of Medicine and Medical Research</i> , 2014, 4, 5154-5166.	0.2	0
2038	Predictor value cytokines for recurrence of arrhythmia in patients with coronary heart disease combined hypertension and persistent atrial fibrillation. <i>Biological Markers and Guided Therapy</i> , 0, 1, 109-114.	0.1	1
2039	The new oral anticoagulants in clinical practice. <i>Revista MÃ©dica De Minas Gerais</i> , 2014, 24, .	0.0	1

#	ARTICLE	IF	CITATIONS
2041	Rhythm Management of the Atrial Fibrillation Patient: Practical Implementation of the 2012 ESC Guidelines. <i>European Cardiology Review</i> , 2014, 9, 120.	0.7	1
2042	The Relationship between <i>Helicobacter pylori</i> Infection and Different Types of Atrial Fibrillation in a Chinese Population. <i>Internal Medicine: Open Access</i> , 2014, 04, .	0.0	0
2043	Arrhythmology and cardiac pacing – an overview of the situation in Croatia.. <i>Cardiologia Croatica</i> , 2014, 9, 3-11.	0.0	0
2045	Cierre percutáneo de la orejuela izquierda: Descripción del primer caso intervenido en el país. <i>Revista Médica Del Hospital José Carrasco Arteaga</i> , 2014, 6, 80-83.	0.0	0
2046	Oclusão Percutânea do Apendice Atrial Esquerdo com Procedure Watchman. <i>Revista Brasileira De Cardiologia Invasiva</i> , 2014, 22, 56-63.	0.1	0
2047	Acquired Hemophilia With Inhibitors Presenting as an Emergency. <i>Deutsches Ärzteblatt International</i> , 2014, 111, 345-8.	0.6	15
2048	Efficacy and Safety of Different Energy Settings for Atrial Fibrillation Ablation using the Duty-cycled Radiofrequency Ablation Catheter (PVAC). <i>Journal of Cardiovascular Medicine and Cardiology</i> , 0, , 007-010.	0.1	0
2049	Fibrilhação auricular num ACS da Região Norte – sua prevalência e proporção de terapêuticas antitrombóticas. <i>Revista Portuguesa De Clínica Geral</i> , 2014, 30, 292-298.	0.1	0
2050	Interventional treatment for structural heart disease: Who is deciding, and can we afford it?. <i>Swiss Medical Weekly</i> , 2014, 144, w14046.	0.8	1
2051	Transcatheter left atrial appendage occlusion in the prevention of stroke and death in patients with atrial fibrillation. <i>Kardiologia Polska</i> , 2014, 72, 1127-1134.	0.3	1
2052	Atrial fibrillation: A moving target. <i>Swiss Medical Weekly</i> , 2014, 144, w14078.	0.8	2
2053	Oral Anticoagulant Therapy and Bleeding Events with Vitamin K Antagonists in Patients with Atrial Fibrillation in a Hungarian County Hospital. <i>Medical Science Monitor</i> , 2015, 21, 518-525.	0.5	4
2054	Clinical Outcomes and Anticoagulant Intensity in Japanese Nonvalvular Atrial Fibrillation Patients ≥65 Years of Age with a CHADS ₂ Score 0-1 and Taking Warfarin. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2015, 46, 191-197.	0.1	0
2055	Recent advances in management of anti-coagulation in atrial fibrillation. <i>Journal of Heart and Cardiology</i> , 2015, 2, 1-5.	0.1	0
2056	Effect of anti-arrhythmic drugs on non-invasive electrophysiologic indexes-predictors of sudden cardiac death. <i>Kardiologiya i Serdechno-Sosudistaya Khirurgiya</i> , 2015, 8, 57.	0.1	2
2057	Antithrombotic treatment in chronic heart failure and sinus rhythm: Systematic review. <i>World Journal of Meta-analysis</i> , 2015, 3, 36.	0.1	0
2058	Mitralstenose. , 2015, , 1-17.		0
2059	Use of Mechanical Devices to Reduce Stroke in Atrial Fibrillation. , 2015, , 1081-1099.		0

#	ARTICLE	IF	CITATIONS
2060	What is Established and What is New in Ablation of Persistent Atrial Fibrillation?. Arrhythmia and Electrophysiology Review, 2015, 04, 80.	1.3	0
2061	New Role of Biomarkers in Atrial Fibrillation. , 2015, , 1-33.		1
2063	An epidemiological study to evaluate the use of vitamin K antagonists and new oral anticoagulants among nonvalvular atrial fibrillation patients in Turkey- AFTER-2 Study Design. Turk Kardiyoloji Dernegi Arsivi, 2015, 43, 169-77.	0.6	1
2064	The fifth anniversary of clinical use of new oral anticoagulants in non-valvular atrial fibrillation. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2015, 7, 4-9.	0.2	1
2065	Algorithm for analysis of Atrial Fibrillation by cancellation of ventricular activity on electrocardiogram. , 0, , .		0
2066	Udar mÅ³zgu jako pierwsza manifestacja migotania przedsionkÅ³w â€” opis dwÅ³ch przypadkÅ³w klinicznych. Folia Cardiologica, 2015, 10, 136-141.	0.1	1
2067	Do we always need anticoagulation before cardioversion of atrial fibrillation in ladies?. Anatolian Journal of Cardiology, 2015, 15, 602-604.	0.5	0
2068	Prevalence of arterial hypertension in patients with atrial fibrillation undergoing ablation â€” a prospective, cohort study. Arterial Hypertension, 2015, 19, 135-139.	0.2	1
2070	Updated Management of Atrial Fibrillation. Eurasian Journal of Emergency Medicine, 2015, 14, 138-141.	0.1	0
2071	Does obstructive sleep apnoea influence BNP concentrations in atrial fibrillation patients?. Arterial Hypertension, 2015, 19, 179-186.	0.2	0
2072	Predictors of typical atrial flutter recurrence following radiofrequency ablation of cavotricuspid isthmus using extracardially irrigated-tip catheters. Srce I Krvni Sudovi, 2016, 35, 46-52.	0.1	0
2073	Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease. British Journal of Medicine and Medical Research, 2016, 13, 1-9.	0.2	0
2074	Nye antikoagulasjonsmidler i kombinasjon med platehemmere. Tidsskrift for Den Norske Laegeforening, 2016, 136, 1543-1546.	0.2	2
2075	Practical Experience with Anticoagulation Therapy in an Elderly Polymorbid Rehabilitation Population: What did we Learn?. Journal of Gerontology & Geriatric Research, 2016, 5, .	0.1	0
2076	Anticoagulation Quality and Complications of using Vitamin K Antagonists in the Cardiac Surgery Outpatient Clinic. Brazilian Journal of Cardiovascular Surgery, 2016, 31, 239-245.	0.2	1
2077	The safety and efficacy of sotalol in the management of acute atrial fibrillation: a retrospective case control study. , 2016, 08, .		0
2078	ArtÅ©riopathie athÅ©romateuse de l'aorte. , 2016, , 209-214.		0
2079	Management of atrial fibrillation in specific patient populations. Kardiologia Polska, 2016, 74, 1-8.	0.3	2

#	ARTICLE	IF	CITATIONS
2080	Kardiologiczne konsultacje w ortopedii u chorych przyjmujących leki przeciwzakrzepowe. Folia Cardiologica, 2016, 10, 423-427.	0.1	0
2081	Chirurgische Aspekte. , 2016, , 59-83.		0
2082	Double high risk atrial fibrillation patients. , 2016, 08, .		0
2083	Can we assess the risk of embolic complications of cardioversion?. Polish Archives of Internal Medicine, 2016, 126, 5-6.	0.3	0
2084	Description of selected diagnostic tools in assessing the risk of venous thromboembolic disease. Pielęgniarstwo XXI Wieku, 2016, 15, 5-8.	0.2	0
2085	Anticoagulation for the prevention of stroke in non-valvular AF in general practice: room for improvement. Drugs in Context, 2016, 5, 1-6.	1.0	3
2086	Back to sinus rhythm from atrial flutter or fibrillation: dabigatran is safe without transoesophageal control. Kardiologia Polska, 2016, 74, 425-430.	0.3	6
2087	Barriers for a Wider Use of Left Atrial Appendage Occlusion as an Alternative to Oral Anticoagulation. Journal of Cardiology & Current Research, 2016, 6, .	0.1	0
2088	FIRE AND ICE: The quest for the perfect modality in atrial fibrillation ablation. Global Cardiology Science & Practice, 2016, 2016, e201623.	0.3	2
2089	The Role of Multimodality Cardiac Imaging in the Management of Patients with Atrial Fibrillation. Cardiovascular Imaging Asia, 2017, 1, 177.	0.1	0
2090	Evolution of Force Sensing Technologies. Arrhythmia and Electrophysiology Review, 2017, 6, 75.	1.3	1
2091	Anticoagulants for Atrial Fibrillation. Cardiovascular Medicine, 2017, , 105-114.	0.0	0
2092	Naujojo antikoagulianto " dabigatrano " saugumas ir efektyvumas taikant elektrinį kardioversiją... Health Sciences, 2017, 26, 169-172.	0.0	0
2093	Myokardinfarkt mit Herzrhythmusstörungen. , 2017, , 97-108.		0
2095	Left Atrial Appendage Morphology, Does it Matter?. Journal of Clinical & Experimental Cardiology, 2017, 08, .	0.0	0
2096	Comparison of Warfarin use in terms of efficacy and safety in two different polyclinics. Anatolian Journal of Cardiology, 2017, 18, 328-333.	0.5	2
2098	Effectiveness and Safety of Direct Oral Anticoagulants Compared With Vitamin K Antagonists in Non-Valvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. Journal of Clinical Trials in Cardiology, 2017, 4, 1-4.	0.3	0
2099	Perspectives on the modern management of non-valvular atrial fibrillation. SA Heart Journal, 2017, 12, .	0.0	0

#	ARTICLE	IF	CITATIONS
2101	Case Report. Non-Obvious, Post-Traumatic, Life-Threatening Bleeding in Two Elderly Patients. The Journal of Critical Care Medicine, 2017, 3, 79-83.	0.3	0
2102	Preprocedural and procedural transesophageal echocardiography in patients with left atrial appendage occluder implantation. <i>Cardiologia Croatica</i> , 2017, 12, 131-131.	0.0	0
2103	Notification of international normalized ratio test in atrial fibrillation patients treated with warfarin via short message service: Study protocol for a randomized controlled trial. <i>Electronic Physician</i> , 2017, 9, 4732-4736.	0.2	0
2104	Can pacemaker protect against ischemic stroke?. In <i>A Good Rythm</i> , 2017, 3, 27-30.	0.0	0
2105	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. <i>Healthcare Policy</i> , 2017, 13, 68-78.	0.3	2
2106	Survey of Direct-Acting Oral Anticoagulants for Non-Valvular Atrial Fibrillation. <i>Journal of the Japanese Association of Rural Medicine</i> , 2018, 67, 58-64.	0.0	0
2107	Changes in stroke risk by freedom-from-stroke time in simulated populations with atrial fibrillation: Freedom-from-event effect when event itself is a risk factor. <i>PLoS ONE</i> , 2018, 13, e0194307.	1.1	1
2110	Telecardiology Tools and Devices. , 2018, , 463-487.		0
2112	Living with atrial fibrillation. <i>Cardiologia Croatica</i> , 2018, 13, 509-509.	0.0	0
2113	Effect of Acute Termination of Atrial Fibrillation on the Outcome of Ablation of Persistent Atrial Fibrillation. <i>Journal of the Nihon University Medical Association</i> , 2018, 77, 383-388.	0.0	0
2114	The Impact of Cancer on Major Bleeding and Stroke/Systemic Emboli in Patients Using Direct Oral Anticoagulants:From the Database of a Single-Center Registry. <i>Journal of Atrial Fibrillation</i> , 2018, 11, 2105.	0.5	5
2115	Relationship between Epicardial Fat Accumulation and Left Atrial Reverse Remodeling after Catheter Ablation of Atrial Fibrillation. <i>Journal of the Korean Society of Radiology</i> , 2019, 80, 930.	0.1	0
2116	Riesgo emb�lico, riesgo isqu�mico y riesgo hemorr�gico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019, 18, 3-8.	0.2	0
2117	Role of CHA2DS2-VASc-HS Score as Predictor for Failed Reperfusion After Fibrinolytic in St-Elevation Myocardial Infarction. <i>International Journal of ChemTech Research</i> , 2019, 12, 110-118.	0.1	0
2118	The Feasibility and Efficacy of Ablation of Paroxysmal Atrial Fibrillation Using Different Technologies. <i>International Journal of Cardiac Science and Research</i> , 2019, 2019, .	0.0	0
2119	Combination of pulmonary vein isolation and left atrial appendage closure for non-valvular atrial fibrillation. <i>Complex Issues of Cardiovascular Diseases</i> , 2019, 7, 86-93.	0.3	0
2120	A Retrospective Study of Atrial Fibrillation Following Cavotricuspid Isthmus Ablation for Atrial Flutter. <i>Medical Science Monitor</i> , 2019, 25, 3316-3320.	0.5	6
2121	Usefulness of CartoMerge image integration module in catheter ablation of atrial fibrillation. <i>European Journal of Translational and Clinical Medicine</i> , 2019, 2, 48-52.	0.0	0

#	ARTICLE	IF	CITATIONS
2122	The effect of cardiac rehabilitation at 4 weeks postoperatively on quality of life in patients treated with totally thoracoscopic ablation. <i>Journal of Exercise Rehabilitation</i> , 2019, 15, 610-615.	0.4	1
2123	Cost-benefit analysis of VKA versus NOAC treatment in German patients with atrial fibrillation utilizing patient self-testing. <i>Journal of Health Economics and Outcomes Research</i> , 2019, 6, 142-159.	0.6	1
2124	The association between CHA2DS2-VASc score and erectile dysfunction: a cross-sectional study. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2019, 45, 1204-1208.	0.7	1
2126	VKORC1 and CYP2C9*3 Polymorphisms and Their Impacts to Acenocoumarol Dosage in Vietnamese Heart Valve Replacement Patients. <i>Walailak Journal of Science and Technology</i> , 2019, 16, 207-215.	0.5	0
2127	Two-dimensional versus three-dimensional transesophageal echocardiography in percutaneous left atrial appendage occlusion. <i>Cardiology Journal</i> , 2020, 26, 687-695.	0.5	2
2128	Antiarrhythmic Medications. , 2020, , 305-333.		0
2129	The impact of continuous positive airway pressure on cardiac arrhythmias in patients with sleep apnea. <i>Journal of Research in Medical Sciences</i> , 2020, 25, 42.	0.4	7
2130	Left Atrial Appendage Anatomy: Implications for Endocardial Catheter-based Device Closure. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020, 11, 4179-4186.	0.2	1
2131	Smart Touch Radiofrequency Catheter Ablation versus Cryoballoon Ablation of Pulmonary Veins in Patients with Paroxysmal Atrial Fibrillation. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 563-568.	0.1	1
2132	Predictors of Oral Anticoagulants Utilization in Patients with Atrial Fibrillation. <i>Journal of Health and Allied Sciences</i> , 2020, 10, 40-48.	0.0	0
2133	Application of Transesophageal Echocardiography in Percutaneous Left Atrial Appendage Occlusion. <i>International Journal of Cardiovascular and Cerebrovascular Disease</i> , 2020, 7, 7-10.	0.1	0
2134	Current Anticoagulant Usage Patterns and Determinants in Korean Patients with Nonvalvular Atrial Fibrillation. <i>Yonsei Medical Journal</i> , 2020, 61, 120.	0.9	1
2135	Correlation between serum homocysteine, Galectin-3 concentration and atrial structural remodeling in atrial fibrillation patients. <i>Pteridines</i> , 2020, 31, 83-90.	0.5	1
2136	Cardiovascular Comorbidities in the Elderly Undergoing Surgery. , 2020, , 45-65.		1
2137	Clinical outcomes of non-variceal upper gastrointestinal bleeding and its relation to aspirin and anticoagulants.. <i>Open Access Macedonian Journal of Medical Sciences</i> , 2020, 8, 11-19.	0.1	0
2138	Percutaneous left atrial appendage closure for stroke prevention in patients with chronic renal disease. <i>Archives of Medical Science</i> , 2020, , .	0.4	0
2139	Using mobile ECG devices to increase detection of atrial fibrillation across a range of settings in south London. <i>Future Healthcare Journal</i> , 2020, 7, 86-89.	0.6	1
2140	Quality of care in patients with atrial fibrillation in primary care: a cross-sectional study comparing clinical and claims data. <i>GMS German Medical Science</i> , 2016, 14, Doc13.	2.7	2

#	ARTICLE	IF	CITATIONS
2141	New oral anticoagulants for atrial fibrillation: are they worth the risk?. P and T, 2014, 39, 54-64.	1.0	10
2142	Major themes for 2013 in cardiothoracic and vascular anaesthesia and intensive care. Heart, Lung and Vessels, 2014, 6, 79-87.	0.4	1
2143	Optimization Of Stroke Prophylaxis Strategies In Nonvalvular AF -Drugs, Devices Or Both?. Journal of Atrial Fibrillation, 2015, 8, 1156.	0.5	0
2144	Coagulation Testing For New Oral Anticoagulants. Journal of Atrial Fibrillation, 2015, 8, 1089.	0.5	4
2145	The Optimal Treatment For Atrial Fibrillation In Less Developed Countries. Journal of Atrial Fibrillation, 2014, 7, 1147.	0.5	2
2146	Lone AF: is There a Rationale?. Journal of Atrial Fibrillation, 2015, 8, 1246.	0.5	0
2147	Techniques To Improve Left Atrial Appendage Imaging. Journal of Atrial Fibrillation, 2014, 7, 1059.	0.5	4
2148	Subclinical Atrial Tachyarrhythmias:Implantable Devices and Remote Monitoring. Journal of Atrial Fibrillation, 2015, 8, 1249.	0.5	6
2149	Who Needs Catheter Ablation And Which Approach?. Journal of Atrial Fibrillation, 2015, 8, 1335.	0.5	1
2150	Significance and Management Strategies for Patients with Asymptomatic Atrial Fibrillation. Journal of Atrial Fibrillation, 2015, 7, 1169.	0.5	2
2151	Atrial Fibrillation In Heart Failure: New Directions In Diagnosis, Risk Assessment And Risk Reduction. Journal of Atrial Fibrillation, 2014, 6, 1036.	0.5	0
2152	Stroke And Bleeding Risk Assessment: Where Are We Now?. Journal of Atrial Fibrillation, 2014, 6, 1042.	0.5	1
2153	Contact Force Assessment In Catheter Ablation Of Atrial Fibrillation. Journal of Atrial Fibrillation, 2014, 6, 1047.	0.5	5
2154	New Insights On Ablation Of Persistent Atrial Fibrillation: Evidence From The SARA Trial. Journal of Atrial Fibrillation, 2014, 7, 1114.	0.5	1
2155	Surgery for Atrial Fibrillation: Selecting the Procedure for the Patient. Journal of Atrial Fibrillation, 2013, 6, 743.	0.5	0
2156	Differences In Tissue Injury and Ablation Outcomes In Atrial Fibrillation Patients - Manual versus Robotic Catheters. Journal of Atrial Fibrillation, 2013, 6, 785.	0.5	0
2157	Left Atrial Appendage Closure Device With Delivery System: A Health Technology Assessment. Ontario Health Technology Assessment Series, 2017, 17, 1-106.	3.0	1
2158	Propafenone suppresses esophageal cancer proliferation through inducing mitochondrial dysfunction. American Journal of Cancer Research, 2017, 7, 2245-2256.	1.4	5

#	ARTICLE	IF	CITATIONS
2159	Role of transesophageal echocardiography during left atrial appendage occlusion device closure in a patient with non-valvular atrial fibrillation and angiodysplasia of the colon. <i>Annals of Cardiac Anaesthesia</i> , 2018, 21, 88-91.	0.3	1
2160	Should atrial fibrillation patients with hypertension as an additional risk factor of the CHA2DS2-VASc score receive oral anticoagulation?. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 229-234.	0.2	2
2161	The trend of change in catheter ablation versus antiarrhythmic drugs for the management of atrial fibrillation over time: a meta-analysis and meta-regression. <i>Journal of Geriatric Cardiology</i> , 2018, 15, 441-450.	0.2	6
2162	Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1200-1215.	0.7	0
2163	Predictors of Acute Atrial Fibrillation and Flutter Hospitalization across 7 U.S. Emergency Departments: A Prospective Study. <i>Journal of Atrial Fibrillation</i> , 2021, 13, 2355.	0.5	2
2164	Late cardiac toxicity of neo-adjuvant chemoradiation in esophageal cancer survivors: a prospective cross-sectional pilot study. <i>Radiotherapy and Oncology</i> , 2021, , .	0.3	4
2165	Schlaganfallprophylaxe bei Vorhofflimmern: Hohe Akzeptanz von NOAK. , 0, , .		0
2166	Speed Spot as a method of graphical visualization and analysis of the state of the heart activity. , 2020, , .		0
2167	Evaluating the cost-effectiveness of catheter ablation of atrial fibrillation. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 1200-1215.	0.7	0
2168	Acute Mitral Valve Injury Following Percutaneous Left Atrial Appendage Occlusion: A Case Report and Literature Review. <i>Heart Surgery Forum</i> , 2020, 23, E743-E745.	0.2	2
2169	CHA2DS2-VASC SCORE AS A PREDICTOR FOR CONTRAST-INDUCED NEPHROPATHY IN PATIENT WITH ISCHEMIC HEART DISEASE TREATED WITH PERCUTANEOUS CORONARY INTERVENTION. <i>Al Azhar Medical Journal = Majallat Al-Tibb Al-Azhar</i> , 2020, 49, 1803-1816.	0.0	0
2170	The Characteristics and Clinical Outcomes of Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease: From the Database of A Single-Center Registry. <i>Journal of Atrial Fibrillation</i> , 2020, 13, 2308.	0.5	2
2171	Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 2022, 9, 199-209.	0.7	11
2172	Left Atrial Dysfunction, Fibrosis and the Risk of Thromboembolism in Patients With Paroxysmal and Persistent Atrial Fibrillation. <i>International Journal of Heart Failure</i> , 2022, 4, 42.	0.9	9
2173	2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2022, 45, 535-555.	0.5	6
2174	Appropriateness of Prescribing Rivaroxaban at King Khalid University Hospital Riyadh. <i>Cureus</i> , 2022, 14, e20977.	0.2	0
2175	Effects of direct oral anticoagulants dabigatran and rivaroxaban on the blood coagulation function in rabbits. <i>Open Life Sciences</i> , 2022, 17, 1-9.	0.6	0
2176	Detection of atrial fibrillation by implantable loop recorders following cryptogenic stroke: A retrospective study of predictive factors and outcomes. <i>Journal of Electrocardiology</i> , 2022, 71, 54-58.	0.4	3

#	ARTICLE	IF	CITATIONS
2177	Utility of Simultaneous Biatrial Atrial Anti-Tachycardia Pacing for the Termination of Atrial Fibrillation during Catheter Ablation of Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 575.	1.0	0
2178	4Sâ€AF scheme and ABC pathway guided management improves outcomes in atrial fibrillation patients. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13751.	1.7	20
2179	Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-9.	0.8	13
2180	Sacubitril/Valsartan Can Reduce Atrial Fibrillation Recurrence After Catheter Ablation in Patients with Persistent Atrial Fibrillation. <i>Cardiovascular Drugs and Therapy</i> , 2023, 37, 549-560.	1.3	10
2181	Ischemic Stroke Severity and Mortality in Patients With and Without Atrial Fibrillation. <i>Journal of the American Heart Association</i> , 2022, 11, e022638.	1.6	16
2182	High Plasma Concentration of Apolipoprotein C-III Confers an Increased Risk of Cerebral Ischemic Events on Cardiovascular Patients Anticoagulated With Warfarin. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 781383.	1.1	1
2184	Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease. <i>European Heart Journal Supplements</i> , 2022, 24, A19-A31.	0.0	6
2185	Socioeconomic and geographic differences in ablation of atrial fibrillation in Norway - a national cohort study. <i>BMC Public Health</i> , 2022, 22, 303.	1.2	9
2186	Cryoballoon Ablation for Persistent and Paroxysmal Atrial Fibrillation: Procedural Differences and Results from the Spanish Registry (RECABA). <i>Journal of Clinical Medicine</i> , 2022, 11, 1166.	1.0	0
2187	Undertreatment of Anticoagulant Therapy in Hospitalized Acute Ischemic Stroke Patients With Atrial Fibrillation. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 841020.	1.1	3
2188	<scp>JCS</scp>/<scp>JHRS</scp> 2020 Guideline on Pharmacotherapy of Cardiac Arrhythmias. <i>Journal of Arrhythmia</i> , 2022, 38, 833-973.	0.5	8
2189	Why do people take part in atrial fibrillation screening? Qualitative interview study in English primary care. <i>BMJ Open</i> , 2022, 12, e051703.	0.8	5
2190	Mental Health Conditions and Nonpersistence of Direct Oral Anticoagulant Use in Patients With Incident Atrial Fibrillation: A Nationwide Cohort Study. <i>Journal of the American Heart Association</i> , 2022, 11, e024119.	1.6	10
2191	Concomitant Atrial Fibrillation Procedures During Cardiac Surgery in a UK Center: Reflection of Worldwide Practice?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 780893.	1.1	1
2192	The Strengths and Weaknesses of Left Atrial Appendage Ligation or Exclusion (LARIAT, AtriaClip,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 1	0.2	2
2193	Risk of Stroke With Mitral Stenosis: The Underlying Mechanism, Treatment, and Prevention. <i>Cureus</i> , 2022, 14, e23784.	0.2	1
2196	Fiveâ€year mortality of heart failure with preserved, mildly reduced, and reduced ejection fraction in a 4880 Chinese cohort. <i>ESC Heart Failure</i> , 2022, 9, 2336-2347.	1.4	11
2197	Real-world cost-effectiveness analysis of NOACs versus VKA for stroke prevention in Spain. <i>PLoS ONE</i> , 2022, 17, e0266658.	1.1	6

#	ARTICLE	IF	CITATIONS
2198	Safety and efficacy of direct oral anticoagulants in comparison with warfarin across different BMI ranges: A systematic review and meta-analysis. <i>Annals of Medicine and Surgery</i> , 2022, 77, .	0.5	4
2199	Prevalence of atrial fibrillation and the risk of cardiovascular mortality among hypertensive elderly population in northeast China. <i>Journal of Clinical Hypertension</i> , 2022, , .	1.0	2
2209	Left atrial appendage occlusion with the Amplatzer Cardiac Plug could improve survival and prevent thrombo-embolic and major bleeding events in atrial fibrillation patients with increased bleeding risk. <i>Acta Cardiologica</i> , 2016, 71, 135-43.	0.3	2
2246	Simulation of monitoring strategies for atrial arrhythmia detection. <i>Annali Dell'Istituto Superiore Di Sanita</i> , 2013, 49, 176-82.	0.2	4
2250	Effects of Cognitive Behavior Therapy on Depression, Illness Perception, and Quality of Life in Atrial Fibrillation Patients. <i>Frontiers in Psychiatry</i> , 2022, 13, .	1.3	6
2251	Can CHA2DS2-VASc and HASâ€œBLED Foresee the Presence of Cerebral Microbleeds, Lacunar and Non-Lacunar Infarcts in Elderly Patients With Atrial Fibrillation? Data From Stratâ€œAF Study. <i>Frontiers in Neurology</i> , 2022, 13, .	1.1	1
2252	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIA Registry. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856222.	1.1	4
2253	Temporal Trends in Oral Anticoagulant Prescription in Atrial Fibrillation Patients between 2004 and 2019. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5584.	1.2	1
2254	Integrating Multidisciplinary Individualized Medication Recommendations Into the Traditional Pharmacistsâ€™ Consultation Method: A Retrospective Study Using Propensity Score Matching Analysis. <i>Inquiry (United States)</i> , 2022, 59, 004695802210814.	0.5	2
2255	Association of income and educational levels with adherence to direct oral anticoagulant therapy in patients with incident atrial fibrillation: A Finnish nationwide cohort study. <i>Pharmacology Research and Perspectives</i> , 2022, 10, .	1.1	9
2256	ABO Blood Type Is Associated with Thrombotic Risk in Patients with Nonvalvular Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2022, 11, 3064.	1.0	1
2257	Inversion of Left Atrial Appendage Will Cause Compressive Stresses in the Tissue: Simulation Study of Potential Therapy. <i>Journal of Personalized Medicine</i> , 2022, 12, 883.	1.1	5
2259	Qualitative Evaluation of an Artificial Intelligenceâ€œBased Clinical Decision Support System to Guide Rhythm Management of Atrial Fibrillation: Survey Study. <i>JMIR Formative Research</i> , 2022, 6, e36443.	0.7	1
2260	Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. <i>PLoS Medicine</i> , 2022, 19, e1004003.	3.9	10
2261	Atrial fibrillation and 24â€œh ambulatory blood pressure pattern. <i>Journal of Clinical Hypertension</i> , 2022, 24, 848-850.	1.0	1
2262	Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Caseâ€œControl Study from The Netherlands, Italy and Germany. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	7
2263	Embolic Cerebrovascular Accident Secondary to Device-Related Thrombus Post WATCHMAN Device Implantation. <i>Cureus</i> , 2022, , .	0.2	0
2264	CACHET-CADB: A Contextualized Ambulatory Electrocardiography Arrhythmia Dataset. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	2

#	ARTICLE	IF	CITATIONS
2265	Epidemiology of atrial fibrillation and risk of CVD mortality among hypertensive population: A prospective cohort study in Northeast China. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	0
2266	Heterogeneity of outcomes within diabetic patients with atrial fibrillation on edoxaban: a sub-analysis from the ETNA-AF Europe registry. <i>Clinical Research in Cardiology</i> , 0, , .	1.5	1
2267	Changes in primary care management of atrial fibrillation patients following the shift from warfarin to non-vitamin K antagonist oral anticoagulants: a Norwegian population based study. , 2022, 23, .		1
2268	Stroke risk evaluation for patients with atrial fibrillation: Insights from left atrial appendage. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
2269	Application of plasma metabolome for monitoring the effect of rivaroxaban in patients with nonvalvular atrial fibrillation. <i>PeerJ</i> , 0, 10, e13853.	0.9	0
2270	Concurrent use of Chinese herbal medicine and anticoagulants may reduce major bleeding events. <i>PLoS ONE</i> , 2022, 17, e0271965.	1.1	2
2271	Impact of Catheter Ablation on Long-Term Outcomes in Patients With Atrial Fibrillation: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	1
2272	Oral anticoagulant treatment in rheumatoid arthritis patients with atrial fibrillation results of an international audit. <i>IJC Heart and Vasculature</i> , 2022, 42, 101117.	0.6	1
2273	The Association Between High CHA ₂ DS ₂ -VASc Scores and Short and Long-Term Mortality for Coronary Care Unit Patients. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962211179.	0.7	1
2274	Predictors of Adherence to Stroke Prevention in the BALKAN-AF Study: A Machine-Learning Approach. <i>TH Open</i> , 2022, 06, e283-e290.	0.7	0
2275	A novel wide-band dielectric imaging system for electro-anatomic mapping and monitoring in radiofrequency ablation and cryoablation. <i>Journal of Translational Internal Medicine</i> , 2022, 10, 264-271.	1.0	3
2276	Association of CHA ₂ DS ₂ -VASC Score with in-Hospital Cardiovascular Adverse Events in Patients with Acute ST-Segment Elevation Myocardial Infarction. <i>International Journal of Clinical Practice</i> , 2022, 1-7.	0.8	1
2277	Stand-Alone Left Atrial appendage occlusion for thromboembolism prevention in nonvalvular Atrial fibrillation Disease Registry (SALAMANDER): protocol for a prospective observational nationwide study. <i>BMJ Open</i> , 2022, 12, e063990.	0.8	0
2278	GARFIELD-AF: risk profiles, treatment patterns and 2-year outcomes in patients with atrial fibrillation in Germany, Austria and Switzerland (DACH) compared to 32 countries in other regions worldwide. <i>Clinical Research in Cardiology</i> , 2023, 112, 759-771.	1.5	3
2279	Long term follow up of direct oral anticoagulants and warfarin therapy on stroke, with all-cause mortality as a competing risk, in people with atrial fibrillation: Sentinel network database study. <i>PLoS ONE</i> , 2022, 17, e0265998.	1.1	0
2280	Comparison of Efficacy and Safety of Anticoagulant Monotherapy and Combined Therapy of Anticoagulant and Antiplatelets in Patients With Stable Coronary Artery Disease and Atrial Fibrillation: A Meta-Analysis. <i>Cureus</i> , 2022, , .	0.2	0
2281	Mining of Potential Biomarkers and Pathway in Valvular Atrial Fibrillation (VAF) via Systematic Screening of Gene Coexpression Network. <i>Computational and Mathematical Methods in Medicine</i> , 2022, 2022, 1-21.	0.7	3
2282	Disruption of Sarcoplasmic Reticulum-Mitochondrial Contacts Underlies Contractile Dysfunction in Experimental and Human Atrial Fibrillation: A Key Role of Mitofusin 2. <i>Journal of the American Heart Association</i> , 2022, 11, .	1.6	4

#	ARTICLE	IF	CITATIONS
2283	The characteristics of pre-excitation syndrome concomitant with atrial tachyarrhythmia and the effect of radiofrequency ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 0, , .	0.5	1
2284	Characteristics of patients with atrial fibrillation and history of stroke or transient ischemic attack - some results from the FACTS Database. <i>Romanian Journal of Neurology/ Revista Romana De Neurologie</i> , 2013, 12, 53-57.	0.1	0
2285	Changes in fibrinolytic activity and coagulation factors after epicardial left atrial appendage closure in patients with atrial fibrillation. <i>Journal of Thoracic Disease</i> , 2022, 14, 4226-4235.	0.6	5
2286	A Prognostic Score To Predict Atrial fibrillation Recurrence After External Electrical Cardioversion – SLAC Score. <i>Critical Pathways in Cardiology</i> , 2022, 21, 194-200.	0.2	1
2287	Time trends in antithrombotic therapy prescription patterns: Real-world monocentric study in hospitalized patients with atrial fibrillation. <i>World Journal of Cardiology</i> , 0, 14, 576-598.	0.5	1
2288	Identifying unmet antithrombotic therapeutic need, and implications for stroke and systemic embolism in atrial fibrillation patients: a population-scale longitudinal study. <i>European Heart Journal Open</i> , 2022, 2, .	0.9	1
2289	Use of Diltiazem in Chronic Rate Control for Atrial Fibrillation: A Prospective Case-Control Study. <i>Biology</i> , 2023, 12, 22.	1.3	2
2290	Social App to Improve Warfarin Therapy in Post-MHVR Chinese Patients: A Randomized Controlled Trial. <i>Cardiovascular Therapeutics</i> , 2023, 2023, 1-10.	1.1	0
2291	Clinical significance of the rivaroxaban – dronedarone interaction: insights from physiologically based pharmacokinetic modelling. <i>European Heart Journal Open</i> , 2023, 3, .	0.9	1
2292	Association between circulating leukocytes and arrhythmias: Mendelian randomization analysis in immuno-cardiac electrophysiology. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
2293	Leap or lag: left atrial appendage closure and guidelines. <i>Europace</i> , 0, , .	0.7	0
2294	The Strengths and Weaknesses of Left Atrial Appendage Ligation or Exclusion (LARIAT, AtriaClip,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.7	0
2295	The effect of two different methods of planning landing zone for left atrial appendage closure by cardiac computed tomography angiography: a comparative study. <i>Annals of Translational Medicine</i> , 2023, 11, 75-75.	0.7	0
2296	Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands. <i>Drugs - Real World Outcomes</i> , 0, , .	0.7	1
2297	An open-label randomized noninferior study of generic name and brand name of propafenone for rhythm control in patients with paroxysmal atrial fibrillation. <i>Journal of the Chinese Medical Association</i> , 2023, 86, 472-478.	0.6	0
2298	Time trends in atrial fibrillation-related stroke during 2001 – 2020 in Sweden: a nationwide, observational study. <i>Lancet Regional Health - Europe, The</i> , 2023, 28, 100596.	3.0	8
2299	Clinical Characteristics and Predictors of Long-Term Prognosis of Acute Peripheral Arterial Ischemia Patients Treated Surgically. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 3877.	1.2	0
2300	Inappropriate Combined Antiplatelet and Anticoagulant Therapy in Older Patients with Atrial Fibrillation: Trend over Time (2009 – 18). <i>Drugs and Aging</i> , 2023, 40, 273-283.	1.3	0

#	ARTICLE	IF	CITATIONS
2301	Percutaneous left atrial appendage closure: beyond the classic indications. <i>AsiaIntervention</i> , 2023, 9, 70-77.	0.1	1
2302	Prevalence and clinical characteristics of atrial fibrillation in hospitalized patients with coronary artery disease and hypertension: a cross-sectional study from 2008 to 2018. <i>Chinese Medical Journal</i> , 2023, 136, 588-595.	0.9	2
2303	Family Physician Prescribing Practices and Perspectives on Shared Decision-Making Regarding the Use of Oral Anticoagulants for Stroke Prevention in Patients 75â€™Years or Older With Atrial Fibrillation. <i>Journal of Primary Care and Community Health</i> , 2023, 14, 215013192311640.	1.0	0
2304	Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer. <i>Cardio-Oncology</i> , 2023, 9, .	0.8	4
2310	Secondary Stroke Prevention in Patients with Atrial Fibrillation: From no Treatment to Direct Oral Anticoagulants. , 2023, , 171-180.		0